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 SUMMARY 
Summary 
The immunological competence to fight infections and to generate protective immunity, for 
example upon vaccination, progressively declines with advancing age. Although the aged 
immune system has been extensively studied at steady state and in aged animal models, there 
is only rudimentary understanding on how aging affects the immune response to a primary 
infection in humans. Involving complex individual systemic immune properties, such 
investigations have been very challenging particularly with the given restrictions of 
experimental infections in humans. 
In our study, we explored age-related changes in human immunity during experimental, 
primary immunization with live-attenuated yellow fever (YF) vaccine. In 11 young (median 
age: 26 years) and 12 elderly (median age: 60 years) vaccinees, we assessed individual viral 
burden and compared humoral and cellular immunity by advanced flow cytometric analysis 
over the entire course of the acute infection and up to 3 years after it. 
We discovered that aged subjects developed fewer neutralizing antibodies, mounted 
diminished YF-specific CD8+ T-cell responses and showed quantitatively and qualitatively 
altered YF-specific CD4+ T-cell immunity. A comparatively late peak in YF viremia suggested 
impaired infection control and viral clearance in the elderly. Among numerous immune 
signatures, low in vivo numbers of naive CD4+ recent thymic emigrants (CD4+ RTE) prior 
immunization and peripheral dendritic cells (DCs) in the early phase of the innate response 
phase were indicative for reduced acute responsiveness and altered long-term persistence of 
human cellular immunity to YF vaccination in the elderly. Thus, we reveal by this study that 
essential elements of immune responses such as CD4+ RTEs and DCs affect productive 
immunity in the elderly, explaining conclusively diminished responsiveness to vaccination with 
neo-antigens and infection with de novo pathogens in aged people. 
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 ZUSAMMENFASSUNG 
Zusammenfassung 
Mit zunehmendem Alter verringert sich die Fähigkeit des menschlichen Organismus 
Infektionen erfolgreich zu bekämpfen und, z.B. nach Impfung, einen protektiven Immunschutz 
aufzubauen. Es wird vermutet, dass die Alterung des Immunsystems eine wichtige Rolle dabei 
spielt. Wichtige Ergebnisse liefern dazu vor allem tierexperimentelle Studien, welche jedoch 
die Komplexität menschlicher Immunität, insbesondere in Bezug auf das Altern, nur bedingt 
abbilden können. Nur ansatzweise erforscht ist der Einfluss immunologischer 
Alterungsprozesse auf eine primäre Immunantwort im Menschen, was vor allem auf hohe 
experimentelle und ethische Hürden zurückzuführen ist. 
Um ein besseres Verständnis über primäre Immunantworten im Alter zu erlangen, haben wir 
für diese Arbeit erstmals junge (n=11, ∅=26 Jahre) und ältere (n=12, ∅=60 Jahre) Erwachsene 
mit einem viralen Erreger experimentell infiziert und die akute Immunreaktion und 
Entwicklung langlebiger Protektion eingehend untersucht und verglichen. Dafür verwendeten 
wir den attenuierten Lebendimpfstoff gegen Gelbfieber (GF), der ein hervorragendes 
Modelsystem darstellt, um vollständige, anti-virale Primärantworten im Menschen zu 
erforschen. 
Wir konnten zeigen, dass ältere Impflinge weniger Gelbfiebervirus-(GFV)-neutralisierende 
Antikörper produzierten, schwächere GFV-spezifische CD8+ T-Zellantworten erzeugten und 
sowohl quantitativ als auch qualitativ veränderte GFV-spezifische CD4+ T-Zellantworten 
generierten. Zudem wiesen ältere Impflinge häufiger eine vergleichsweise späte Virämie im 
Serum auf, welche durch die altersbedingten Veränderungen der immunologischen Abwehr 
verursacht sein könnte. Mittels systembiologischer Untersuchung konnten wir weiterhin 
zeigen, dass vor allem die niedrige Zahl von frisch aus dem Thymus ausgewanderten naiven 
CD4+ T Zellen, sogenannten CD4+ Recent thymic emigrants (CD4+ RTE), sowie der Mangel an 
dendritischen Zellen vor bzw. am Beginn der Infektion ausschlaggebend für die schlechtere 
Immunreaktion und niedrigere Langzeit-Immunität bei Älteren war. Aus unseren 
Untersuchungen schließen wir, dass insbesondere in älteren Menschen die Verfügbarkeit 
eines breiten Repertoires naiver CD4+ T-Zellen und eine effektive Induktion des angeborenen 
Immunsystems in der frühen Phase einer primären Infektion kritisch für die erfolgreiche akute 
Abwehr viraler Erreger und die Ausbildung langlebiger, protektiver Immunität ist. 
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 INTRODUCTION 
1. Introduction 
1.1 Pandemic aging of world’s population 
Aging of mankind has been identified as one of the major challenges of the 21st century. 
According to the World Health Organization (WHO) numbers of people aged >65 years will rise 
from 524 million nowadays to 1.5 billion by 2050, which will be 16 % of world’s total 
population (Services, 2011). Accelerated aging is a consequence of increasing life expectancy 
and declining fertility and will confront societies with enormous socioeconomic challenges 
especially in the health system. Importantly, rapid aging is not only limited to Western 
developed nations, but will even more dramatically occur in today’s developing countries. For 
example India’s elderly population will almost triple until 2050 from nowadays 60 million to 
227 million. The same is true for Brazil, for which an increase of those aged >65 from 20 
million in 2010 to 65 million in 2050 is predicted (Gragnolati et al., 2011). As aging is 
connected with many physiologic alterations, potentially leading to age-related clinical 
syndromes (Stanziano et al., 2010), it can be considered as a pandemic affecting world’s 
population. Thus, a better understanding of underlying physiological mechanisms of aging is 
imperative to facilitate efforts for the prevention of disease and the improvement of life 
quality of elderly people. 
1.2 The aging of the immune system 
The human immune system, mediating protection against viral, bacterial and parasitic 
pathogens and malign neoplasms, undergoes a complex transformation with age, eventually 
leading to a decline in immunological competence. As individuals age, this transformation, 
also called “immunosenescence”, causes an increased susceptibility to infections, resulting in 
greater morbidity and mortality than in young subjects (Gavazzi and Krause, 2002). For 
example, in an outbreak of West Nile virus (WNV) infection in New York in 1999, 88 % of the 
hospitalized patients were at least 50 years old and an age of 75 years or older was the factor 
most strongly associated with death (Nash et al., 2001). Also the fatal outcomes from 
influenza virus or respiratory syncytial virus infections were highest in persons aged ≥75 years 
(Matias et al., 2014). Immunosenescence is furthermore a major contributor to the increasing 
incidence of malignancies and autoimmunity in the elderly (Goronzy and Weyand, 2012; 
Fulop, Larbi, Kotb, et al., 2013; Fulop, Larbi, Witkowski, et al., 2013; Goronzy et al., 2013). 
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Changes associated with immunesenescence are very diverse and a multitude of components 
of the immune system are affected, as illustrated in fig. 1.1 and outlined in the next chapters. 
Importantly, though immunological aging appears to be progressive, the decline in 
immunological function is not linear, but a highly individual process affected by a complex 
combination of many factors, such as genetic variation (Poland et al., 2014), psychological 
stress (Bauer, 2008), diet (Maijó et al., 2014), gut microbiota (Rehman, 2012; Duncan and 
Flint, 2013) and chronic infections (Le Saux et al., 2012). In consequence, longevity and frailty 
are critically influenced by the individual immunological fitness at advanced age (Ferguson et 
al., 1995; Remarque and Pawelec, 1998; DelaRosa et al., 2006; Desquilbet et al., 2007; De 
Fanis et al., 2008; Wang and Casolaro, 2014). 
 
Figure 1.1: Age-associated changes of the human immune system 
Much of the current knowledge about the aged immune system at the steady state has been 
obtained from large population studies (Ferguson et al., 1995; Wikby et al., 2008). Moreover, 
the impact of chronic infections on the immune system has been extensively studied in young 
and aged individuals (Brunner et al., 2011; Fülöp et al., 2013; Sansoni et al., 2014). Further 
research has been conducted on aged-animal models such as mice (Maue et al., 2009) and 
non-human primates (Wertheimer et al., 2010), however much higher life expectancy, highly 
individual immune properties and obvious differences in the immune system between mice 
and man, complicate the direct translation of these results to humans (Davis, 2008; Vallejo, 
2011). The response of the human aged immune system to a challenge has been investigated 
so far mostly after secondary immunizations, such as influenza, tetanus or Varicella-zoster 
Modified from Poland et al. (2014) 
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vaccination (Hainz et al., 2005; Weinberg et al., 2009; McElhaney, 2011; Weinberger and 
Grubeck-Loebenstein, 2012). However, how the aged immune system reacts against a primary 
threat to a pathogenic neoantigen still remains obscure, due to the fact that studying primary 
acute immune responses in humans is very challenging. On the one hand, analyzing natural 
occurring primary infections in the elderly lacks usually knowledge about the exact time point 
of infection, rendering data interpretation difficult (Parsons et al., 2008; Lindgren et al., 2011; 
Lelic et al., 2012; Walsh et al., 2013; Blom et al., 2015). On the other hand, the number of 
human experimental primary infections is very limited and ethically highly restricted; 
especially when applied to elderly study volunteers. Despite these aggravating circumstances, 
there is the need for more research on the immune response to primary infections in the 
elderly, which therefore was the main focus in the work of this dissertation. 
1.3 Aging of the innate immune system 
The innate immune system represents the first line of defense against infections and forms 
the basis for efficient initiation of a subsequent adaptive immune response. It comprises a 
number of different innate cell types, specialized in their functions, which have in common 
that they generically recognize pathogens and their activity through a multitude of invariable, 
germline-encoded receptors, such as Toll-like receptors (TLRs) and RIG-I-like receptors (Kumar 
et al., 2011). Aging affects the innate immune system at various levels (Mahbub et al., 2011; 
Shaw et al., 2013), which is hallmarked by low-grade elevated levels of pro-inflammatory 
cytokines, clotting factors and acute phase reactants at steady state, termed “inflamm-aging” 
(Franceschi et al., 2000; Singh and Newman, 2011). Though the exact underlying mechanisms 
are still incompletely understood and highly complex (Morrisette-Thomas et al., 2014), this 
chronic pro-inflammatory basal state renders elderly individuals more prone to frailty and 
functional disability (Ferrucci et al., 1999; Bruunsgaard et al., 2003; Cohen et al., 2003; Matias 
et al., 2014). Beside this systemic phenotype, elderly individuals present also various 
qualitative and quantitative alterations in innate immune cell populations. Though, numbers 
of neutrophils are not decreased in the elderly, their functional and chemotactic capacity is 
compromised (Tseng and Liu, 2014). Data on other granulocyte populations in the context of 
aging is very sparse. Whereas eosinophils show a functional decline with age (Mathur et al., 
2008), basophils exhibit an age-related increased release of histamine upon stimulation 
(Marone et al., 1986) although their absolute number decreases (Cohen et al., 2013). 
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Monocytes are established circulating precursors for tissue macrophages and dendritic cells 
(DCs) and exert important innate functions such as phagocytosis, antigen presentation and 
cytokine production. In peripheral human blood three monocyte subsets can be distinguished: 
CD14++/CD16- classical, CD14++/CD16+ intermediate and CD14+/CD16+ nonclassical monocytes 
(Guilliams et al., 2014), with the latter two being constitutively more activated and superior in 
their capacity at secreting proinflammatory cytokines (Tacke and Randolph, 2006; 
Zimmermann et al., 2010). Elderly individuals exhibit in their monocyte compartments a 
strong skew towards nonclassical monocytes (Sadeghi et al., 1999; Seidler et al., 2010; Hearps 
et al., 2012), In addition, dysregulated monocyte function, such as decreased phagocytosis 
and increased basal TNFα levels (Hearps et al., 2012), likely contribute to the phenotype of 
“inflamm-aging”. 
Immunological aging affects also the peripheral DC compartment (Agrawal et al., 2008; 
Agrawal and Gupta, 2011). Plasmacytoid DCs (pDCs), which are crucial in the defense against 
viral infections through secreting copious amounts of anti-viral type I IFN (Liu, 2005), seem to 
decline in numbers and frequencies with age (Shodell and Siegal, 2002; Pérez-Cabezas et al., 
2007; Jing et al., 2009; Garbe et al., 2012; Orsini et al., 2012). Additionally, studies have shown 
functional impairments in pDCs, such as decreased expression of TLR7 and 9 (Jing et al., 2009; 
Garbe et al., 2012) and diminished secretion of activation-induced type I and III IFNs and TNFα 
(Panda et al., 2010; Qian et al., 2011; Sridharan et al., 2011). Beside pDCs, peripheral blood 
contains myeloid DCs (mDCs), which can be further subdivided into two subsets on the basis 
of CD1c and CD141 expression, termed type I and type II mDCs, respectively. Myeloid DCs are 
very potent antigen-presenting cells that possess the capacity to prime naive T cells with 
antigen of phagocytosed pathogens, thereby eliciting adaptive immunity against infections. 
There are conflicting reports, whether numbers of mDCs decrease or are preserved in elderly 
subjects (Pérez-Cabezas et al., 2007; Jing et al., 2009; Orsini et al., 2012). However it seems 
that similar to pDCs, expression of certain TLRs and secretion of cytokines after stimulation is 
impaired in mDCs from aged individuals (Della Bella et al., 2007; Panda et al., 2010; Qian et 
al., 2011), although antigen-presentation and T-cell stimulation seems to be unaffected 
(Steger et al., 1997; Castle et al., 1999). In respect to “inflamm-aging”, it is of note that an 
increased low-grade basal expression of proinflammatory cytokines such as IL6 and TNFα has 
been observed in unstimulated pDCs and mDCs from the elderly (Panda et al., 2010). 
Natural killer (NK) cells, which are crucial modulators of anti-tumor and anti-viral immunity, 
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exert their function mostly through direct lysis of malign/infected cells and release of 
proinflammatory cytokines such as IFNγ and TNFα. Human NK cells can be broadly divided 
into a CD56bright population which predominantly secretes cytokines and CD56dim NK cells 
which have strong cytotoxic activity. In the elderly, the proportion of CD56bright NK cells 
declines, whereas CD56dim cells expand (Solana and Mariani, 2000). Nevertheless, overall 
cytotoxicity does not increase but rather decreases with age, as cytotoxic capacity on a per-
cell basis diminishes (Mariani et al., 1990; Hazeldine et al., 2012). 
Finally, there are further innate and innate-like cell subsets such as Natural killer T (NKT) cells, 
γδ T cells and mucosal-associated invariant T (MAIT) cells which are as well subject to immune 
aging as reviewed elsewhere (Peralbo et al., 2007; Mocchegiani et al., 2009; Roux et al., 2013; 
Novak et al., 2014; Vasudev et al., 2014). 
Overall, aging of innate immunity reduces the ability to properly respond to infections and to 
initiate the adaptive immune response. For example, reduced neutrophils and NK cell activity 
in the elderly are predictive of increased mortality (Niwa et al., 1989; Ogata et al., 2001) and 
age-impaired TLR function can be associated with reduced vaccine responsiveness (van Duin 
et al., 2007).  
1.4 Aging of the adaptive immune system 
1.4.1 T-cell immunosenescence 
T lymphocytes are major players in cellular adaptive immunity and can be broadly divided into 
CD4+ T cells, predominantly assisting other leukocytes in immunologic processes, and CD8+ T 
cells, which main function is to sense and destroy infected or malign cells. T cells can be 
classified into immunologically naive T cells and antigen-experienced memory or effector 
T cells according to expression of CD45RA and CCR7 (Michie et al., 1992; Sallusto et al., 1999). 
Within the naive CD4+ T-cell compartment, cells having recently emigrated from the thymus, 
the central organ of T-cell generation, can be identified by their expression of CD31 (Kimmig et 
al., 2002). CD4+ T cells can be classified also by their functional fate and the combination of 
cytokines they express (Nakayamada et al., 2012; Swain et al., 2012). Well characterized are 
CD4+ T helper 1 (TH1) and TH2 cells, which are identified by their production of IFNγ and IL4, 
respectively. Further subsets include CD4+ TH17 cells, which secrete IL17, and regulatory CD4+ 
T cells (Treg). 
Aging strongly affects the T-cell compartment (Goronzy and Weyand, 2005). A hallmark is the 
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age-dependent decline of naive T cells, probably because of thymic involution and exposure to 
specific antigen in the periphery (Aspinall and Andrew, 2000). Thymic involution starts already 
in childhood and becomes clearly evident after puberty, although residual thymic activity still 
can be found at advanced age (Flores et al., 1999; Jamieson et al., 1999). Thymectomized 
children, who develop an altered T-cell constitution similar to those in the elderly, served as 
evidence for the impact of reduced thymic output on the naive T-cell compartment (Halnon et 
al., 2005; Prelog et al., 2009; Sauce et al., 2009). In line with this, numbers of CD4+ recent 
thymic emigrants (CD4+ RTE) negatively correlate with chronological age (Kohler and Thiel, 
2009). Whereas in young adults reduced thymic output can be compensated by naive 
peripheral homeostatic proliferation (Kilpatrick et al., 2008), shrinkage of the naive T-cell 
compartment becomes more evident in individuals older than 50 years (Douek et al., 1998; 
Goronzy and Weyand, 2005) and affects more and earlier naive CD8+ T cells than naive CD4+ 
T cells (Fagnoni et al., 2000). Concomitantly, the high diversity of T-cell receptors (TCR) 
expressed by naive T cells declines with age, though this becomes apparent not before the last 
decades of life (Johnson et al., 2012). From animal experiments it has been suggested, that 
the age-related decline in naive T-cell numbers and constrictions in the TCR diversity critically 
affect primary immune responses against pathogens (Yager et al., 2008; Cicin-Sain et al., 2010; 
Blackman and Woodland, 2011). It is very likely that this is true also for the human situation as 
elderly individuals are particularly susceptible to infections of newly arising pathogens, such 
as West Nile Virus or severe acute respiratory syndrome (SARS) coronavirus (Peiris et al., 2003; 
Jean et al., 2007), though this has never been investigated experimentally in humans. 
The other hallmark of T-cell immunosenescence is the age-related inflation of memory and 
effector T cells (Fülöp et al., 2013) especially in the CD8+ T-cell compartment (Czesnikiewicz-
Guzik et al., 2008), due to the individual’s immune exposure history to normal infections and 
particularly to chronic or persistent infections such as human cytomegalovirus (CMV), which 
cause specific T cells to clonally expand through repetitive stimulation (Looney et al., 1999; 
Pourgheysari et al., 2007). As a result, terminally differentiated (memory) T cells accumulate in 
the elderly and dominate the total T-cell compartment. Though, these cells show an 
exhausted phenotype, are less functional and replication senescent (Ouyang et al., 2004; 
Fletcher et al., 2005), their sheer number (Sylwester et al., 2005) provides sufficient control of 
persistent infections, at the expense of other T cells for which they compete for resources and 
space (Almanzar et al., 2005; Weinberger et al., 2007; Brunner et al., 2011). Thus age-related 
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memory inflation is another important mechanism impairing immunity to vaccination and 
infection (Goronzy et al., 2001; Saurwein-Teissl et al., 2002). 
Beside, numerical und phenotypic alterations also numerous age-related T-cell intrinsic 
defects have been reported; though most of the data has been produced in animal models or 
stems from total T-cell populations, not discriminating quantitative aging effects (Chen et al., 
2013). Upon stimulation, naive T cells from aged mice showed defects in T-cell synapses, early 
TCR signaling events as well as cytokine secretion capacity (Poenaru et al., 1990; Sadighi Akha 
and Miller, 2005). The only human data, describes defects in signaling downstream of the TCR 
in naive CD4+ T cells (Li et al., 2012). Hence, not only quantitative but also qualitative 
alterations in naive T-cell compartments might contribute to diminished induction of de-novo 
T-cell responses in aged individuals (Jiang et al., 2013; Appay and Sauce, 2014). 
1.4.2 Senescence of B-cell and humoral immunity  
The primary purpose of the B-cell compartment is to produce antibodies, which are 
indispensable soluble effector molecules capable of neutralizing and opsonizing invading 
pathogens. Naive B cells, generated in the bone marrow, become activated after encountering 
cognate antigen and differentiate into acutely antibody-producing cells (also called 
plasmablasts), long-lived plasma cells or memory B cells, which can be discriminated by 
expression of surface molecules such as IgD, CD27, CD38 and CD138 (Fink, 2012). Studies in 
mouse models and humans revealed that during aging the B-cell compartment becomes 
increasingly dominated by antigen-experienced memory B cells, whereas numbers of naive B 
cells modestly decline (Johnson and Cambier, 2004). Concomitantly, the B cell and antibody 
repertoire of the elderly is less diverse (Gibson et al., 2009), serum antibodies are more 
frequently directed against auto-antigens (Hallgren et al., 1973; Mariotti et al., 1992) and 
antibody affinities are lower than in young adults (Dunn-Walters et al., 2003; Howard et al., 
2006). Also molecular changes, such as decreased expression of activation-induced cytidine 
deaminase (AID) leading to reduced in vitro class switch recombination (Frasca et al., 2008) 
have been documented, though many aspects of cellular dysfunction are still unclear for 
human B cells (Ademokun et al., 2010). Altogether, age-related defects in the B-cell 
compartment in combination with impairments of interacting T-cells and innate cells are 
associated with frailty (Gibson et al., 2009) and reduced humoral immunity to various 
vaccinations as outlined in chapter 1.6. 
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1.5 Influence of persistent viral infections 
Persistent viral infections have been implicated as one of the main factors driving immune 
aging (Brunner et al., 2011). Different viruses, such as CMV, Epstein-Barr virus (EBV), Varicella-
zoster virus (VZV), hepatitis B and C virus or human immunodeficiency virus (HIV) can 
establish chronic infections and constantly challenge the immune system of their host. As 
outlined before, most of these viruses are constantly present in an infected host and thereby 
lead to chronic antigenic stimulation resulting in clonal expansion of memory/effector T cells, 
which has been particularly well examined for CMV persistence (Pawelec, 2013). CMV, 
primarily residing in cells of the myeloid lineage where it can be intermittently reactivated 
(Sinclair, 2008), has a seroprevalence of approximately 60 % for the general population in 
industrialized countries and above 90 % in older persons (Staras et al., 2006), while in 
developing countries it is almost 100 % (Cannon et al., 2010). Similar to what is seen in aging, 
a clonally expanded memory T-cell pool can be observed already in CMV infected young 
adults, which lead to the concept that CMV persistence leads to immunosenescence already 
at relatively young age, or in other words CMV infection accelerates immune aging 
(Weinberger et al., 2007; Chidrawar et al., 2009; Karrer et al., 2009). Additionally, CMV 
infection perpetually affects the NK cell and B cell compartment (Solana et al., 2014; Wang et 
al., 2014) and might be also associated with the phenotype of inflamm-aging, as increased IL6 
and TNFα levels have been observed in CMV positive individuals (Trzonkowski et al., 2003; 
Roberts et al., 2010), though this has been recently challenged (Bartlett et al., 2012). The 
entity of CMV-induced immune alterations probably negatively impacts on vaccination 
outcomes as it has been observed for flu vaccinations (Trzonkowski et al., 2003; Moro-García 
et al., 2012; Derhovanessian et al., 2013), however no such investigations have been 
conducted for primary vaccinations.  
EBV is another widely spread persistent virus having a seroprevalence of over 90 % in the 
general populations (Cohen, 2000). At latency, EBV resides in resting memory B cells (Babcock 
et al., 1998). Although in healthy EBV carriers about 5-10 % of CD8+ T cells are specific for EBV 
epitopes (Tan et al., 1999; Hislop et al., 2002), EBV has not been associated so far with strong 
memory inflation as seen in persistent CMV infection (White et al., 2012), which might be 
attributed to a more dormant latency of EBV than of CMV. Further, EBV-specific T cells seem 
to be qualitatively comparable in young and older carriers (Cárdenas Sierra et al., 2014). 
Instead, the B-cell compartment seems to be strongly affected by EBV persistence as it drives 
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clonal B cell expansion similar to what is seen during aging (Wang et al., 2014), which might 
be disadvantageous in immune responses. Collectively, the contribution of persistent EBV 
infection to immune aging is less apparent than in comparison to CMV, but it is also less well 
understood as many aspects and consequences of EBV persistence on immunosenescence 
have not been investigated yet. 
1.6 Vaccinations in the elderly 
Vaccinations are the most effective medical intervention to prevent infectious diseases. Given 
the increased susceptibility and severity of infections in the elderly, preventive vaccinations 
seem to be the optimal strategy to promote healthy aging. However, the aforementioned age-
related immune impairments, such as innate dysfunction, constrictions in the naive T-cell 
repertoire, memory inflation, humoral defects and co-infection with persistent viruses have to 
be considered when immunizing aged individuals. Indeed, numerous studies have shown that 
vaccination in the elderly is predominantly less effective in comparison to young adults 
(Weinberger and Grubeck-Loebenstein, 2012). Thus, influenza vaccination in young adults 
provides 65-90 % protection, whereas in the elderly only 30-50 % is achieved (Goodwin et al., 
2006; Nichol et al., 2007). Moreover, antibody titers against tetanus and tick-borne 
encephalitis (TBE) virus have been shown to depend on the time since last vaccination, as well 
as on age (Hainz et al., 2005). In this regard, pre-vaccination antibody titers are important as 
they positively influence vaccination outcome (Kaml et al., 2006), indicating that booster 
vaccinations may still induce sufficient protection in aged individuals. Reduced vaccination 
efficiency has not only been shown for inactivated or subunit, but also for live-viral 
immunizations such as VZV vaccines (Levin, 2012). Although the vaccine boosts specific T cells 
and antibodies in the elderly (Levin et al., 1992), the established CD8+ T-cell immunity wanes 
relatively quickly (Patterson-Bartlett et al., 2007), which might be the cause for the poor 
efficiency of only 38 % to prevent shingles in persons aged more than 69 (Oxman et al., 2005). 
Importantly, primary immune responses to vaccination might be even more compromised, as 
illustrated by a 1.5 fold increased risk of non-response for Hepatitis B vaccination among older 
individuals (Fisman et al., 2002). 
With increasing life expectancy and mobility growing numbers of travelers in tropical regions 
are of advanced age (Hill, 2006; Gautret et al., 2012). In addition, rapid aging can be observed 
also in developing countries, where the population is often threatened by a multitude of 
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tropical diseases such as Dengue fever, Japanese encephalitis or yellow fever. Therefore, 
vaccination in travel and tropical medicine in the elderly becomes an increasingly important 
topic. Yet, not many studies have examined the efficiency of travel vaccines in elderly people 
(Leder et al., 2001), which is why such studies are absolutely needed. 
1.7 Vaccination against yellow fever as a model to study primary immune responses in 
humans 
Since its introduction 78 years ago by Theiler (Theiler and Smith, 1937), yellow fever (YF) 
vaccination has been administered to more than half a billion people and proven to be one of 
the most efficient vaccines in humans with an average seroconversion rate of >91 % and 
humoral protection lasting for several decades or even life-long (Poland et al., 1981; Barrett et 
al., 2007). Immunization with this live-attenuated vaccine prevents from wild type yellow 
fever virus (YFV) infection an otherwise highly lethal, mosquito-transmitted disease endemic 
to the tropical regions of Africa and South America. Infection with wild type YFV, a positive-
sense, single-stranded RNA virus of the genus Flavivirus, family Flaviviridae, is in the first days 
characterized by abrupt fever, myalgia and chills potentially progressing in the next days to a 
very severe disease that include serious liver and renal dysfunction, circulatory shock and 
haemorrhage with a 20-50 % fatal outcome (Monath, 2008). As only symptomatic treatment is 
available, vaccination is the only possibility to prevent the disease. 
Current YF vaccines contain the YFV-17D-204 or YFV-17DD strains, deriving from the original 
YFV Asibi strain through multiple passaging. By this, 48 mutations (17D) were introduced, 
which cause in their collectivity the attenuation (Galler et al., 1998). Similar to other 
flaviviruses (Johnston et al., 2000; Wu et al., 2000; Libraty et al., 2001), YFV-17D infects and 
activates monocytes and DCs (Liprandi and Walder, 1983; Barba-Spaeth et al., 2005; Querec et 
al., 2006; Palmer et al., 2007) initiating a strong induction of innate immunity in the first days 
after vaccination (Gaucher et al., 2008; Querec et al., 2009). Furthermore, it is thought that 
the virus disseminates through infected DCs to lymphoid tissues, where it continues to 
replicate (Monath et al., 2006) and finally spreads via the blood stream to its target organs 
such as liver, kidney and heart (Monath and Barrett, 2003). Around day 4 after vaccination a 
transient viremia can be detected in about 60 % of the vaccinees (Reinhardt et al., 1998; 
Monath et al., 2003, 2006), which can be found slightly delayed also in the urine (Domingo et 
al., 2011). About one week after immunization YF-specific antibodies, CD4+ T cells and CD8+ T 
cells start to appear in peripheral blood (Reinhardt et al., 1998; Martins et al., 2007; Barrett 
10 
 INTRODUCTION 
and Teuwen, 2009; Kohler et al., 2012), eventually clearing the infection and giving rise to 
long-lasting cellular and humoral immunity. YF-specific CD4+ T cells precede the cellular 
response peaking between day 10 and day 14 (Kohler et al., 2012), whereas YF-specific CD8+ T 
cells culminate a few days later (Miller et al., 2008; Akondy et al., 2009; Blom et al., 2013). A 
remarkable finding is that in about 90 % of HLA-A0201+ vaccinees up to 87 % of the YF-specific 
CD8+ T-cell response is directed against one single immunodominant epitope in the NS4b 
protein, which still can be detected two years after vaccination (Akondy et al., 2009). 
The YF vaccine is considered to be one of the safest attenuated viral vaccines and most of the 
vaccinees experience only mild reactions such as low-grade fever, mild headache and myalgias 
(Monath et al., 2005; Bae et al., 2008). However, in rare cases serious YFV-related adverse 
events (YF-SAE) can occur, which can manifest as a neurologic (YFV-associated neurotropic 
disease (YEL-AND)) or viscertropic syndrome (YFV-associated viscerotropic disease (YEL-AVD)) 
(Monath, 2012). The incidence for YEL-AND, characterized by a post-vaccinal acute 
encephalitis or meningitis, has been estimated to be about 1:100.000. Risk factors that 
increase susceptibility to YEL-AND are very young age (<6 months) or advanced age (>60 
years), reflecting an immature or age-compromised blood-brain-barrier that allows the virus 
to gain access to the brain or spinal cord (Monath, 2012). Usually the encephalitis is self-
limiting and deaths are rare (1-2 %). This is contrasted by YEL-AVD, a syndrome closely 
resembling a YF-wild type infection (Hayes, 2007), which has a high case-fatality rate of about 
50 %, mostly due to multiorgan failure. YEL-AVD occurs with an incidence of about 1:250.000 
and unlike the live oral polio vaccine, no revertant mutations have so far been found in YF-
vaccine strains that could explain a loss of attenuation (Barrett and Teuwen, 2009). Hence, 
unrestricted spread of YF vaccine virus and fulminant disease progression seen in YEL-AVD 
(Gershman et al., 2012) have been attributed to unfavorable individual immunological 
predispositions. For example, the coincidence of a CCR5-∆32 mutation with polymorphisms in 
RANTES was identified to be detrimental in a single case report of YEL-AVD (Pulendran et al., 
2008). Moreover, studies have shown an increased risk for developing YEL-AVD if vaccinees 
have thymus diseases (e.g. thymectomized individuals and thymoma patients (Eidex, 2004)), 
are strongly immunocompromised (e.g. HIV-infected persons with very low CD4+ T-cell counts 
(Kengsakul et al., 2002), autoimmune patients under immunosuppressive therapy 
(Whittembury et al., 2009; Martins et al., 2014) or are of advanced age (Monath et al., 2005; 
Rafferty et al., 2013). With growing numbers of elderly travelers, the 4-13 fold higher 
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incidence of YEL-AVD in vaccinees aged >60 years becomes particularly precarious and an 
individual risk-benefit analysis is indicated. It is though that mechanisms of 
immunosenescence are the underlying cause for the vulnerability of elderly vaccinees to 
develop YEL-AVD, but only two studies have so far addressed this issue. A retrospective study 
by Monath et al. compared YF-neutralizing antibodies between 2852 young and 257 elderly 
participants, but could not find any difference, though no YEL-AVD was observed in this study 
(Monath et al., 2005). Another much smaller study by Roukens et al. observed a prolonged 
viremia and delayed neutralizing antibody kinetics to YF vaccination in elderly individuals, but 
cellular immune parameters were not assessed (Roukens et al., 2011). Importantly, a 
comprehensive and integrated analysis of immune parameters involved in immunological 
aging in correlation with response kinetics to YF vaccination in aged individuals has never 
been conducted so far. Although this has been repeatedly suggested by several leading 
scientist in the field (Monath et al., 2005; Pawelec et al., 2010; Appay and Sauce, 2014), such a 
study has not been realized so far. 
Beyond pure vaccinology, YF vaccination has caught the attention of basic immunologists as it 
provides the unique opportunity to study experimentally infections in humans (Gaucher et al., 
2008; Ahmed and Akondy, 2011; Kohler et al., 2012). In contrast to naturally acquired 
infections, live-viral YF vaccination permits investigation of the immune response from the 
beginning of infection to the time the virus is eliminated and protective memory is formed 
without complications of virus persistence. Furthermore, YFV is not endemic to Europe and 
the US thereby true primary acute immune responses can be studied in volunteering YF 
vaccinees. Finally, YF vaccine is currently the only licensed live-viral primary immunization that 
is widely applied to adults in Europe and the US, as vaccination against smallpox has become 
obsolete due to its eradication. Thus, YF vaccination is an ideal experimental model infection 
to explore the effects of immunosenescence on a primary acute infection. 
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1.8 Objectives of the thesis 
Elderly people have a higher susceptibility to infections and develop more often severe 
courses of disease, particularly when there is no pre-existing immunity, e.g. in case of newly 
arising pathogens such as West Nile or SARS virus. Moreover, preventive vaccinations, 
especially primary immunizations, have shown to be less effective and less durable in the 
elderly. 
Mechanisms underlying the reduced immune competence to de novo challenges in the elderly 
remain largely obscure. The only data available are derived from studies with aged animals 
that certainly do not model the complexity and variability of human individuals. For these 
reasons, the primary goal of this study was to investigate and compare entire primary acute 
immune responses in young and elderly humans. Furthermore, we wanted to explore the 
impact of features of immunosenescence, such as innate dysfunction, reduced thymic activity 
and co-infection with persistent viruses on primary immune responses. In this respect, we 
intended to identify pre-immune or early immunological signatures that critically influence 
the acute response and the generation of protective memory. Finally, it was the goal to 
explore whether long-term stability of induced immunological memory is altered in the 
elderly. 
To achieve this, we employed live-viral vaccination against yellow fever as a unique and 
powerful model to investigate primary acute infections in humans in an exploratory study. 
Furthermore, we developed a multitude of advanced, polychromatic FACS panels that allowed 
comprehensive characterization of human immunity before, during and after a viral challenge 
at close intervals in a high-throughput manner. Together with important serological 
parameters such as viremia and antibody response, we aimed to generate a detailed picture 
of YF-specific immune responses in young and aged vaccinees. Finally, we explored our data 
set by multivariate and correlation analysis seeking for age-related differences in the YF-
specific immunity and the general immune constitution that could explain the reduced 
responsiveness to infections in the elderly. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Consumables 
Name Vendor 
BD Safety-Lok™ blood collection set 21G BD Biosciences, Plymouth, UK 
BD Vacutainer® 170 U/mL Li-Hep 10 mL  BD Biosciences, Plymouth, UK 
BD Vacutainer® 1.8 mg/mL K2EDTA 2.5 mL BD Biosciences, Plymouth, UK 
BD Vacutainer® SST™ Advance K2EDTA 8.5 mL BD Biosciences, Plymouth, UK 
BD Trucount® tubes  BD Biosciences, San Jose, USA 
Leucosep™ tubes 50 mL Greiner, Kremsmünster, Austria 
Stimulation tubes round-bottom PS 12 mL  Greiner, Kremsmünster, Austria 
FACS tubes round-bottom PS 5 mL BD Biosciences, Bedford, USA 
Conical tube PP 50 mL BD Biosciences, Durham, USA 
Eppendorf tubes 0.5, 1.5, 2.0 mL Safe-Lock™ Eppendorf, Hamburg, Germany 
Serological pipets 1, 5, 10, 25 and 50 mL BD Biosciences, Franklin Lakes, USA 
Pipet tips 10, 100, 1000 µL Greiner, Kremsmünster, Austria 
Riplate®, 96-deep-well, 1.2 mL, PP, v-bottom  Ritter, Schwabmünchen, Germany 
2.1.2 Reagents 
Reagent Vendor/Provider Remarks 
10X BD FACS™ Lysing Solution BD Biosciences, San Jose, USA  
10X BD FACS™ Permeabilizing Solution 2 BD Biosciences, San Jose, USA  
Fixation/Permabilization Concentrate Ebioscience, San Diego, USA  
Fixation/Permabilization Diluent Ebioscience, San Diego, USA  
10X Permeabilization Buffer Ebioscience, San Diego, USA  
Beriglobin CSL Behring, King of Prussia, USA 1 mg/mL in PBS 
Bovine serum albumin (BSA) Roche Applied Science, Penzberg, 
Germany 
 
Brefeldin A Sigma-Aldrich, Munich, Germany 5 mg/mL in 70 % ethanol 
BD GolgiStop™ (Monensin) BD Biosciences, San Jose, USA  
Anti-human CD28 NA/LE BD Biosciences, San Jose, USA 1 mg/mL in PBS 
DMSO Sigma-Aldrich, Munich, Germany  
DAPI Roche, Basel, Switzerland 1 µg/mL in PBS 
Casy®ton Roche, Basel, Switzerland  
EL (Erythrocyte Lysis) buffer Qiagen, Hilden, Germany  
Human AB serum Lonza, Basel, Switzerland Heat-inactivated at 56 °C 
Live/Dead® Fixable Aqua Life Technologies, Carlsbad, USA Solved in 500 µL DMSO 
Live/Dead® Fixable Red Life Technologies, Carlsbad, USA Solved in 500 µL DMSO and 
pre-diluted 1:100 before usage 
Lymphocyte separation medium LSM 
1077 
PAA, Pasching, Austria  
Yellow fever vaccine (Stamaril®) Sanofi Pasteur MSD, Berkshire, UK Used for vaccination 
Yellow fever vaccine (RKI) Robert Koch-Institute, Berlin 
Germany 
Used for stimulation 
1 human dose solved with 
150 µL RPMI/AB 
NS4b 9mer JPT peptide technologies, Berlin, 
Germany 
LLWNGPMAV 0.25 µg/µL in 
50 % DMSO / 50 % PBS  
Staphylococcus enterotoxin B (SEB) Sigma-Aldrich, Munich, Germany 1.5 µg/µL in PBS 
Toxic shock syndrome toxin 1 (TSST1) Sigma-Aldrich, Munich, Germany 1.0 µg/µL in PBS 
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CMV pp65 peptide pool JPT peptide technologies, Berlin, 
Germany 
Swiss Prot ID.: P06725, 
138 15mers, 11 aa overlap, 
0.25 µg/µL per peptide solved 
in 50 % DMSO / 50 % PBS 
CMV IE-1 peptide pool JPT peptide technologies, Berlin, 
Germany 
NCBI seq.: CAA35325.1, 
120 15mers, 11 aa overlap, 
0.25 µg/µL per peptide solved 
in 50 % DMSO / 50 % PBS 
EBV EBNA1 peptide pool JPT peptide technologies, Berlin, 
Germany 
NCBI seq.: YP401677, 
158 15mers, 11 aa overlap 
0.25 µg/µL per peptide solved 
in 50 % DMSO / 50 % PBS 
EBV BZLF1 peptide pool JPT peptide technologies, Berlin, 
Germany 
NCBI seq.: YP_401673, 
59 15mers, 11 aa overlap 
0.25 µg/µL per peptide solved 
in 50 % DMSO / 50 % PBS 
Penicillin Merckmillipore, Darmstadt, 
Germany 
 
Streptomycin Merckmillipore, Darmstadt, 
Germany 
 
Gibco® RPMI 1640 GlutaMAX™ cell 
culture medium 
Life Technologies, Carlsbad, USA  
10X PBS pH 7.2 Life Technologies, Carlsbad, USA  
EDTA Merckmillipore, Darmstadt, 
Germany 
 
BD FACSFlow™ BD Biosciences, San Jose, USA  
MACSQuant Storage Solution Miltenyi, Bergisch-Gladbach, 
Germany 
 
MACSQuant Washing Solution Miltenyi, Bergisch-Gladbach, 
Germany 
 
MACSQuant Running Buffer Miltenyi, Bergisch-Gladbach, 
Germany 
 
SPHERO™ Rainbow Calibration Particles BD Biosciences, San Jose, USA  
Millipore H2O   
2.1.3 Kits 
Kit name Vendor 
Anti-Flavivirus mosaic IIFA Euroimmun, Lübeck, Germany 
Anti-Yellow fever virus IIFA with IgM, IgG, IgA Euroimmun, Lübeck, Germany 
CMV IgG-Elisa PCS Medac, Wedel, Germany 
EBV IgG-Elisa PCS Medac, Wedel, Germany 
QIAamp viral RNA minikit Qiagen, Hilden, Germany 
QuantiTect Virus + ROX Vial kit Qiagen, Hilden, Germany 
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2.1.4 Solutions 
Solution Preparation 
1X PBS 10X PBS diluted 1:10 in H2O 
1X PBS/BSA 1X PBS + 5 g/L BSA 
20 nM EDTA EDTA solved in PBS 
1X BD FACS™ Lysing Solution 10X BD FACS™ Lysing Solution 1:10 in H2O 
1X BD FACS™ Permeabilizing Solution 2 10X BD FACS™ Permeabilizing Solution 2 1:10 in H2O 
1X FoxP3 fixation buffer Fixation/Permabilization Concentrate diluted 1:4 with 
Fixation/Permabilization Diluent 
1X FoxP3 permeabilization buffer  10X Permeabilization Buffer diluted 1:10 in H2O 
RPMI/AB RPMI + 10 % AB serum + 100 U/mL Penicillin + 0.1 mg/mL 
Streptomycin  
2.1.5 Software 
Software Vendor/Provider 
BD FACSDiva 6 BD Biosciences, San Jose, USA 
MACSQuantify software Miltenyi, Bergisch-Gladbach, Germany 
Flowjo 9.7.x Tree Star, Ashland, USA 
SPICE 5.3 Joshua Nozzi & Mario Roederer, Vaccine Research Center, NIAID, NIH 
Pestle 1.7 Mario Roederer, Vaccine Research Center, NIAID, NIH 
GraphPad Prism 5.x GraphPad Software, La Jolla, USA 
R 3.02 R Foundation for Statistical Computing, Vienna, Austria 
2.1.6 Equipment 
Device Vendor 
CO2 incubator Innova CO-170 New Brunswick Scientific, Enfield, USA 
BD™ LSR II flow cytometer BD Biosciences, San Jose, USA 
MACSQuant® analyzer Miltenyi, Bergisch-Gladbach, Germany 
Eppendorf Research® pipets  Eppendorf, Hamburg, Germany 
Pipetboy® pipet controller Integra, Zizers, Switzerland 
HERAsafe® biosafety cabinet Heraeus, Hanau, Germany 
Centrifuges 5804R and 5810R Eppendorf, Hamburg, Germany 
Centrifuges Microfuge® 22, Allegra® X-15R and X22 Beckman Coulter, Krefeld, Germany 
Vortex Mixer VWR International, Darmstadt, Germany 
CASY Model TTC cell counter Roche Applied Science, Penzberg, Germany 
Nalgene® Test tube rack, 16 mm for stimulation Thermo Fisher Scientific, Waltham, USA 
Vacuum pump BVC 21 Vacuubrand, Wertheim, Germany 
ELISA processor BEP III Siemens, Erlangen, Germany 
Sysmex XE-5000 Sysmex, Kobe, Japan 
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2.1.7 Optical configurations of flow cytometers 
Table 2.1: Laser and optical filter settings on LSR II 
LSR II 
W
B leukocyte 
counting panel 
Dendritic cell 
panel 
Recent thym
ic 
em
igrant panel 
T-cell activation 
panel 
W
B CD4
+ T-cell 
stim
. panel &
 
PBM
C stim
. panel 
Laser line Detector name 
Long 
pass 
Band 
pass 
Long 
pass 
Band 
pass 
Long 
pass 
Band 
pass 
Long 
pass 
Band 
pass 
Long 
pass 
Band 
pass 
Blue 
488 nm 
SSC n.a. 488/10 n.a. 488/10 n.a. 488/10 n.a. 488/10 n.a. 488/10 
B525 505 525/50 505 525/50 505 525/50 505 525/50 505 525/50 
B685 685 710/40 685 710/40 685 710/40 685 710/40 685 710/40 
Yellow-
green 
561 nm 
YG582 n.a. 582/15 n.a. 582/15 n.a. 582/15 n.a. 582/15 n.a. 582/15 
YG610 600 610/20 600 610/20 600 610/20 600 610/20 600 610/20 
YG670 630 670/14 630 670/14 630 670/14 630 670/14 630 670/14 
YG710 685 710/50 685 710/50 685 710/50 685 710/50 685 710/50 
YG780 755 780/60 755 780/60 755 780/60 755 780/60 755 780/60 
Red 
640 nm 
R660 n.a. 660/13 n.a. 660/13 n.a. 660/13 n.a. 660/13 n.a. 660/13 
R720 685 720/30 685 720/30 685 720/30 685 720/30 685 720/30 
R780 755 780/60 755 780/60 755 780/60 755 780/60 755 780/60 
Violet 
405 nm 
V450 n.a 450/50 n.a 450/50 n.a 450/50 n.a 450/50 n.a 450/50 
V525 505 525/50 505 525/50 505 525/50 505 525/50 505 525/50 
V610 595 610/20 595 610/20 570 575/25 570 575/26 595 610/20 
V710 685 710/50 650 661/20 595 610/20 595 610/20 650 661/20 
V780 755 780/60 755 780/60 650 661/20 755 780/60 755 780/60 
 
Table 2.2: Laser and optical filter settings on MACSQuant 
MACS 
Quant 
W
B leukocyte 
counting panel 
B cell panel 
N
K cell panel 
Laser line Detector name Filter Filter Filter 
Blue 
488 nm 
SSC 488/10 488/10 488/10 
B525 525/50 525/50 525/50 
B585 585/40 585/40 585/40 
B655 655LP 655LP 655LP 
B750 750LP 750LP 750LP 
Red 
633 nm 
R655 655LP 655LP 655LP 
R750 750LP 750LP 750LP 
Violet 
405 nm 
V450 450/50 450/50 450/50 
V525 525/50 525/50 525/50 
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2.2 Methods 
2.2.1 Vaccination and study cohort 
Approval for the study was obtained from the ethics committee of the Faculty of Medicine - 
Charité, Humboldt University Berlin. After informed consent and prior vaccination sera of 26 
volunteers were analyzed for potentially cross-reactive antibodies against flaviviruses by a 
Euroimmun anti-Flavivirus mosaic indirect immunofluorescence assay (IIFA) (Chap. 2.2.2). Two 
donors showed tick-borne encephalitis virus-specific antibodies and hence were omitted from 
analysis. Another donor retrospectively demonstrated unusual immunological features (high 
steady state T-cell activation) preventing proper evaluation and was therefore excluded from 
analysis as well. The remaining 23 volunteers were assigned into two age groups: “Young” 
(11 donors, 20-30 years, median age 26 years, 5 female/6 male) and “Elderly” (12 donors, 
55-70 years, median age 60 years, 5 female/7 male). The upper age limit for participation was 
70 years set by the ethical approval. Health status and current medication was assessed by 
questionnaire to exclude individuals with acute illness, a history of cancer, autoimmune 
disease, allergies or innate or acquired immunosuppression. Two of the elderly subjects were 
on medication for hypertension, 1 for Diabetes mellitus type II and 1 for benign prostatic 
hyperplasia. Immunization was performed by a single subcutaneous injection of YFV-17D 
vaccine (Stamaril®). Any adverse reactions (erythema, swelling, myalgia, fever) were 
documented. Fifty mL of venous blood was drawn immediately before vaccination (day 0) and 
at eight further time-points (day 2 (only donors 15 to 28), 4, 7, 10, 14, 17, 21 and 28) after 
vaccination into sodium heparin, serum gel or EDTA tubes. To study long-term YF-specific 
memory formation and stability, we collected in each case 50 mL of venous blood from 19 of 
23 vaccinees re-invited 33 (donor 1 - 6), 30 (donor 8 - 14) or 20 (donor 15 - 27) months after 
vaccination. Heparinized blood was processed and analyzed directly. Sera were stored 
at -80 °C until use. 
2.2.2 Anti-Flavivirus mosaic indirect immunofluorescence assay 
In order to exclude individuals with pre-existing, potentially cross-reactive antibodies against 
flaviviruses, an anti-Flavivirus mosaic IIFA specific for YF wildtype and vaccine virus, Japanese 
encephalitis virus, dengue virus (type 1-4), tick-borne encephalitis virus and West Nile virus 
was performed according to the manufacturer’s protocol by the group of Prof. Niedrig, 
19 
 MATERIALS AND METHODS 
Robert Koch-Institute (RKI), Berlin. Briefly, sera from day 0 were diluted 1:10 and applied to 
the reaction fields of a reagent tray. Then, a microscope slide containing the flavivirus mosaic 
biochips was placed upside down on the reagent tray. After 30 min of incubation at RT and a 
PBS/Tween buffer washing step, biochips were incubated with FITC-labeled anti-human IgG. 
Titers of pre-existing flavivirus-crossreactive antibodies were determined by fluorescence 
microscopy according to the Euroimmun standard procedure based on fluorescence intensity. 
Titers of ≥1∶10 were considered positive. 
2.2.3 Detection of serum viremia with quantitative real-time PCR (RT-PCR) 
Sera were tested for the presence of YFV-17D genomes at days 0, 2, 4, 7 and 10 after 
vaccination by quantitative RT-PCR as described elsewhere (Domingo et al., 2012) in 
collaboration with the group of Prof. Niedrig, RKI, Berlin. In short, viral RNA was extracted 
with a QIAamp viral RNA minikit. Next, a quantitative RT-PCR was performed with the 
QuantiTect Virus + ROX Vial kit, using YF-specific primers and 2 µL of viral RNA in a 25 µL 
reaction. In order to standardize the measurement, a serial dilution of in-vitro generated viral 
RNA of known concentration was simultaneously run. The assay has a limit of detection of 
0.8 plaque forming units per mL (95 % CI). 
2.2.4 Assessment of YF-specific serum response 
We examined the YF-specific IgM, IgG and IgA response at all study days in collaboration with 
the group of Prof. Niedrig using an anti-Yellow fever virus IIFA. For IgM and IgA analysis, sera 
were pre-diluted 1:10 and for IgG analysis 1:100. Then, samples were incubated with anti-
Yellow fever virus biochips as described in chap. 2.2.2 After this, biochips were incubated 
either with FITC-labeled anti-human IgM, IgA or IgG. Antibody titers were determined by 
fluorescence microscopy according to the Euroimmun standard procedure, rating 
fluorescence intensities in levels from 0 to 5. In a 1∶10 dilution, level 1 was rated as an 
antibody titer of 1∶10, level 2 as 1∶32, level 3 as 1∶100 and level 4 and 5 were rated as more 
than 1∶100. Accordingly, in a 1:100 dilution, level 1 was rated as 1:100, level 2 as 1:320 and so 
on. Titers above 1:10 (IgM, IgA) or 1:100 (IgG) were considered positive. 
2.2.5 Plaque reduction neutralization test (PRNT90) 
PRNT90 assays of stored sera from all study time-points were carried out by the group of Prof. 
Niedrig, according to the protocol established by Reinhardt (Reinhardt et al., 1998). Briefly, 
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two-fold dilutions of sera ranging from 1:10 to 1:320 were prepared and mixed with YFV-17D 
in DMEM. After 1 h of incubation at 37 °C, 1.2x105 PS cells were added to each dilution and 
the mixes (400 µL) were plated into a 24 well plate. After 4 h of incubation at 37 °C in the 
incubator, cultures were overlaid with 400 µL high-viscous carboxylmethyl cellulose DMEM. 
Plaques were counted after 4 days of incubation at 37 °C, 3.7 % formaldehyde fixation and 
naphthalene black staining. The 90 % neutralization titers were calculated according to Reed 
and Muench (Reed and Muench, 1938) 
2.2.6 Complete blood count 
Complete blood counts were performed by Labor Berlin – Charité Vivantes GmbH, Berlin, 
Germany for vaccinees 8 – 28. For this freshly collected EDTA blood was analyzed by the 
automated cell counter Sysmex XE-5000 for absolute whole blood number of leukocytes, 
lymphocytes, monocytes, basophils, eosinophils and neutrophils. 
2.2.7 CMV and EBV serology 
Specific IgG responses against CMV and EBV were measured in day 0 sera of all vaccinees in 
cooperation with Labor Berlin – Charité Vivantes GmbH, Berlin, Germany. Sera were 
automatically analyzed with the CMV or EBV IgG-Elisa PCS on an ELISA processor BEP III. 
2.2.8 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMCs were isolated from freshly drawn heparinized whole blood in 50 mL Leucosep tubes 
filled with 14 mL Ficoll-Hypaque (LSM 1077) according to the manufacturer’s protocol. In brief, 
blood was diluted 1:1 with PBS/BSA and transferred to Leucosep tubes. Following 10 min of 
centrifugation at 1000 g at RT, supernatant above the leukocyte layer was removed and 
PBMCs were recovered by pouring them into a fresh 50 mL tube. Next, PBMCs were washed 
twice with PBS/BSA by centrifugation at 490 g, 10 min 4 °C and 180 g, 15 min, 4 °C, 
respectively. Finally, a sample of 10 µL of PBMCs was counted with a CASY Model TTC cell 
counter equipped with a 150 µm capillary and with exclusion of cell debris and dead cells. 
Finally, PBMCs were re-suspended at a concentration of 1x107 cells/mL with PBS/BSA and 
freshly used in subsequent assays. 
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2.2.9 Flow cytometric analysis 
2.2.9.1 Analysis of absolute frequencies of leukocyte populations in peripheral blood 
To determine absolute counts of the analyzed leukocyte populations in freshly drawn 
peripheral blood, 50 µL of heparinized whole blood was incubated for 15 min at RT with 50 µL 
fluorescence-labeled monoclonal antibody cocktail (Table 2.3). Exact volumes were achieved 
by reverse pipetting. Staining was stopped and erythrocytes lysed by adding 500 µL Buffer EL. 
Following 15 min incubation at 4 °C, samples were immediately analyzed on a MACSQuant or 
LSR II flow cytometers without prior centrifugation. The optical configurations are listed in 
table 2.1 and 2.2. The cell trigger on the instruments was set to the CD45 channel. An example 
gating strategy is depicted in Fig. 2.1. By analyzing a defined sample up-take volume (350 µL), 
MACSQuant gave direct cell counts for the labeled populations. Cell counts measured on the 
LSR II were based on the use of BD TruCount™ tubes containing a defined number of 
fluorescent quantification beads. Counts of major leukocyte populations were used for 
calculations of any given cell subpopulation determined by other FACS panels. 
Table 2.3: Antibody cocktails for whole blood leukocyte counting 
Name Fluorochrome Clone Isotype Vendor/Provider Dilution 
Whole blood leukocyte counting panel (Round 1 & 2, LSR II) 
CD3 PacBlue OKT3 mouse IgG2a Biolegend 1:50 
CD8 efluor605 RPA-T8 mouse IgG1 Ebioscience 1:50 
CD14 FITC M5E2 mouse IgG2a BD Biosciences 1:50 
CD4 PerCpCy5.5 OKT4 mouse IgG2b Biolegend 1:50 
CD19 PE BU12 mouse IgG1 in house DRFZ 1:200 
CD56 PECy7 NCAM16.2 mouse IgG2b BD Biosciences 1:50 
CD11c APC MJ4-27G12 mouse IgG2b Miltenyi 1:20 
CD45 APCCy7 HI30 mouse IgG1 Biolegend 1:20 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Whole blood leukocyte counting panel (Round 3, MACSQuant) 
CD14 Vioblue TÜK4 mouse IgG2a Miltenyi 1:100 
CD45 Viogreen 5B1 mouse IgG2a Miltenyi 1:20 
BDCA2 FITC AC144 mouse IgG1 Miltenyi 1:100 
CD56 PE AF12-7H3 mouse IgG1 Miltenyi 1:40 
CD8 PerCp BW135/80 mouse IgG2a Miltenyi 1:10 
CD19 PEVio770 LT19 mouse IgG1 Miltenyi 1:20 
CD4 APC VIT4 mouse IgG2a Miltenyi 1:20 
CD3 APCH7 SK7 mouse IgG1 BD Biosciences 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
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Figure 2.1: Gating strategy for the whole blood counting panel measured on MACSQuant. 
Cells from lysed whole blood were gated on CD45. After exclusion of cell aggregates, pDCs were directly 
determined by expression of BDCA2. Alternatively monocytes (CD14+) and B cells (CD19+) were identified. Cells 
being neither a monocyte nor a B cell were further distinguished into T cells (CD3+) and NK cells (CD56+). T cells 
were sub-divided into CD4+ and CD8+ T cells. Calculations of whole blood cell counts from other panels based on 
measured events of populations determined in this panel. Depicted is donor 15 (young) at day 0. 
2.2.9.2 Dendritic cell panel 
Innate cell subsets, such as monocytes and DCs were assessed by a 12-color FACS panel on 
days 0, 4, 7, 10, 14, 17, 21 and 28. For this, 5x106 PBMCs of each donor re-suspended in 60 µL 
PBS/BSA were stained with 40 µL fluorescence-labeled monoclonal antibody cocktail (Table 
2.4) for 15 min at RT and in the dark in FACS tubes. Then, cells were washed once with 
PBS/BSA (490 g, 10 min, 4 °C) and analyzed on a LSR II flow cytometer (optical filter setting see 
table 2.1). Prior acquisition DAPI was added at concentration of 0.01 µg/mL. Figure 2.2 
illustrates the gating strategy for this panel. We identified the following innate cell types: 
plasmacytoid DCs, myeloid DCs type I and type II, classical monocytes, intermediate 
monocytes, nonclassical monocytes and basophils. Absolute whole blood counts of these cell 
populations were calculated based on events acquired in the CD14++ gate. 
Table 2.4: Antibody cocktail for dendritic cell panel 
Name Fluorochrome Clone Isotype Vendor Dilution 
Dendritic cell panel (LSR II) 
CD56 BV421 HCD56 mouse IgG1 Biolegend 1:100 
CD19 V500 HIB19 mouse IgG1 BD Biosciences 1:100 
CD3 V500 SP34-2 mouse IgG1 BD Biosciences 1:50 
CD14 efluor605 61D3 mouse IgG1 Ebioscience 1:50 
CD123 efluor650 6H6 mouse IgG1 Ebioscience 1:50 
BDCA2 FITC AC144 mouse IgG1 Miltenyi 1:100 
BDCA1 (CD1c) PerCpCy5.5 L161 mouse IgG1 Biolegend 1:50 
BDCA3 (CD141) PE AD5-14H12 mouse IgG1 Miltenyi 1:10 
HLA-DR PECy7 L243 mouse IgG2a Biolegend 1:100 
CD11c APC MJ4-27G12 mouse IgG2b Miltenyi 1:20 
CD16 Alexa700 3G8 mouse IgG1 Biolegend 1:100 
CD45 APCH7 2D1 mouse IgG1 BD Biosciences 1:200 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
23 
 MATERIALS AND METHODS 
 
Figure 2.2: Gating strategy for the dendritic cell panel. 
For analysis of innate cell subsets from PBMCs, a broad gate was used for the pre-selection of leukocyte scatter. 
After exclusion of cell aggregates, CD45+/CD3-/CD19-/live cells were selected and NK cells (HLA-DR-/CD56+) 
excluded. From remaining cells monocytes subsets were determined by gating on CD14 and CD16. Intermediate 
monocytes were distinguished from classical monocytes by their increased expression of HLA-DR. Cells that did 
not belong to any monocyte subset were further analyzed for their HLA-DR expression. HLA-DR-/CD123+ cells 
could be identified as basophils, whereas HLA-DR+ cells were DCs. Within the DC population, pDCs were defined 
as BDCA2+/CD123+. DCs, negative for BDCA2 and CD123 were assessed for their expression of CD11c (expressed 
by all mDCs) and CD141 (positive on type 2 mDCs (mDC2) only). Lastly, CD141neg cells were examined for their 
expression of BDCA1 defining type 1 mDCs (mDC1). Depicted is donor 15 (young) at day 0. 
2.2.9.3 Recent thymic emigrant (RTE) panel 
RTEs, a subset of naive CD4+ T cells, were assessed on day 0 by an 11-color FACS panel. The 
general staining procedure was similar to the DC panel staining, except for the incubation 
temperature, which was 37 °C. The antibody cocktail used is listed in table 2.5. Optical filter 
settings on LSR II are shown in table 2.1. Figure 2.3 illustrates the gating strategy for RTEs. 
Absolute whole blood counts of cell populations were calculated based on events acquired in 
the CD4+ gate. This panel included also an anti-HLA-A2 staining, which allowed discrimination 
of HLA-A0201 positive and negative individuals. 
Table 2.5: Antibody cocktail for RTE panel 
Name Fluorochrome Clone Isotype Vendor Dilution 
Recent thymic emigrant panel (LSR II) 
CD45RO PacBlue UCHL1 mouse IgG2a Biolegend 1:50 
CD8 BV570 RPA-T8 mouse IgG1 Biolegend 1:50 
CD45RA efluor605 HI100 mouse IgG2b Ebioscience 1:100 
CD3 efluor650 OKT3 mouse IgG2a Ebioscience 1:50 
HLA-A2 FITC BB7.2 mouse IgG2b Biolegend 1:200 
CCR7 PerCpCy5.5 G043H7 mouse IgG2a Biolegend 1:50 
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Name Fluorochrome Clone Isotype Vendor Dilution 
CD31 PE WM59 mouse IgG1 Biolegend 1:100 
CD27 PECy7 M-T271 mouse IgG1 BD Biosciences 1:100 
CD62L APC DREG-56 mouse IgG1 Biolegend 1:50 
CD4 Alexa700 OKT4 mouse IgG2b Biolegend 1:200 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
 
Figure 2.3: Gating strategy for RTE panel. 
RTEs and other CD4+ and CD8+ T-cell subsets were analyzed in PBMCs by gating on lymphocytes by light scatter 
and excluding cell aggregates and dead cells. T cells were identified by CD3 expression and further sub-divided 
into CD4+ and CD8+ T cells. For determination of RTEs, CD4+ T cells were sequentially gated on several markers 
indicating the naivety, such as CD45RA, CD27 and CD62L. From these naive CD4+ T cells, RTEs could be assessed 
by their expression of CD31. For determination of T-cell subsets such as naive, central-memory (CM), effector-
memory (EM) and effector (Eff) T cells, CD4+ or CD8+ T cells were investigated for combinatorial expression of the 
markers CD45RA and CCR7, respectively. Depicted is donor 15 (young) at day 0. 
2.2.9.4 B-cell panel 
Various B-cell subsets were examined at days 0, 4, 7, 10, 14, 17, 21 and 28 after vaccination. 
For this, 5x106 PBMCs of each donor were transferred into a 96-deep well plate. Then, PBMCs 
were spun down at 490 g, 10 min, 4 °C and supernatant was completely removed. Next, each 
cell pellet was re-suspended in 90 µL PBS/BSA and 22 µL of fluorescence-labeled monoclonal 
antibody cocktail (Table 2.6) was added. This surface staining was performed at RT for 15 min. 
After 5 min of incubation 1 µL of L/D Aqua was supplemented to each well and the plate was 
shortly vortexed. Staining was stopped by adding 800 µL PBS/BSA, then cells were centrifuged 
10 min, 310 g, 4 °C and supernatant was removed. Next, surface stained PBMCs were fixed by 
re-suspension in 800 µL 1X BD FACS Lysing solution for 10 min at RT. Fixed cells were directly 
spun down (10 min, 490 g, 4 °C), supernatant discarded and 300 µL 1X BD Perm 2 solution 
added to each well in order to permeabilize the samples. The reaction was stopped by adding 
700 µL PBS/BSA, followed by a centrifugation step (10 min, 490 g, 4 °C). Fixed and 
permeabilized PBMCs were washed again with 1 mL PBS/BSA (10 min, 490 g, 4 °C) and 
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supernatant was discarded. Finally, each cell pellet was re-suspended in 100 µL PBS/BSA and 
intracellularly stained 30 min at RT for Ki-67 expression. After a washing step with 900 µL 
PBS/BSA and final centrifugation (10 min, 490  g, 4 °C), each cell pellet was re-suspended in 
400 µL PBS/BSA and automatically acquired on a MACSQuant flow cytometer (uptake volume 
300 µL) with an optical configuration listed in table 2.2. An exemplary gating is shown in 
fig. 2.4. Absolute whole blood counts of cell populations were calculated based on events 
acquired in the CD19+ gate. 
Table 2.6: Antibody cocktail for B-cell panel 
Name Fluorochrome Clone Isotype Vendor Dilution 
B-cell panel (MACSQuant) – surface staining 
CD3 V500 SP34-2 mouse IgG1 BD Biosciences 1:50 
CD14 V500 M5E2 mouse IgG2a BD Biosciences 1:100 
IgD FITC IA6-2 mouse IgG2a Biolegend 1:20 
CD19 PE BU12 mouse IgG1 in house DRFZ 1:200 
CD20 PerCp LT20 mouse IgG1 Miltenyi 1:20 
CD38 PECy7 HIT2 mouse IgG1 Biolegend 1:100 
CD27 APC L128 mouse IgG1 BD Biosciences 1:20 
HLA-DR APCH7 G46-6 mouse IgG2a BD Biosciences 1:100 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
B-cell panel (MACSQuant) – intracellular staining 
Ki-67 V450 B56 mouse IgG1 BD Biosciences 1:50 
 
Figure 2.4: Gating strategy for the B-cell panel. 
B-cell subsets and their proliferation status were assessed in fixated PBMCs by loosely gating on lymphocytes by 
light scatter and excluding cell aggregates and dead cells. Then B cells were identified by gating on CD19+ cells 
omitting cells expressing CD3 and CD14. A relatively large CD19 gate was used to prevent unintended trimming of 
plasmablast having a low CD19 expression. Plasmablasts were identified in CD19low/+ cells by the high co-
expression of CD38 and CD27. To ensure correct plasmablast assignment, CD38+/CD27+ cells were checked for 
absence of CD20 expression. Reported percentages of plasmablasts always refer to CD19low/+ B cells. Other B-cell 
subsets were determined from plasmablast negative and CD19low/+ B cells (Boolean gating). Expression of IgD and 
CD27 allowed for differentiation of memory (IgD-/CD27+) and naive (IgD+/CD27-) B cells, which were further 
analyzed for their proliferation status by Ki-67 expression. Depicted is donor 15 (young) at day 0. 
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2.2.9.5 NK-cell panel 
NK cells were assessed at days 0, 4, 7, 10, 14, 17, 21 and 28 after vaccination. The protocol 
used was similar to the B cell panel staining procedure. The antibody cocktail is listed in table 
2.7. Automated acquisition was done on a MACSQuant (uptake volume 300 µL) with an optical 
configuration listed in table 2.2. An exemplary gating is shown in fig. 2.5. Absolute whole 
blood counts of cell populations were calculated based on events acquired in the CD56+ gate.  
Table 2.7: Antibody cocktail for NK-cell panel 
Name Fluorochrome Clone Isotype Vendor Dilution 
NK-cell panel (MACSQuant) – surface staining 
CD56 BV421 HCD56 mouse IgG1 Biolegend 1:100 
CD3 V500 SP34-2 mouse IgG1 BD Biosciences 1:50 
CD14 Viogreen TÜK4 mouse IgG2a Miltenyi 1:20 
CD62L PE DREG-56 mouse IgG1 Biolegend 1:20 
CD27 PerCp O323 mouse IgG1 Biolegend 1:150 
CD69 PECy7 FN50 mouse IgG1 Biolegend 1:200 
CD57 Alexa647 HCD57 mouse IgM Biolegend 1:80 
CD16 APCH7 3G8 mouse IgG1 BD Biosciences 1:200 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
NK-cell panel (MACSQuant) – intracellular staining 
Ki-67 Alexa488 B56 mouse IgG1 BD Biosciences 1:100 
 
Figure 2.5: Gating strategy for NK-cell panel 
NK-cell subsets and their proliferation status were assessed in fixated PBMCs by gating on lymphocytes by light 
scatter and excluding cell aggregates and dead cells. Then, NK cells were identified by gating on CD56+ cells 
omitting cells expressing CD3 and CD14. Next, CD56bright NK cells were distinguished from CD56dim NK cells by the 
help of CD16, that is higher expressed in the latter. CD56bright NK cells were almost exclusively CD62L+ and CD57-, 
whereas CD56dim NK cells could be sub-divided into four subsets by both markers. Depicted is donor 15 (young) 
at day 0. 
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2.2.9.6 T-cell activation panel 
Diverse T-cell subsets and their activation and proliferation status were analyzed at days 0, 2, 
4, 7, 10, 14, 17, 21 and 28 after vaccination. This included also measurement of regulatory 
T-cells in donors 15 to 28. For this, 5x106 PBMCs of each donor re-suspended in 100 µL 
PBS/BSA were surface stained with 11 µL fluorescence-labeled monoclonal antibody cocktail 
(Table 2.8) for 15 min at 37 °C and in the dark in FACS tubes. After 5 min of incubation 1 µL L/D 
Red was supplemented to each sample. Next, staining was stopped by washing PBMCs with 
4 mL PBS/BSA and centrifugation (10 min, 490 g, 4 °C). Then, stained cells were fixed by re-
suspending them in 1 mL 1X FoxP3 fixation buffer. After an incubation of 30 min in the dark at 
4 °C, fixed cells were washed once with PBS/BSA and spun down (10 min, 490 g, 4 °C). In order 
to permeabilize the samples, PBS/BSA supernatant was removed and cell pellets re-suspended 
in 1X FoxP3 permeabilization buffer. Cells were directly centrifuged (10 min, 490 g, 4 °C) and 
supernatant carefully removed. Next, PBMCs were again re-suspended in 70 µL 1X FoxP3 
permeabilization buffer and intracellularly stained 30 min at RT with 30 µL antibody cocktail 
listed in Table 2.8. After a final washing step with 1X FoxP3 permeabilization buffer, cells were 
centrifuged (10 min, 490 g, 4 °C) and pellets re-suspended in 250 µL PBS/BSA. Samples were 
acquired on a LSR II flow cytometer with an optical filter configuration listed in table 2.1. An 
exemplary gating is shown in fig. 2.6. All calculations of absolute whole blood cell counts for 
this panel based on the CD3+ gate. 
Table 2.8: Antibody cocktails for T-cell activation panel 
Name Fluorochrome Clone Isotype Vendor Dilution 
T-cell activation panel (LSR II) – surface staining 
CD8 BV570 RPA-T8 mouse IgG1 Biolegend 1:50 
CD45RA efluor605 HI100 mouse IgG2b Ebioscience 1:100 
CCR7 PerCpCy5.5 G043H7 mouse IgG2a Biolegend 1:50 
γδTCR PE 11F2 mouse IgG1 BD Biosciences 1:20 
CD19 PE-CF594 HIB19 mouse IgG1 BD Biosciences 1:100 
CD14 PE-CF594 MφP9 mouse IgG2b BD Biosciences 1:100 
CD38 PECy7 HIT2 mouse IgG1 Biolegend 1:100 
CD4 Alexa700 OKT4 mouse IgG2b Biolegend 1:200 
HLA-DR APCH7 G46-6 mouse IgG2a BD Biosciences 1:100 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
T-cell activation panel (LSR II) – intracellular staining 
Ki-67 V450 B56 mouse IgG1 BD Biosciences 1:50 
CD3 V500 SP34-2 mouse IgG1 BD Biosciences 1:50 
FoxP3 Alexa488 259D/C7 mouse IgG1 BD Biosciences 1:5 
Helios Alexa647 22F6 ar. hamster IgG BD Biosciences 1:40 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
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Figure 2.6: Gating strategy for T-cell 
activation panel  
T-cell subsets and their 
activation/proliferation status were 
analyzed in fixated PBMCs by gating on 
lymphocytes by light scatter. Next non-
T cells and dead cells were excluded and 
CD3+ T cells were selected. Staining for 
γδTCR distinguished γδ T cells from 
mostly αβ T cells, which were further 
segregated into several subsets for 
example CD4+, CD8+ and CD4+/CD8+ T 
cells. Within the CD4+ T-cell 
compartment we distinguished between 
natural regulatory T cells (nTreg) and 
conventional CD4+ T cells by co-expression of the transcription factors FoxP3 and Helios. From all T-cell subsets 
we could determine the sub-phenotypes (Naive, CM, EM and Eff) by combinatorial expression of CD45RA and 
CCR7. Additionally, we could determine the activation/proliferation status by assessing CD38, HLA-DR and Ki-67. 
Although every combination of these markers is theoretically applicable, we choose for CD4+ T cells co-
expression of Ki-67/CD38 and for CD8+ T cells CD38/HLA-DR for the definition of activated cells. Depicted is donor 
15 (young) at day 2. 
2.2.9.7 Assessment of specific CD4+ T cells after YF vaccine stimulation 
YF-specific CD4+ T cells were measured after ex vivo stimulation of whole blood with vaccine 
at study days 0, 2, 4, 7, 10, 14, 17, 21 and 28. At each day and for each donor three 
stimulations were performed: negative control (un-stimulated), positive control (SEB/TSST1 
stimulated) and a YF-vaccine stimulation. For each stimulation, 1 mL of freshly drawn 
heparinized blood was transferred into 12 mL round bottom stimulation tubes. Then 
stimulation cocktails were added as listed in table 2.9. Tubes were then capped permeable to 
air and incubated for 2 h at 37 °C under humid conditions and in 5 % CO2 atmosphere. During 
the stimulation, tubes were locked in a 45° position. After 2 h, stimulation was shortly 
interrupted in order to supplement Brefeldin A (10 µg/mL) to each tube, preventing 
retrograde protein transport from the Golgi apparatus and thereby enabling intracellular 
detection of induced cytokine expression. After continuing the stimulation for another 4 h at 
same conditions, 100 µL 20 nM EDTA was added to each sample to stop the stimulation. Next, 
erythrocytes were lysed through addition of 10 mL Qiagen Buffer EL to each stimulation tube 
and intensive vortexing. Lysis reaction was increased by a 10 min incubation step on ice, 
during which tubes were repeatedly inverted. This was followed by a centrifugation step 
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(10 min, 490 g, 4 °C). Supernatant was carefully aspirated, including the viscous, orange 
erythrocyte debris resulting in whitish cell pellets which were washed once again with 4 mL 
Qiagen Buffer EL and centrifuged (10 min, 490 g, 4 °C). Next, cell pellets were re-suspended in 
PBS/BSA, transferred into 5 mL FACS tubes and washed with PBS/BSA (10 min, 490 g, 4 °C). 
Then, the protocol proceeded as outlined for the B-cell panel (surface staining, fixation, 
permeabilization and intracellular staining). The antibody cocktails used for both staining steps 
are listed in table 2.10. As live/dead discriminator 1 µL LD Red was used. Samples were 
measured on a LSR II flow cytometer with an optical filter setting shown in table 2.1. The 
gating strategy is depicted in fig. 2.7. All measured frequencies of cytokine or activation 
marker expressing cells were background subtracted by the matching un-stimulated sample. 
Calculation of whole blood counts based on the CD4+ gate. For multi-dimensional assessment 
of cytokine expression a SPICE analysis was performed. For this a combinatorial Boolean 
gating of cytokine expression on vaccine-stimulated cells was conducted in FlowJo. The 
obtained relative frequencies of cytokine producing cells (percentages within CD40L+ 
CD4+ T cells) were imported into SPICE (Roederer et al., 2011) and analyzed according to 
discriminators such as age, gender and/or study day. Polyfunctionality (number of co-
expressed cytokines) was automatically assigned by SPICE and relative frequencies of single, 
double, triple, etc. cytokine producing cells was analyzed in a similar way in SPICE. Assessment 
of vaccine-specific CD4+ T cells at the very late follow-up study day was conducted in a similar 
way with a modified FACS panel indicated in table 2.10. 
Table 2.9: Stimulations used in the whole blood CD4+ T cell stimulation panel 
Stimulation RPMI/AB anti hu CD28 Stimulants Distributed volume 
Master mixes for whole blood CD4+ T-cell stimulation 
SEB/TSST1 96.5 µL 1 µL 1.5 µL SEB 1.0 µL TSST1 100 µL 
YF-vaccine 49.0 µL 1 µL 50 µL YF-vaccine 
(⅓ single dose)  100 µL 
un-stimulated 99.0 µL 1 µL - 100 µL 
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Table 2.10: Antibody cocktails for whole blood CD4+ T cell stimulation panel (acute phase and follow up) 
Name Fluorochrome Clone Isotype Vendor Dilution 
Whole blood CD4+ T-cell stimulation panel (LSR II) – surface staining 
CD8 V500 RPA-T8 mouse IgG1 BD Biosciences 1:50 
CD19 PE-CF594 HIB19 mouse IgG1 BD Biosciences 1:100 
CD14 PE-CF594 MφP9 mouse IgG2b BD Biosciences 1:100 
CD4 A647 TT1 mouse IgG1 in house DRFZ 1:300 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Whole blood CD4+ T-cell stimulation panel (LSR II) – intracellular staining 
CD40L PacBlue 24-31 mouse IgG1 Biolegend 1:100 
IL2 BV605 MQ1-17H12 rat IgG2a Biolegend 1:200 
CD3 efluor650 OKT3 mouse IgG2a Ebioscience 1:50 
IL4 Alexa488 MP4-25D2 rat IgG1 Biolegend 1:100 
TNFα PerCpCy5.5 MAb11 mouse IgG1 Biolegend 1:30 
RANKL PE MIH24 mouse IgG2b Biolegend 1:200 
IL22 PECy7 22URTI mouse IgG1 Ebioscience 1:200 
IFNγ Alexa700 B27 mouse IgG1 Biolegend 1:400 
IL17 APCCy7 BL168 mouse IgG1 Biolegend 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Follow up day – Whole blood CD4+ T-cell stimulation panel (LSR II) – surface staining 
CD8 BV510 RPA-T8 mouse IgG1 Biolegend 1:200 
CCR7 PE G043H7 mouse IgG2a Biolegend 1:20 
CD19 PE-CF594 HIB19 mouse IgG1 BD Biosciences 1:100 
CD14 PE-CF594 MφP9 mouse IgG2b BD Biosciences 1:100 
CD45RA PECy7 L48 mouse IgG1 BD Biosciences 1:50 
CD4 Cy5 TT1 mouse IgG1 in house DRFZ 1:600 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Follow up day – Whole blood CD4+ T-cell stimulation panel (LSR II) – intracellular staining 
CD40L BV421 24-31 mouse IgG1 Biolegend 1:200 
IL2 BV605 MQ1-17H12 rat IgG2a Biolegend 1:200 
CD3 efluor650 OKT3 mouse IgG2a Ebioscience 1:50 
IL4 Alexa488 MP4-25D2 rat IgG1 Biolegend 1:100 
TNFα PerCpCy5.5 MAb11 mouse IgG1 Biolegend 1:30 
IFNγ Alexa700 B27 mouse IgG1 Biolegend 1:400 
IL17 APCCy7 BL168 mouse IgG1 Biolegend 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
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Figure 2.7: Gating strategy for the whole blood CD4+ T-cell stimulation panel. 
Activated and cytokine expressing CD4+ T cells were assessed after antigen-specific stimulation in lysed and 
fixated whole blood by gating first on CD3+ T cells. Next, cell aggregates were removed and gating was refined on 
cells with lymphocyte properties, excluding monocytes, B cells and dead cells. After distinguishing CD8+ from 
CD4+ T cells, we analyzed cytokine and activation marker (CD40L, RANKL) expression in CD4+ T cells. If not 
otherwise mentioned co-expression of CD40L and a cytokine are reported in the results. For assessment of the 
qualitative CD4+ T-cell response CD40L+/TNFα+/- CD4+ T cells were further used in a Boolean gating approach 
generating results for all possible cytokine combinations (not shown). Depicted is donor 15 (young) at day 10 
after stimulation with YF vaccine.  
2.2.9.8 Examination of YF-specific CD8+ T cells and CMV/EBV-specific cellular responses 
YF-specific CD8+ T cells were measured after ex vivo stimulation of PBMCs in HLA-A0201 
positive donors (n=10) at study days 0, 4, 7, 10, 14, 17, 21 and 28. In a similar fashion CMV 
and EBV-specific CD4+ and CD8+ T cells were studied in all donors at day 0. At each studied day 
and for each HLA-A0201+ donor the following stimulations were performed: negative control 
(un-stimulated), positive control (SEB/TSST1 stimulated) and a NS4b 9mer peptide 
stimulation. It has been previously shown that for HLA-A0201+ YF-vaccinees about 50 % of the 
virus-specific CD8+ T-cell response is directed against this particular immunodominant epitope 
214–222 of the NS4b protein (Akondy et al., 2009). For the CMV and EBV analysis, the same 
positive and negative controls were used. CMV-specific T cells were assessed by stimulating 
PBMCs with pp65 and IE-1 15mer peptide pools. EBV-specific T cells were studied by 
stimulating PBMCs with EBNA1 and BZLF1 15mer peptide pools. For each stimulation, 5x106 
PBMCs were transferred into 12 mL round bottom stimulation tubes in 500 µL RPMI/AB. Then, 
stimulation cocktails were added as listed in table 2.11, including Monensin A and anti-
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CD107a antibodies enabling examination of cytotoxic functionality. The total stimulation 
volume was 1 mL. Tubes were then capped permeable to air and incubated for 2 h at 37 °C 
under humid conditions and in 5 % CO2 atmosphere. During the stimulation, tubes were 
locked in a 45° position. After 2 h, stimulation was shortly interrupted in order to supplement 
Brefeldin A (10 µg/mL) to each tube. After continuing the stimulation for another 4 h at same 
conditions, 100 µL 20 nM EDTA was added to each sample to stop the stimulation. Then, 
stimulated PBMCs were washed once with 10 mL PBS/BSA (10 min, 490 g, 4 °C) and 
transferred into FACS tubes. The subsequent fixation, permeabilization and staining procedure 
followed the B-cell panel protocol (surface staining, fixation, permeabilization and intracellular 
staining). The antibody cocktails used for both staining steps are listed in table 2.12. As 
live/dead discriminator 1 µL LD Red was used. Samples were measured on a LSR II flow 
cytometer with an optical filter setting shown in table 2.1. The gating strategy is depicted in 
fig. 2.8. All measured frequencies of cytokine or activation marker expressing cells were 
background subtracted by the matching un-stimulated sample. Calculation of whole blood 
counts based on the CD8+ gate. Assessment of YF-specific CD8+ T cells at the very late follow-
up study day was conducted in a similar way with a modified FACS panel indicated in table 
2.12. 
Table 2.11: Stimulations used for the assessment of YF-, CMV- or EBV-specific CD8+ T cells 
Stimulation RPMI/AB anti hu CD28 Monensin 
anti hu  
CD107a A488 Stimulants 
Distributed 
volume 
Master mixes for PBMC stimulation (for assessment of YF-specific CD8+ T cells) 
SEB/TSST1 495 µL 1 µL 0.7 µL 1.43 µL 1.5 µL SEB 1.0 µL TSST1 500 µL 
NS4b 9mer 493 µL 1 µL 0.7 µL 1.43 µL 4.0 µL NS4b 9mer 500 µL 
un-stimulated 493 µL 1 µL 0.7 µL 1.43 µL 4.0 µL DMSO/PBS 500 µL 
Master mix for PBMC stimulation (for assessment of CMV/EBV-specific T cells at day 0) 
SEB/TSST1 495 µL 1 µL 0.7 µL 1.43 µL 1.5 µL SEB 1.0 µL TSST1 500 µL 
CMV 489 µL 1 µL 0.7 µL 1.43 µL 4.0 µL pp65 pool 4.0 µL IE-1 pool 500 µL 
EBV 489 µL 1 µL 0.7 µL 1.43 µL 4.0 µL EBNA1 pool 4.0 µL BZLF1 pool 500 µL 
un-stimulated 489 µL 1 µL 0.7 µL 1.43 µL 8.0 µL DMSO/PBS 500 µL 
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Table 2.12: Antibody cocktails for PBMC stimulation panel (acute phase and follow up) 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
PBMC stimulation panel (LSR II) – surface staining 
CD4 V500 RPA-T4 mouse IgG1 BD Biosciences 1:50 
CD8 efluor605 RPA-T8 mouse IgG1 Ebioscience 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
PBMC stimulation panel (LSR II) – intracellular staining 
CD40L PacBlue 24-31 mouse IgG1 Biolegend 1:100 
CD3 efluor650 OKT3 mouse IgG2a Ebioscience 1:50 
CD107a Alexa488 H4A3 mouse IgG1 Biolegend 1:700 1 
Granzyme A PerCpCy5.5 CB9 mouse IgG1 Biolegend 1:20 
Perforin PE B-D48 mouse IgG1 Abcam 1:50 2 
IFNγ PECy7 B27 mouse IgG1 Biolegend 1:100 
IL2 APC MQ1-17H12 rat IgG2a Biolegend 1:200 
Granzyme B Alexa700 GB11 mouse IgG1 BD Bioscience 1:100 
IL17 APCCy7 BL168 mouse IgG1 Biolegend 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Follow up day – PBMC stimulation panel (LSR II) – surface staining 
CD4 BV510 RPA-T4 mouse IgG1 Biolegend 1:100 
CD45RA BV605 HI100 mouse IgG2b Biolegend 1:200 
CD8 BV785 RPA-T8 mouse IgG1 Biolegend 1:200 
CCR7 PerCpCy5.5 G043H7 mouse IgG2a Biolegend 1:40 
CD19 PE-CF594 HIB19 mouse IgG1 BD Biosciences 1:100 
CD14 PE-CF594 MφP9 mouse IgG2b BD Biosciences 1:100 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
Follow up day – PBMC stimulation panel (LSR II) – intracellular staining 
CD40L BV421 24-31 mouse IgG1 Biolegend 1:200 
CD3 BV650 OKT3 mouse IgG2a Biolegend 1:50 
CD107a Alexa488 H4A3 mouse IgG1 Biolegend 1:700  
Perforin PE B-D48 mouse IgG1 Abcam 1:50 2 
IFNγ PECy7 B27 mouse IgG1 Biolegend 1:100 
IL2 APC MQ1-17H12 rat IgG2a Biolegend 1:200 
Granzyme B Alexa700 GB11 mouse IgG1 BD Bioscience 1:100 
IL17 APCCy7 BL168 mouse IgG1 Biolegend 1:50 
Beriglobin n.a. n.a. n.a. Aventis 1:50 
1 CD107a was added into the stimulation master mix 
2 Each lyophilized Perforin PE vial was solved in 500µL PBS prior usage 
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Figure 2.8: Gating strategy for the assessment of YF-specific CD8+ T cells. 
Activated and cytokine expressing CD8+ T cells were assessed after antigen-specific stimulation in fixated PBMCs 
by gating first on CD3+ T cells. Next, cell aggregates were removed and gating was refined on cells with 
lymphocyte properties, excluding dead cells. CD8+ T cells were distinguished from CD4+ T cells. The CD8 gate was 
drawn very large, as we noticed a strong down regulation of CD8 after stimulation with NS4b 9mer. In 
CD8+ T cells we investigated expression of IFNγ, IL2 and CD40L. We further characterized the expression of 
markers involved in cytotoxicity, such as Perforin, Granzyme A, Granzyme B and CD107a in IFNγ+ CD8+ T cells 
which are depicted as an overlay (red) on total CD8+ T cells. Assessment of activated and cytokine expressing 
CD4+ T cells by this panel was analog to the whole blood CD4+ stimulation panel (not shown). Depicted is donor 
15 (young) at day 17 after stimulation with YF NS4b 9mer 
2.2.10 Data acquisition, analysis and statistics 
FACS data was acquired on LSR II by FACSDiva 6 and on MACSQuant by MACSQuantify 
Software. All FACS data were properly compensated using matching single-stain controls 
acquired 2-3 days prior beginning of each study round. Instrument stability was monitored 
over the study course using BD Rainbow Calibration Particles. Data was exported into fcs-data 
files and analyzed with Flowjo 9.7.4 (MacOS Version). Finalized, gated data was exported into 
data tables. For statistical analysis of any observed data GraphPad Prism 5 was used. 
Multivariate analysis of tabular data was conducted with R 3.02 (R Development Core Team, 
2014) by Karsten Jürchott, AG Neumann. Z-scores for each marker were calculated by 
subtracting the mean and dividing by the standard deviation. Obtained values were used in a 
principle component analysis utilizing a singular value decomposition. The first two principle 
components were displayed in a scatter plot. Furthermore, a hierarchical clustering of the z-
scores was performed using Euclidean distances and complete linkage. Z-scores of response 
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markers were calculated and color coded by applying the color gradient equidistantly from 
minimum to maximum of each marker separately. In regard to statistics, this study had an 
exploratory character with no initial assumptions regarding the effect sizes. Since a power test 
was therefore not possible, the size of the cohort was limited by available donors during the 
study time. The study was performed in 3 independent rounds (n=5, n=5 and n=13). In order 
to avoid an inappropriate increase of type II errors, no adjustment of the significance level for 
multiple testing was done. The Shapiro test was used to test normal distribution of the data, 
which was rejected for most of the groups (p<0.05). Unless stated otherwise, the two-sided 
Mann-Whitney-U test as a non-parametric test to compare differences in groups was used. 
Data were tested for homoscedasticity as a prerequisite for the Mann-Whitney-U test with the 
Levene's test (p<0.05). If not mentioned otherwise, Pearson’s correlation was used to 
determine correlations. A p-value of ≤0.05 was required for significance in group and 
correlation analyses (actual p-values are listed in figure legends). Asterisks in figures indicate 
levels of significance (* p <0.05, ** p <0.01, *** p <0.001). 
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3. Results 
3.1 Serum viremia 
In order to explore age-related differences in virus clearance we first investigated serum 
viremia in both age groups. In collaboration with Prof. Dr. Niedrig’s group at the RKI, we 
measured viremia by RT-PCR (Chap. 2.2.3) before (day 0) and at days 2, 4, 7 and 10 after 
vaccination with the live-attenuated YFV-17D strain. We detected in all except one of the 
elderly subjects (91.7 %) virus in the blood, whereas only 8 of 11 (73.7 %) young vaccinees had 
detectable viremia. In those vaccinees that developed serum viremia no age-related 
difference of the absolute amount of virus in serum was observed (data not shown). However, 
we noticed that maximal viral load occurred later in the elderly. Serum viremia peaked in two 
elderly subjects at day 7 and in two others even at day 10, which was not observed in any 
young vaccinee. Hence late viral burden was significantly associated with age (Fig. 3.1), which 
led us to hypothesize that anti-viral effector functions were affected in the elderly. 
Figure 3.1: Maximal viral load and age 
Individual peak days of viremia (day of maximum YF-genome 
equivalents per mL serum) versus donor’s age (young: n=8, elderly: 
n=11). Individuals, who were tested negatively for viremia at all time-
points (n=4/23) were not included in this analysis. Testing of correlation 
was performed by Spearman correlation. Young: filled circles; elderly: 
open circles 
 
 
3.2 The acute humoral response 
As one essential element of antiviral immune effector mechanisms we studied the humoral 
response before and at eight consecutive time points after vaccination. Prior to vaccination 
we assured by performing an anti-Flavivirus mosaic IIFA that all study participants were 
immunologically truly naive to YFV-17D, i.e. they did not have any detectable antibodies to 
YFV, TBE, JEV, WNV or DENV (Chap. 2.2.2). Next, three different immunoglobulin (Ig) classes 
directed against YFV-17D were assessed in a collaboration with the group of Prof. Dr. Niedrig 
in the sera of all vaccinees by an anti-YFV IIFA (Chap. 2.2.4). As shown in fig. 3.2A-C, we 
observed the profile of a typical primary immune response starting with the generation of YF-
specific IgM antibodies around day 7 followed by the production of YF-specific IgG antibodies 
from day 10 onwards. We also measured YF-specific IgA antibodies that followed the same 
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kinetics as the specific IgG antibodies. By day 14 all vaccinees had developed YF-specific IgM, 
and by day 17 YF-specific IgG and IgA titers, indicating that all immunized subjects were 
responding to the vaccination. Limited by the semi-quantitative nature of the IIFA we could 
not detect any age-specific differences in antibody titers directed against YFV-17D. However, 
we observed the trend of a delayed onset of YF-specific IgM production in the elderly 
(Fig. 3.2D) prompting us to investigate YF-neutralizing antibodies by a quantitative PRNT90 
performed at the RKI (Chap. 2.2.5). All vaccinees, regardless of age, developed protective YF-
neutralizing titers (>1:20) by day 10 (Fig. 3.2E). The peak of neutralizing antibodies was 
reached on day 17 in both age groups. Interestingly, neutralizing titers were distinctly lower in 
aged individuals on day 14 (Fig. 3.2F, p=0.03), a finding that tended to continue until day 21. 
By day 28 neutralizing titers were comparable between both age groups with titers around 
1:100. In conclusion, our investigation of the YF-specific humoral response revealed an age-
related lag in the generation of YF-neutralizing antibodies, which can most likely be explained 
Figure 3.2: Acute humoral YF-specific immune response 
(A-C) Development of YF-specific IgM (A), IgG (B) and IgA (C) 
antibodies measured by IIFA in serum. (D) YF-specific IgM antibodies 
show the tendency of a delayed onset in elderly. (E-F) Development 
of YF-neutralizing antibody titer assessed by PRNT90 (elderly vs. 
young: day 14: p=0.04). Dashed line indicates the cut-off of the 
assay. Lines indicate the median with interquartile error bars. 
(G) Correlation of YF-specific IgM onset and YF-neutralizing 
antibodies at day 10. Young: filled circles; elderly: open circles 
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by a deferred onset of anti-viral IgM production in the elderly, as indicated by a correlation of 
IgM onset and neutralizing antibody titers at day 10 (Fig. 3.2G). 
3.3 Plasmablasts and the B-cell compartment 
After immunization specific antibodies are produced by antibody secreting cells (ASC) that 
transiently appear in blood and are mostly comprised of acutely generated plasmablasts 
deriving from the germinal center reaction (Fink, 2012). We monitored plasmablasts as 
CD19low/CD20neg/CD27hi/CD38hi cells by FACS in the course of the YF immune response 
(Fig. 3.3A) (Chap. 2.2.9.4). Regardless of age, we detected a very distinct and transient peak of 
acute plasmablasts around day 14 after vaccination (Fig. 3.3B). Remarkably, the magnitude of 
 
Figure 3.3: Acute B-cell response 
(A) Example of acutely generated plasmablasts in elderly donor 25. Depicted cells are pre-gated on live, CD19low/+ 
B cells. (B) Absolute, baseline-corrected counts of plasmablasts after YF-vaccination. (C) Increased fold change of 
plasmablasts from day 0 to individual peak days based on absolute counts in the elderly group (p=0.02). 
(D-E) Absolute counts of memory (IgD-/CD27+) and naive (IgD+/CD27-) B cells after YF vaccination (naive B cells: 
elderly vs. young: day 4: p=0.05). (F) Positive correlation of naive B cell counts at day 7 with baseline-corrected 
plasmablast counts at day 10. A similar finding could be obtained with plasmablast counts of day 14. Lines 
indicate the median with interquartile error bars. Young: filled circles; elderly: open circles 
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the plasmablast peak (as fold increase to baseline) was significant higher in elderly individuals 
(Fig. 3.3C, p=0.02), however, this did not positively correlate with neutralizing antibody titers 
(data not shown). 
By the same FACS panel we also analyzed naive (CD27-/IgD+) and memory (CD27+/IgD-) CD19+ 
B cells in the course of the response. Both B-cell subsets showed distinct kinetics 
characterized by a highly significant drop in cell numbers from day 0 to day 7. After day 7 
absolute counts of both subsets increased again, peaking around days 14/17 for naive B cells 
and at day 21 for memory B cells (Fig. 3.3, D and E). Age differences were found only at day 4 
in naive B cells. 
By correlation analysis we wanted to assess the influence of the size of the naive B-cell 
compartment on the subsequent response. The naive B-cell status prior vaccination (day 0) 
revealed no significant correlation to neutralizing antibody titers or plasmablast counts (not 
shown). However, we observed a very significant positive correlation between numbers of 
naive B cells at day 7 and plasmablast at day 10 and 14, i.e. vaccinees, with comparably high 
numbers at the naive B-cell minimum generated subsequently more plasmablasts (Fig. 3.3F). 
Altogether we could observe a distinct response pattern in the B-cell compartment to 
YF vaccination that includes an exaggerated plasmablast response in the elderly. 
3.4 The YF-induced, acute CD8+ T-cell response 
Cytotoxic CD8+ T cells (CTLs) capable of eliminating virus-infected cells represent the other 
essential effector element in immune protection. Hence, we monitored YF-specific 
CD8+ T cells over the course of the immune response, using the activation markers CD38 and 
HLA-DR (Fig. 3.4A) (Chap. 2.2.9.6). Co-expression of both markers can be used to track YF-
specific activated CD8+ T cells after vaccination (Ahmed and Akondy, 2011). We detected a 
strong increase of activated HLA-DR+/CD38+ CD8+ T cells at day 14 and 17, which returned to 
basal levels by day 28 (Fig. 3.4B). Importantly, older vaccinees showed significantly (p=0.04, 
day 10; p=0.02, day 14) weaker CTL responses. 
We alternatively assessed YF-specific CD8+ T cells by intracellular cytokine staining (ICS) after 
stimulation with a YF-derived peptide (Chap. 2.2.9.8). As this peptide is HLA-A0201 restricted 
we could only analyze vaccinees possessing this particular HLA type (HLA-A2+: n=10, young: 
n=5, elderly n=5). YF-peptide specific, IFNγ producing CD8+ T cells could be detected from 
day 7 onwards (Fig. 3.4C). The strongest increase was observed from day 10 to day 14, 
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Figure 3.4: Acute CD8+ T cell response 
(A) Examples of acutely activated HLA-DR+/CD38+ CD8+ T cells in a young and old donor very early at day 2 after 
vaccination and at the peak at day 17. CD8+ T cells were gated on live, CD3+ cells. (B) Absolute counts of acutely 
activated HLA-DR+/CD38+ CD8+ T cells after YF-vaccination (elderly vs. young: day10: p=0.04; day 14: p=0.02). (C) 
Absolute counts of IFNγ+ CD8+ T cells after re-stimulation with NS4b 9mer after YF-vaccination of HLA-A0201 
subjects (n=10). (D) Positive correlation between counts of HLA DR+/CD38+ and IFNγ+ CD8+ T cells at day 14 post 
vaccination. (E-F) Percentages of Granzyme A (E) or Granzyme B (F) expression within YF-specific IFNγ+ CD8+ T 
cells. Results of 10 vaccinees from day 10 to day 28 are stratified by age. Granzyme A: p=0.005; Granzyme B: 
p=0.03 (G) Percentage of Perforin expressing cells among YF-specific IFNγ+ CD8+ T cells. Individual data points are 
connected by gray lines. (H) Absolute counts of Perforin+/Granzyme A+/Granzyme B+/IFNγ+ CD8+ T cells after YF-
vaccination of HLA-A0201 subjects (n=10). Lines indicate the median with interquartile error bars. Young: filled 
circles; elderly: open circles 
reaching a plateau phase lasting at least until day 28. Due to the low number of analyzed 
vaccinees no significant age-related differences in cell numbers could be detected, however 
we were able to correlate ICS data with the CD38/HLA-DR results. As shown in fig. 3.4D 
numbers of activated HLA-DR+/CD38+ CD8+ T cells at day 14 correlated almost linearly with YF-
specific IFNγ+ CD8+ T cells at day 14 (with the exception of 3 subjects). Assessing HLA-DR/CD38 
is hence an appropriate surrogate marker combination for measuring the YF-specific CTL 
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response in the acute phase. 
Moreover, we obtained in HLA-A0201+ vaccinees qualitative functionality of YF-specific IFNγ+ 
CD8+ T cells from day 10 onwards. As illustrated in fig. 3.4, E and F, about 90 % of these cells 
expressed GrzA and B at all investigated days with significantly higher percentages in the 
elderly cohort. In contrast, relative frequencies of Perforin+ cells decreased over time and 
were rather divers among donors but by trend lower in the elderly (Fig. 3.4G). Back-calculating 
these results to absolute counts of YF-specific GrzA+ GrzB+ Perforin+ IFNγ+ CD8+ T cells, there 
was a trend that numbers of these cells were lower in the elderly individuals (Fig. 3.4H). 
Altogether, our data suggested diminished acute YF-specific CD8+ T-cell immunity in elderly 
vaccinees, characterized by lower absolute cell numbers and possibly constrains in Perforin-
mediated cytotoxicity. 
3.5 The YF-induced, acute CD4+ T-cell response 
As both humoral and cellular anti-viral defense mechanisms, which are largely orchestrated by 
CD4+ T helper cells, seemed to be compromised in the elderly, we also studied the CD4+ T-cell 
compartment after YF vaccination. As proposed by Blom, we tracked activated YF-specific 
CD4+ T cells by the co-expression of CD38 and the proliferation marker Ki-67 (Fig. 3.5A) 
(Chap. 2.2.9.6) (Blom et al., 2013). In both age groups, the number of activated CD4+ T cells 
increased strongly until day 10 (Fig. 3.5B). Interestingly, in almost all young vaccinees, the 
highest number of activated and proliferating CD4+ T cells was reached at day 10 (Fig. 3.5C). In 
contrast, in about 50 % of the elderly, CD4+ T cells were still expanding until day 14. Thus, the 
overall expansion was significantly increased (p=0.006) in the elderly cohort (Fig. 3.5D). 
We alternatively assessed YF-specific CD4+ T cells also by ICS after stimulation with YF-vaccine 
(Chap. 2.2.9.7). Specific CD4+ T cells were identified by the expression of CD40L and various 
cytokines. The response was dominated by type 1 T-helper cells (TH1) expressing IL2, TNFα 
and IFNγ. However, smaller fractions of cells also expressed the type 2 T-helper (TH2) cytokine 
IL4 or type 17 T-helper (TH17) cytokines IL17 and IL22 (Fig. 2.7). TH1 and TH2 cytokine 
expressing T cells behaved kinetically very similar: Percentages and numbers of these cells in 
blood strongly increased from day 4 onwards, reached a peak at day 14 and then began to 
decrease till the end of the observation window (Day 28) (Fig. 3.6A-D, Suppl. fig. 1A-D). In 
contrast, TH17/TH22 cytokine producers showed a totally different kinetic profile: They 
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Figure 3.6: YF-specific CD4+ T-cell response after re-stimulation with YF-
vaccine 
(A-F) Absolute counts of YF-specific CD4+ T cells assessed by co-expression 
of CD40L and a cytokine (CD40L/TNFα: day 2 p=0.05; day 7 p=0.03; 
CD40L/IFNγ: day 2 p=0.05; day 7 p=0.009; CD40L/IL4: day 2 p=0.05; day 7 
p= 0.04). Lines indicate the median with interquartile error bars. See also 
suppl. fig. 1. (G) Positive correlation of YF-specific responses measured 
either by re-stimulation or by Ki-67/CD38 co-expression on day 10. Young: 
filled circles; elderly: open circles 
Figure 3.5: Acute ex vivo CD4+ T-cell response 
(A) Examples of acutely activated Ki-67+/CD38+ CD4+ T cells in a young and old donor 
very early at day 2 after vaccination and at the peak at day 10. CD4+ T cells were 
gated on live, CD3+ cells. (B) Absolute counts of activated Ki-67+/CD38+ CD4+ T cells 
after YF-vaccination. (C) Similar data as in B but individual data points of day 10 and 
day 14 were plotted (Wilcoxon matched pairs test: Young: p=0.008). (D) Increased 
overall expansion of activated Ki-67+/CD38+ CD4+ T cells from day 4 to individual peak 
days based on absolute counts in the elderly group (p=0.006). Lines indicate the 
median with interquartile error bars. Young: filled circles; elderly: open circles 
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reached their maximum already at day 7, decreased towards day 14 and had a smaller second 
maximum at day 21 (Fig. 3.6, E and F; Suppl. fig. 1, E and F). Another interesting observation 
was the transient appearance of a small but significant number of TNFα, IFNγ or IL4 producing 
YF-specific CD4+ T cells at day 2 that was more prominent in young individuals. Significantly 
higher numbers of TNFα, IFNγ or IL4 producers were also found in the expansion phase at day 
7 in the young cohort. For validation, we compared the ICS results with the Ki-67/CD38 
assessment of activated CD4+ T cells and found a significant positive correlation e.g. at day 10 
(Fig. 3.6G), indicating a good correspondence of both determination methods in the acute 
phase. 
Next, we investigated the possible association of the CD4+ T-cell response with anti-viral 
effector mechanisms. As shown in fig. 3.7, A and B for day 10, numbers of YF-specific Ki-67+ 
CD38+ CD4+ T cells in the expansion phase (days 4 - 10) correlated positively with neutralizing 
antibody titers and numbers of YF-specific CTLs at day 14. In consequence, individuals with 
more YF-specific CD4+ T cells in the expansion phase, e.g. at day 7, controlled virus earlier (Fig. 
3.7C). In turn, vaccinees with an exaggerated and prolonged expansion of YF-specific 
 
Figure 3.7: Correlation of quantitative, YF-specific CD4+ T-cell response with other immunological read-outs 
and YF viremia 
 (A, B) Numbers of Ki-67+/CD38+ CD4+ T cells at day 10 positively correlate with (A) YF-neutralizing antibody titers 
at day 14 and (B) with numbers of HLA-DR+/CD38+ CD8+ T cells at day 14. (C) There is a negative correlation 
between numbers of Ki-67+/CD38+ CD4+ T cells at day 7 and the peak days of viremia. Total expansion of specific 
CD4+ T cells, measured as fold change day 4 to individual peak days, is associated (D) with late viral burden and 
(E) with the plasmablast peak (fold change). Young: filled circles; elderly: open circles 
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CD4+ T cells, which was characteristic for the elderly (Fig. 3.5, C and D), experienced a delayed 
virus control (Fig. 3.7D). This was further supported by a significant correlation between YF-
specific CD4+ T-cell expansion and the magnitude of the plasmablast peak (Fig. 3.7E). 
Collectively, YF-specific CD4+ T cells in the expansion phase (day 4 to day 10) positively 
affected anti-viral effector mechanisms and thereby promoted viral clearance. In contrast, 
vaccinees with a diminished virus control - mostly elderly - were more likely to experience an 
exaggerated CD4+ T-cell and plasmablast response. 
3.6 Functional analysis of YF-specific CD4+ T cells 
We next performed an in-depth analysis of the YF-specific CD4+ T-cell compartment beyond 
the single cytokine level. For this we conducted a combinatorial SPICE analysis as proposed by 
Roeder et al. (Chap. 2.2.9.7) (Roederer et al., 2011). Figure 3.8A depicts the composition 
within the YF-specific CD40L+ CD4+ T cells at day 14 and reveals that the response is 
dominated by some cytokine combinations, typically defined as TH1 CD4+ T cells (red arrows). 
Interestingly, IL4 producing subpopulations were mostly co-expressing classic TH1 cytokines 
such as TNFα and/or IFNγ (green arrows), whereas IL4 single producers were rarely observed. 
As expected from the IL17 cytokine plots (Fig. 3.6E), subpopulations expressing IL17 were 
virtually absent at day 14 after vaccination. Next, we compared the CD4+ T cell composition 
over time in and between the two age groups and performed a nonparametric permutation 
analysis of cytokine compositions acquired at day 7, day 14 and day 28 after vaccination (Fig. 
3.8B). The test revealed significant compositional changes between day 7/14 and day 14/17 
within each age group but no differences between age groups. A complete compositional time 
course of the 10 dominant YF-specific CD4+ T-cell subpopulations is illustrated in figure 3.8C. 
The data indicated an increase of the relative frequency of IL2 single producers (subpop. G) 
and a decrease of TNFα single producers (subpop. D) towards day 14, which returned to initial 
levels at day 28. This observed change was significantly more prominent in the elderly and 
strongly associated with the Ki-67+/CD38+ CD4+ T-cell expansion, increased in the aged cohort 
(Fig. 3.8D). Elderly had furthermore significantly lower relative frequencies of 
IL2/TNFα/IFNγ/IL4 quadruple (subpop. O) and TNFα/IFNγ double producers (subpop. F) at 
day 17 but more IFNγ single producers (subpop. C) at day 14 than young vaccinees. 
This observation was further supported when we analyzed overall polyfunctionality that has 
been reported to be a crucial factor in defining protective T-cell responses (Seder et al., 2008). 
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As shown in figure 3.9A, elderly vaccinees had significantly lower relative accumulated 
frequencies of quadruple and triple cytokine producers and instead higher frequencies of 
single cytokine producers in the YF-specific CD4+ T-cell compartment. 
 
Figure 3.8: Qualitative composition of the YF-specific CD4+ T-cell response 
(A) Age comparison of qualitative YF-specific CD4+ T-cell responses at day 14. Young: blue dots; Old: red dots. 
Black bars depict medians in each subset. Red arrows indicate typical TH1 CD4
+ subsets, Green arrows indicate 
TH1 CD4
+ subsets co-expressing IL4. (B) Pie charts based on median values for both age groups at day 7, 14 and 
28. Pie slice color code is indicated in A. P-values of partial permutation tests (pie comparisons) are indicated. (C) 
Time course of the YF-specific, qualitative CD4+ composition for selected 8 major subsets of young (left) and 
elderly (right) vaccinees. Charts base on median values of indicated subsets. Significant age differences were 
found in: Day 14: Subset C p=0.05; Day 17: Subset F p=0.02; Subset G p=0.03; Subset O p=0.03. (D) Significant 
correlation between total expansion of Ki-67+ CD38+ CD4+ T cells and percentage of YF-specific IL2+ single 
producers (subset G) at day 14. Young: filled circles; elderly: open circles 
Altogether, the in-depth analysis of the YF-specific CD4+ T-cell compartment revealed in 
addition to age-related quantitative also qualitative differences, such as a decreased level of 
polyfunctionality, which prompted us to investigate the impact on anti-viral effector 
mechanisms. Indeed, the relative percentage of YF-specific quadruple (and also quintuple) 
cytokine producers positively correlated with the YF-specific HLA-DR+/CD38+ CD8+ T-cell 
response at day 14 (Fig. 3.9B). In turn, we observed a negative correlation between the 
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frequency of single cytokine producers and neutralizing antibodies at day 14 (Fig. 3.9C). 
Moreover, we found a very strong positive association between the degree of 
polyfunctionality and the quantity of the YF-specific cytokine response of CD4+ T cells in the 
expansion phase (Fig. 3.9, D and E). In conclusion the quality of the YF-specific CD4+ T-cell 
response is not only linked with the quantity of the CD4+ T-cell response but also crucially 
influences subsequent anti-viral effector mechanisms. 
 
Figure 3.9: Polyfunctionality within YF-specific CD4+ T cells 
(A) Age comparison of single/polyfunctionality of YF-specific CD40L+ CD4+ T cells. Vaccine stimulation data from 
day 7 to day 28 are superimposed. Number of functions is calculated on expression of TNFα, IFNγ, IL2, IL4, IL17 
and RANKL. (1 fct: p=0.0002; 3 fcts: p=0.0006; 4 fcts: p<0.0001; 5 fcts: p=0.02) (B) Correlation between 
percentage of quadruple functionality and numbers of activated HLA-DR+/CD38+ CD8+ T cells at day 14 after 
vaccination. A similar correlation can be found for quintuple functionality. (C) Negative correlation between 
frequency of single functionality and YF-neutralizing titers at day 14 after vaccination. (D, E) Strong positive 
correlations between triple functionality and numbers of YF-specific CD40L/IL2 (D) or CD40L/IL4 (E) CD4+ T cells 
at day 10 after vaccination. Similar correlations exist with quadruple and quintuple functionality. Young: filled 
circles; elderly: open circles. 
3.7 Immunological signatures affecting subsequent anti-viral immunity 
3.7.1 Influence of naive T cells and recent thymic emigrants (RTE) 
As we had discovered age-specific alterations at several levels of the cellular and humoral anti-
viral response we sought to identify immunological signatures manifested before or shortly 
after vaccination that critically govern the subsequent anti-viral mechanisms. 
We hypothesized that the phenotypic composition of the T-cell compartment prior 
vaccination might influence the subsequent response. Hence, we assessed the expression of 
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CD45RA and CCR7 in CD8+ T cells at day 0, which defines four subsets as proposed by Salusto 
et al.: Naive (N), central-memory (CM), effector-memory (EM) and effector (Eff) CD8+ T cells 
(Sallusto et al., 1999) (Chap. 2.2.9.3) (Fig. 2.3). Importantly, we observed highly significantly 
lower numbers and percentages of naive CD8+ T cells in the elderly (Fig. 3.10A). In contrast, 
numbers of CM, EM and Eff CD8+ T-cell subsets were independent of age in our study. We also 
investigated the phenotypic distribution in the CD4+ T-cell compartment. There, we neither 
detected an age-difference in numbers of naive nor in CM, EM and Eff subsets (Fig. 3.10B). We 
next asked whether the reduced numbers of naive CD8+ T cells affect the subsequent YF-
specific CTL response. Indeed, we found a significant positive correlation between numbers of 
naive CD8+ T cells prior vaccination and YF-specific HLA-DR+/CD38+ CD8+ T cells at day 14 
(Fig. 3.10C) indicating that a compromised naive CD8+ T-cell compartment directly translates 
into a diminished CTL response in a primary infection. 
 
Figure 3.10: Phenotypic composition of the CD8+ and CD4+ T-cell compartment prior vaccination 
(A, B) Absolute numbers of naive (N), central-memory (CM), effector-memory (EM) and effector (Eff) CD8+ (A) or 
CD4+ (B) T cells at day 0. Naive CD8+ T cells: p=0.0002 (C) Positive correlation between numbers of naive CD8+ T 
cells prior vaccination and activated HLA-DR+/CD38+ CD8+ T cells at day 14 after vaccination. Lines indicate the 
median with interquartile error bars. Young: filled symbols; elderly: open symbols 
Next, we performed a deep analysis of the naive CD4+ T-cell compartment prior vaccination. It 
has been previously shown that naive CD4+ T cells can be subdivided by the expression of 
CD31 into cells having recently emigrated from the thymus (RTE) and cells that have been 
homeostatically derived (Kimmig et al., 2002). Using the marker CD31 (Chap. 2.2.9.3), we 
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could demonstrate that elderly had highly significantly lower numbers and frequencies of RTE 
than young vaccinees before vaccination (Fig. 3.11A). Analyzing possible consequences on 
subsequent immune mechanisms we found significant positive correlations between numbers 
of CD4+ RTE at day 0 and the early YF-specific Ki-67+/CD38+ CD4+ T-cell response at day 4 and 
day 7 (Fig. 3.11B), indicating that those individuals with lower RTE counts prior to vaccination 
have weaker early CD4+ T-cell responses. Similarly, we also found correlations to the YF-
specific CD4+ cytokine response in terms of quantity (Fig. 3.11C) and quality (Fig. 3.11, D and 
E), suggesting that availability of RTE critically governs quantity and quality of YF-specific 
CD4+ T-cell immunity. Finally, we identified a very strong positive correlation between initial 
RTE numbers and the YF-specific CD8+ T-cell response at day 14 (Fig. 3.11F), indicating that 
high RTE numbers prior to vaccination are also important for a good YF-specific CD8+ T-cell 
response. Collectively, our data demonstrated that high numbers of RTEs, indicative of a broad 
naive TCR repertoire, were pivotal for a competent YF-specific adaptive immunity. 
Figure 3.11: Influence of CD4+ RTE on the YF-specific immune response 
(A) Absolute cell counts and percentage of RTE before vaccination. Counts: 
p=0.005; Percentage: p=0.004 (B) Positive correlations between numbers of 
RTEs prior vaccination and numbers of activated Ki-67+/CD38+ CD4+ T cells at 
day 4 and 7 after vaccination. (C) Positive correlation between numbers of 
RTE at day 0 and numbers of YF-specific CD40L/IL2 CD4+ T cells at day 7 after 
vaccination. A similar association exists with CD40L/IL2 CD4+ T cells at day 
10. (D-E) Correlations between numbers of RTEs at day 0 and qualitative YF-
specific single (D) or quadruple (E) CD4+ functionality. (F) Positive correlation 
between numbers of RTE at day 0 and numbers of activated HLA-DR+/CD38+ 
CD8+ T cells at day 14 after vaccination. Lines indicate the median with 
interquartile error bars. Young: filled circles; elderly: open circles 
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3.7.2 Influence of the innate immune system 
We also hypothesized that early response signatures of the innate immune system might 
affect the YF-specific adaptive immune responses. For this, we developed a FACS panel that 
allowed a comprehensive analysis of major peripheral innate cell types over the entire study 
course. Our analysis included: Three different DC subsets, such as plasmacytoid DCs (pDCs), 
myeloid type 1 DCs (CD11c+ mDCs) and myeloid type 2 DCs (CD141+ mDCs), as well as three 
monocyte subsets: CD14++/CD16- classical, CD14++/CD16+ intermediate and CD14+/CD16+ 
nonclassical monocytes (Chap. 2.2.9.2) and basophils (Fig. 2.2). In addition we assessed 
neutrophils and eosinophils in 18 of 23 vaccinees by complete blood count (Chap. 2.2.6). 
We observed distinct innate response patterns after YF vaccination (Fig. 3.12A-I). Neutrophils, 
pDCs, CD11c+ mDCs and CD14++/CD16- classical monocytes were characterized by a significant 
and transient increase of cell numbers around day 2/4, followed by a drop towards day 7/10 
and a secondary increase at the late phase of the response (Day 14 - 21). Other innate cell 
types, such as eosinophils, basophils and CD141+ mDCs did not show this pronounced primary 
peak at day 2/4 but a decrease in numbers around day 7/10 and a subsequent re-appearance 
or even slight peak in the late phase of the response. In contrast to the aforementioned cell 
types, CD14++/CD16+ intermediate and CD14+/CD16+ nonclassical monocytes peaked at day 7 
after vaccination and subsequently converged to baseline levels. We furthermore found 
remarkable age-differences in some innate cell subsets: Elderly had highly significantly fewer 
pDCs and CD11c+ mDCs particularly at the primary peak at day 4. Conversely, they possessed 
significantly more CD14++/CD16+ intermediate monocytes at day 10 and also higher numbers 
of CD14+/CD16+ nonclassical monocytes from day 10 onwards, indicating deferred kinetics of 
both monocyte subsets in elderly individuals. Interestingly, calculating ratios of classical to 
nonclassical monocytes revealed very significant differences at all study days between the age 
groups (Day 4, Fig. 3.12K). Thus, the relative proportion of CD14+/CD16+ nonclassical 
monocytes was generally elevated in the monocyte compartment of the elderly.  
We applied multivariate analysis to our multiplex innate immune data of day 4 and generated 
complex, systemic views of our vaccinees (Chap. 2.2.10). The automated cluster analysis (ACA) 
revealed a relatively continuous distribution of innate immune states among our subjects that 
could only approximately segregate between different clusters (Fig. 3.13A). However we 
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 observed an accumulation of young vaccinees in clusters 3 and 4 characterized by mostly 
higher numbers of CD11c+ mDCs, pDCs, basophils and partly lower numbers of CD16+/CD14+ 
nonclassical monocytes (cluster 3). In contrast, clusters 1 and 2 were dominated by older 
vaccinees with intermediate to high levels of CD16+/CD14+ nonclassical monocytes and lower 
numbers of CD11c+ mDCs, pDCs and basophils. Exceptional and separated from all other 
Figure 3.12: Innate immunity during YF vaccination 
(A-I) Absolute counts of classical (A), non-classical (B), intermediate (C) 
monocytes, pDCs (D), CD11c+ mDCs (E), CD141+ mDCs (F), basophils (G), 
neutrophils (H) and eosinophils (I). P-values are listed in suppl. table 1. (K) Age 
comparison of the ratio classical/non-classical monocytes at day 4. p=0.01 Lines 
indicate the median with interquartile error bars. Young: filled circles; elderly: 
open circles 
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Figure 3.13: Multivariate analysis of innate immunity 
(A) Automated cluster analysis of innate immunity at day 4 based on whole blood counts of nine major innate 
cell subsets. Values are scaled and normalized. (C) Below, normalized YF response parameters are assigned to the 
cluster analysis. Dark blue indicates low, red high values, empty fields data not available (B) PCA of innate 
immunity at day 4 based on whole blood counts of seven innate cell subsets. Vector arrows indicate contribution 
of innate components on PCA (2fold magnified). Young: filled circles; elderly: open circles 
vaccinees was donor 28, who had very high amounts of nonclassical and transitional 
monocytes, basophils and eosinophils. Additionally, we assessed our innate dataset by PCA. 
Here, we excluded donor 28 from the analysis as he was disproportionally influencing the 
scaling of the data. As illustrated in fig. 3.13B, YF vaccinees could be segregated into two large 
clusters following largely the age criterion with only one old and three young misclassified 
individuals (two-tailed Fisher’s test: p=0.007). Thereby, PCA produced a similar classification 
as the automated cluster analysis, i.e. PCA cluster 1 (mostly elderly) corresponded to ACA 
cluster 1 and 2, whereas PCA cluster 2 (mostly young vaccinees) was congruent with ACA 
cluster 3 and 4. Altogether, by multivariate analysis we could comprehensively and unbiasedly 
compare the young and senescent innate immune system. Similar to the univariate analysis, 
age was identified as the most determining factor manifested e.g. by decreased DC and 
increased nonclassical monocyte numbers. 
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We noticed that the innate immune peak at day 4/7 coincided with the occurrence of mild 
adverse reactions such as fever, myalgia and erythema. Remarkably, young vaccinees were 
reporting more frequently side effects than elderly vaccinees (young: 64 %, elderly: 33 %). 
Grouping vaccinees according to mild adverse symptoms, revealed a clear difference in pDC 
numbers at day 4, i.e. high numbers of pDCs were characteristic for vaccinees reporting any 
symptoms (Fig. 3.14A). 
 
Figure 3.14: Influence of DCs on the YF-specific T-cell response 
(A) Absolute numbers of pDCs at day 4 in groups with or without occurrence of mild adverse events after 
vaccination. p=0.005 Without symptoms: filled triangles; With symptoms: open triangles (B-C) Positive 
correlations of absolute numbers of pDCs (B) or CD11c+ mDCs (C) at day 4 with numbers of activated HLA-
DR+/CD38+ CD8+ T cells at day 14 after vaccination. For pDCs positive correlations exists also for the CD8+ T-cell 
response at day 17 and 21. (D) Numbers of CD11c+ mDCs at day 4 correlate with numbers of Ki-67+/CD38+ CD4+ T 
cells at day 7. (E-F) Numbers of pDCs at day 4 correlate with qualitative functionality of the YF-specific CD4+ T-cell 
response. Lines indicate the median with interquartile error bars. Young: filled symbols; elderly: open symbols 
We next analyzed whether early innate signatures translated into YF-specific adaptive immune 
responses. We discovered that numbers of pDCs and CD11c+ mDCs at the peak of innate 
immunity (day 4) were highly correlative with the specific T-cell response, e.g. both DC 
subsets positively correlated with numbers of YF-specific HLA-DR+/CD38+ CD8+ T cells at 
days 14, 17 and 21 (Day 14, Fig. 3.14, B and C). Moreover CD11c+ mDCs also correlated with 
YF-specific Ki-67+/CD38+ CD4+ T cells in the expansion phase at day 4 and 7 (Day 7, Fig. 3.14D). 
In line with this, early DC responses also translated positively into YF-specific CD4+ cytokine 
responses at day 7 and 10 (not shown) and were significantly related to polyfunctionality of 
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YF-specific CD4+ T cells (Fig. 3.14, E and F). We further connected cluster analysis of innate cell 
subsets at day 4 with major adaptive response parameters (e.g. acutely activated CD4+ and 
CD8+ T cells) that were scaled and color-coded for better visualization (Fig. 3.13C). The 
distribution of some of these parameters amongst the clustered vaccinees followed very 
interesting patterns: For example YF-specific HLA-DR+/CD38+ CD8+ T cells at day 14 and 17 
were clearly higher in clusters 3 and 4 than in cluster 1 and 2. The same could be observed for 
CD4+ cytokine polyfunctionality (3 and 4 functions), whereas the opposite was true for CD4+ 
single functionality. It was of note that these patterns did not solely follow the age criterion, 
but the true individual innate immune state. For example donor 12 was grouped despite its 
age to cluster 4 and demonstrated equally high levels of e.g. YF-specific HLA-DR+/CD38+ 
CD8+ T cells as young vaccinees of cluster 3 and 4. Conversely, two of three young vaccinees (4 
and 17), who belonged to cluster 2, showed similar low levels of YF-specific HLA-DR+/CD38+ 
CD8+ T cells as elderly subjects of cluster 1 and 2. Consistently, we could visualize these 
associations also in our PCA when we overlaid median-segregated YF-specific response 
signatures (Suppl. fig. 2A-D). Thus multivariate analysis strongly supported the correlations 
observed by univariate analysis demonstrating a close connection of innate signatures 
particularly of pDCs and CD11c+ mDCs with quantity and quality of the YF-specific adaptive 
T-cell response. 
3.7.3 Influence of early immune cell migration 
Our multiplex quantitative immune assessment enabled us to investigate the temporospatial 
distribution and composition of immune cells and their subsets in peripheral blood. Plotting 
absolute cell numbers against time revealed distinct kinetic patterns of each immune subset. 
As shown in fig. 3.15A-C peripheral numbers of B and T cells highly significantly dropped from 
day 0 to day 7. This drop was transient, as numbers quickly reached or partially even exceeded 
pre-vaccination cell counts. Furthermore, we could observe the same characteristic drop in 
some, but not all subpopulations of B, T and NK cells. For example, peripheral numbers of 
naive and CM T cells pronouncedly dropped from day 0 to day 7, whereas EM and Eff CD4+ 
and CD8+ T-cell numbers did not significantly change (Fig. 3.15D-G; Suppl. fig. 3A-C). In the 
B-cell compartment, numbers of naive and memory cells transiently dropped as well (Suppl. 
fig. 3, F and G), whereas in the NK-cell compartment (Chap. 2.2.9.5) only CD56bright cells 
showed this behavior (Suppl. fig. 3, D and E). Interestingly, these subset-specific cell migration 
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Figure 3.15: Temporospatial distribution and composition of immune cells in peripheral blood 
(A-G) Absolute cell counts of (A) B cells, (B) CD4+, (C) CD8+, (D) naive CD8+, (E) CM CD8+, (F) EM CD8+ and (G) 
effector CD8+ T cells in peripheral blood in the course of the vaccine-induced immune response. Lines indicate 
the median with interquartile error bars. Wilcoxon paired signed rank tests were performed for each age group. 
Asterisks indicate significances in young and stars in elderly vaccinees. P-values are listed in suppl. table 2. (H) 
“Day 0/day 7 drops” correlate with each other, exemplified by the change of CD8+ T-cell numbers versus B-cell 
numbers from day 0 to day 7. (I) “Day 0/day 7 drops” correlate with initial numbers of the respective immune cell 
subset. As an example numbers and changes of B cells are shown. Young: filled circles; elderly: open circles 
patterns extensively correlated with each other, e.g. a strong reduction of naive CD8+ T-cell 
numbers was associated with a steep B-cell drop (Fig. 3.15H). In contrast, we could not find 
any influence of age (not shown). Hypothesizing that innate immune signatures might provoke 
more pronounced migration patterns, we correlated innate cell numbers and early innate cell 
increases with the level of decrease of T, B and NK-cell subset numbers from day 0 to day 7. 
However we could not detect any significant association (not shown). In contrast, we found 
highly significant correlations between pre-vaccination cell numbers and the respective cell 
number drop of each subset, i.e. individuals with higher numbers of e.g. peripheral B cells 
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prior vaccination experienced a more pronounced B-cell drop than vaccinees with lower initial 
B-cell counts (Fig. 3.15I). We further hypothesized that the early cell number drop may 
influence subsequent adaptive immune responses. However, the correlation analysis revealed 
no significant associations with YF-neutralizing antibody titers, plasmablast responses or YF-
specific T-cell responses (not shown). Collectively, we identified a remarkable YF-induced early 
cell migration pattern characteristic for certain B, T, and NK-cell populations that was strongly 
influenced by respective initial cell counts but not by age. 
3.7.4 Influence of chronic infections 
Chronic viral infections such as CMV and EBV infections are thought to constantly challenge 
and shape the immune system of their host. Hence, we obtained the CMV and EBV status of 
the vaccinees and investigated the influence on the YF-specific response (Chap. 2.2.7). As 
indicated in fig. 3.16A, we detected in all vaccinees EBV-specific IgG antibody titers that did 
not differ between both age groups. On the contrary, CMV-specific IgG antibodies were found 
in 58 % elderly and 45 % young vaccinees. CMV IgG titers were equal in both CMV+ age groups 
(Fig. 3.16B). We further assessed CMV and EBV-specific CD4+ and CD8+ T-cell responses before 
vaccination (Chap 2.2.9.8). All vaccinees showed an EBV-specific CD8+ T-cell response 
(Fig. 3.16C). With respect to CMV, 58 % old and 45 % young vaccinees had detectable specific 
CD8+, and 67 % old and 45 % young detectable specific CD4+ T cells (Fig. 3.16, D and E). Similar 
to the EBV/CMV serostatus we did not observe any age difference in the EBV/CMV-specific 
cellular responses. The overlap between serological and cellular CMV states was nearly 
perfect as illustrated in fig. 3.16, F and G, cross-validating our assessment of CMV response. 
Interestingly, EBV and CMV IgG serostatus (CMV+ individuals only) exhibited a high degree of 
concordance (Fig. 3.16H), which becomes important in the interpretation of the YF follow up 
study (Chap. 3.8). 
We further investigated whether CMV/EBV status affects the baseline immune constitution of 
vaccinees. From all investigated innate cell subsets (Chap. 2.2.9.2) only numbers of CD11c+ 
and CD141+ mDCs were negatively associated with EBV IgG serostatus (Fig. 3.17, A and B). 
Also, it seemed that the CMV status might influence mDC and monocyte development or 
distribution as CMV positive vaccinees had a significantly higher ratio of CD11c+ and 
CD141+ mDC numbers to classical monocytes (Fig. 3.17C and not shown). Regarding 
phenotypic T-cell composition we identified an association of EBV/CMV status with Eff, EM 
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Figure 3.16: EBV and CMV status of YF vaccinees prior vaccination 
(A) EBV and (B) CMV IgG sero status of young and elderly vaccinees. Frequencies of (C) EBV-specific and (D) CMV-
specific CD8+ T cells after antigen-specific re-stimulation. (E) Frequencies of CMV-specific CD4+ T cells after CMV-
specific re-stimulation. No significant age-specific differences were observed. (F, G) High congruence between 
CMV sero-status and measurements of CMV-specific (F) CD8+ and (G) CD4+ T cells. (H) CMV and EBV IgG sero 
titers correlate with each other (only CMV+ donors). Dashed lines indicate assay-specific cut-off values for CMV 
positivity. Note that due to the logarithmic scale zero values cannot be displayed. Lines indicate the median with 
interquartile error bars. Young: filled circles; elderly: open circles 
and CM frequencies. For example, individuals with high EBV IgG titers exhibited CD8+ and 
CD4+ T-cell compositions skewed towards higher Eff and lower CM T-cell frequencies (Fig. 
3.17, D and E). Some individuals having been CMV positive showed increased frequencies of 
Eff CD8+ T cells and EM CD4+ T cells (Fig. 3.17F and not shown). Generally, compositional 
changes observed as percentage could be found also in absolute cell numbers of T-cell 
subsets. Importantly, CMV/EBV status affected neither frequencies nor numbers of naive CD4+ 
and CD8+ T cells or CD4+ RTEs in our study.  
We also explored the YF-specific adaptive immune response for any correlations with 
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Figure 3.17: Influence of EBV and CMV status on baseline immune properties and acute YF-specific adaptive 
immunity 
Negative correlation of EBV IgG sero titers with absolute numbers of (A) CD11c+ mDCs and (B) CD141+ mDCs at 
day 0. (C) Significantly increased ratio of CD11c+ mDCs to classical monocytes at day 0 in CMV positive vaccinees. 
p=0.04 (D, E) EBV IgG titers are associated with (D) increased frequencies of effector and (E) decreased 
frequencies of CM CD8+ T cells at day 0. (F) Some CMV positive vaccinees exhibit increased frequencies of 
effector CD8+ T cells at day 0. (G, H) Examples showing that (G) EBV IgG titers and (H) CMV IgG titers do not 
correlate with activated HLA-DR+/CD38+ CD8+ T cells at day 14 after vaccination. Lines indicate the median with 
interquartile error bars. Dashed line indicates assay-specific cut-off values for CMV positivity. Young: filled circles; 
elderly: open circles; CMV IgG negative: filled squares, CMV IgG positive: open squares 
CMV/EBV status, however we could neither discover any significant impact on YF-neutralizing 
antibody titers (not shown) nor on quantity and quality of YF-specific CD4+ or CD8+ T cells (Fig. 
3.17, G and H). Altogether, our results indicate that CMV and EBV infection affected steady 
state innate immunity and T-cell constitution in terms of memory/effector phenotypic 
composition. However, it was not possible to prove any influence on the naive constitution or 
the YF-specific adaptive immune response. 
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3.8 Long-term YF-specific immunity 
So far our analysis was focused on the acute phase after YF vaccination. However, 
establishment of long-lasting immunity conveying protection against dangerous YF wild type 
infection was another important aspect that we wanted to address in our study. For this, we 
were able to re-invite 8 of 11 young and of 11 of 12 elderly study participants 20 to 35 months 
after YF vaccination and assessed their YF-specific humoral and adaptive immunity. As 
indicated in fig. 3.18A, all vaccinees still demonstrated protective titers of YF-neutralizing 
antibodies, which did not differ between the age groups. In comparison to day 28, titers 
decreased in most of the individuals (Fig. 3.18B) regardless of age (Fig. 3.18C). We next 
searched for factors influencing long-term YF-specific humoral immunity, but identified 
neither associations with acute YF-specific humoral nor cellular immune responses. However, 
we found an unexpected association between the decline of YF-neutralizing titers and EBV-
specific IgG antibody titers (Fig. 3.18D), i.e. individuals with high EBV IgG titers had an 
improved stability of long-term humoral protection against YF. 
 
Furthermore, we tracked in ten HLA-A0201+ vaccinees IFNγ-producing YF-specific CD8+ T cells 
after peptide stimulation. Numbers of these cells decreased about 7 fold in comparison to 
day 28, but still were clearly detectable (Fig. 3.19, A and B). We could not reveal any 
significant age difference in terms of long-term cell numbers and contraction (Fig. 3.19C). 
Figure 3.18: Long-term YF-neutralizing antibody response 
(A) YF-neutralizing antibody titers 20-35 months post vaccination. (B) 
Individual changes in YF-neutralizing titers from day 28 to 20-35 
months after vaccination. The decrease is significant (p=0.03) if both 
age groups are taken together. (C) The same changes depicted as 
percentages of day 28 titer levels. (D) These changes positively 
correlate with EBV IgG antibody titers. Lines indicate the median with 
interquartile error bars. Young: filled circles; elderly: open circles 
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However, comparing the acute YF-specific IFNγ+ CD8+ T-cell response with long-term 
immunity we could identify a strong, positive relationship between acute and long-term YF-
specific CD8+ T-cell levels (Fig. 3.19D). We further noticed that strong cellular CMV-specific 
T-cell responses tended to be associated with a deficient long-term stability of YF-specific 
CD8+ T cells (Fig. 3.19E). Other parameters of the acute phase, such as cell numbers of various 
innate subsets or phenotypic composition of the T-cell compartment, did not seem to 
correlate with the long-term persistence of YF-specific CD8+ T cells. 
 
Figure 3.19: Long-term YF-specific CD8+ T-cell response 
(A) Absolute numbers of YF-specific CD8+ T cells 20-35 months post vaccination. (B) Individual decreases of YF-
specific CD8+ T-cell numbers from day 28 to 20-35 months after vaccination. (C) The same decreases depicted as 
percentages of day 28 levels. (D) Magnitudes of YF-specific CD8+ T-cell responses at day 17 and 20-35 months 
post vaccination correlate with each other. Similar correlations were found with day 21 and 28 and with 
percentages of the respective days. (E) Long-term stability of YF-specific CD8+ T-cell response correlates with 
percentage of CMV-specific (E) CD4+ and CD8+ (not shown) T cells. Lines indicate the median with interquartile 
error bars. Young: filled circles; elderly: open circles 
We additionally analyzed the long-term YF-specific CD4+ T-cell response by vaccine stimulation 
and ICS. All analyzed subjects demonstrated detectable numbers of YF-specific CD4+ T cells, 
expressing at least one cytokine (Fig. 3.20A-D). Remarkably, numbers of IFNγ-producing YF-
specific CD4+ T cells were significantly lower in the elderly cohort, whereas numbers of other 
cytokine producers did not differ. Three elderly individuals even had no detectable IFNγ+ 
CD4+ T cells upon vaccine re-stimulation. In comparison to day 28, most of the vaccinees 
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Figure 3.20: Long-term YF-specific CD4+ T-cell response 
(A-D) Absolute numbers of YF-specific CD4+ cytokine producing cells 20-35 months post vaccination. CD40L+ 
IFNγ+ CD4+ T cells: p=0.002 (E-F) Individual changes of YF-specific (E) CD40L+/IL2+ and (F) CD40L+/IFNγ+ CD4+ T-cell 
numbers from day 28 to 20-35 months after vaccination. (Wilcoxon matched pairs test: Elderly CD40L+/IL2+ 
p=0.03; Elderly CD40L+/IFNγ+ p=0.001) (G) Changes in CD40L+/IFNγ+ CD4+ T-cell numbers depicted as percentage 
of day 28 levels. p=0.002 (H) Age comparison of the qualitative YF-specific CD4+ T-cell response 20-35 months 
after vaccination. Young: blue dots; Old: red dots. Black bars depict medians in each subset. Significant 
differences are indicated by hashes. (I) Changes in the YF-specific qualitative CD4+ composition (major subsets) 
from day 28 to 20-35 months after vaccination in both age groups. (K) Disproportional decrease of subsets M and 
O in elderly 20-35 months after vaccination when compared to day 28 levels. Subset M: p=0.007 Lines indicate 
the median with interquartile error bars. Young: filled circles; elderly: open circles 
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showed decreasing YF-specific CD4+ T-cell levels (about 1.2 fold for CD40L+ IL2+ CD4+ T cells) 
(Fig. 3.20, E and F). Notably, IFNγ-producing YF-specific CD4+ T cells disproportionally declined 
in the elderly cohort (Fig. 3.20G). Multiparametric analysis by SPICE revealed the long-term 
qualitative composition of YF-specific CD40L+ CD4+ T cells (Fig. 3.20H). 20 to 35 months after 
vaccination the immune response was still dominated by certain subpopulations, such as 
TNFα single producers (subpop. D) or TNFα/IL2 double producers (subpop. J). At this very late 
time point significant age differences were only observed in subpop. M and O, i.e. elderly 
possessed lower relative frequencies of TNFα/IL2/IFNγ triple and TNFα/IL2/IFNγ/IL4 
quadruple producers than young vaccinees. In comparison to the qualitative composition at 
day 28 relative proportions of some subpopulations (e.g. C and D) increased and other 
subpopulations (e.g. J and O) decreased (Fig. 3.20I). Whereas most of these changes were 
insignificant between both age groups, relative frequencies of polyfunctional subpop. M and 
O disproportionally declined in the elderly (Fig. 3.20K). As both subsets were also expressing 
IFNγ, this qualitative reduction of CD4+ polyfunctionality in long-term immunity substantially 
affected the observed decreased CD4+ IFNγ production in the elderly.  
Searching for immune signatures of the acute phase influencing long-lasting YF- specific 
CD4+ T-cell immunity, we discovered very significant correlations between acute and long-
term CD4+ T-cell responses (Fig. 3.21A). Thus and in analogy to long-term YF-specific 
CD8+ immunity, individuals with strong acute YF-specific CD4+ responses demonstrated 20 - 30 
months later increased YF-specific CD4+ memory responses, which was true for all measured 
cytokines. Since robust acute YF-specific CD4+ T-cell responses were strongly related to high 
numbers of pDCs, CD11c+ mDCs and RTEs, we could as well reveal these underlying 
associations in long-term YF- specific CD4+ T-cell immunity (Fig. 3.21, B and C). Regarding 
CMV/EBV status of the vaccinees we could not identify any effect on long-term YF-specific 
CD4+ T-cell immunity, contrasting the results found in CD8+ T cells.  
Collectively, our analysis demonstrated presence of protective long-lasting YF-specific humoral 
and cellular immunity in all vaccinees regardless of age. We could show that up to 3 years post 
vaccination the magnitude of remnant cellular immunity was largely determined by strength 
of the previous acute cellular response. Moreover chronic infection with CMV and EBV 
seemed to differentially influence stability of YF-specific humoral and CD8+ T cell responses. 
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Figure 3.21: Correlation of long-term YF-specific CD4+ T-cell immunity with the acute YF response 
(A) YF-specific long-term CD4+ T-cell responses significantly correlate with YF-specific acute CD4+ T cell responses 
from day 7 to 28. Shown is the correlation with values from day 17. (B) Correlation between initial numbers of 
CD4+ RTE and long-term numbers of CD40L+ IFNγ+ CD4+ T cells. (C) Correlation between numbers of pDCs at day 4 
and long-term numbers of CD40L+ IL2+ CD4+ T cells. Young: filled circles; elderly: open circles 
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4. Discussion 
4.1 Challenges of investigating primary immune responses in humans 
As entire primary acute immune responses have never been investigated in such detail before 
in human elderly, we conceptualized a study with an exploratory, discovery-driven character 
and with very general initial assumptions. Given also the ethical restrictions for live 
vaccinations in human elderly, our approach was determined by some limitations, that one 
has to become aware of, before discussing the results. 
First, our study was restricted in the upper age of the elderly cohort, due to ethical concerns. 
With a reporting rate of 1-2.3 per 100,000 vaccinations, persons aged more than 60 years are 
at 4-13 fold higher risk than young adults to develop serious YEL-AVD (Monath, 2012) and 
therefore require careful risk-benefit analysis when YF-vaccinated in Germany. In other 
countries YF vaccination of this age group is even contraindicated. For this reason, we 
recruited most of the elderly volunteers in the range of 55-65. Only 3 participants were in the 
range of 65-70. Although our aged cohort was hence at the ethically permitted most upper 
age border for YF vaccination, it was relatively “young” in comparison to other studies in the 
field of immunological aging, usually focusing on persons being significantly older than 70 
(Pawelec, 2012).  
Second, and mostly due to our very restrictive recruitment, our study was relatively small with 
only 26 enrolled participants. Of these, we had to omit two vaccinees due to pre-existing tick-
borne encephalitis virus-specific antibodies originating perhaps from natural, occult infection 
(Gustafson et al., 1993; Kaiser et al., 1997; Hunfeld et al., 1998). As these antibodies cross-
react with YFV (Allwinn et al., 2002; Holzmann, 2003; Litzba et al., 2014), they potentially 
impede the generation of a truly primary immune response. From all published YF vaccination 
studies, this is the first study that did not solely rely on vaccination records, but in addition 
applied laboratory testing for pre-existing cross-reactive antibodies. The exclusion of two 
participants confirmed the necessity of this thorough pre-screening. 
Third, as a consequence of the small sample number, statistical analysis was complicated by 
low statistical power. A further difficulty was the high individual variability, inherent to human 
studies. To account for this, we applied very robust statistics, i.e. medians, interquartile ranges 
and two-sided Mann-Whitney-U test were used. Furthermore, we performed the study in 
three independent rounds and avoided further sub-grouping, which would make proper 
evaluation impossible. Due to the small sample size we did not adjust the significance level for 
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multiple testing. Since we applied correlation analyses one should be aware that correlation 
does not necessarily imply causality, but e.g. could instead involve a third unknown variable. 
To increase certainty, we considered correlations usually only when they were observed (at 
least by trend) on consecutive days. 
And fourth, the study design was exploratory. For example, the blood drawing scheme was 
assumed from experience with young YF vaccinees, thought it was unclear whether this would 
apply also to old YF vaccinees who might have a different time course. As we measured YF 
responses in the elderly for the first time and for this analyzed leukocyte subsets not even 
having been assessed in such a context in young vaccinees, we started mostly with very 
general initial hypotheses, e.g. that elderly YF vaccinees have weaker or slower immune 
responses in comparison to young adults. 
In view of such premises and the fact that we obtained more than 16,000 individual data 
points, it should be noted that most results require validation from large confirmatory studies. 
Nevertheless, some results could be already demonstrated in animal studies or fit well to 
long-suspected assumptions. Thus this study provides ample interesting findings and 
associations, providing the basis for further experimental human aging studies. 
4.2 Late viremia and reduced neutralizing antibody titers in elderly vaccinees 
The first key finding of our study was that elderly vaccinees did not only develop 1.2 fold more 
often a detectable serum viremia but also that the viremia occurred significantly later than in 
young adults. In particular remarkable were four old vaccinees with peak viremia on day 7 or 
10, which is a very unusual feature as viremia in young adults occurs between day 2 to 7 
(Reinhardt et al., 1998; Monath et al., 2003; Akondy et al., 2015). Also a recent YF modeling 
paper reports that peak viral load in the blood in young adults is reached on average on day 5 
(Le et al., 2014). Our observations were in strong concordance with data from Roukens et al., 
the only yet published aging study investigating the acute response after YF vaccination 
(Roukens et al., 2011), who report for their old cohort an increased frequency of serum 
viremia as well as virus detectable in blood for longer periods and on late time points (day 10). 
Late occurrence of viremia seems to be a detrimental feature and an indication for ineffective 
virus control as late viremia has been also reported for a 64-year-old vaccinee, who 
experienced YF-SAE (Pulendran et al., 2008) and in aged mice models, challenged with 
sublethal, primary flu or LCMV infections (Murasko and Jiang, 2005). Thus, we propose that 
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late viremia in the elderly is a consequence of impaired viral clearance, possibly due to 
diminished anti-viral immune effector mechanisms. 
Indeed and in line with Roukens et al. (Roukens et al., 2011), we observed reduced YF-
neutralizing antibody titers in elderly vaccinees between days 14 to 21. Of note, both age 
groups reached by day 28 comparable neutralizing titers, which were maintained equally in 
both groups 2-3 years post vaccination, which is in agreement with results from other large YF 
vaccination trials (Monath et al., 2005; Vratskikh et al., 2013). Interestingly, in primary TBE 
vaccination significantly lower neutralizing antibody titers were achieved in aged cohorts 
(Hainz et al., 2005; Weinberger et al., 2010; Stiasny et al., 2012), suggesting that underlying 
mechanisms might differ between live-virus vaccinations, such as against YFV, imperatively 
requiring complete virus elimination, and inactivated whole-virus vaccinations, such as against 
TBE virus. 
In contrast to other YF studies, we additionally analyzed different isotype classes of YF-specific 
antibodies. Interestingly, YF-specific IgM production seemed to start in young vaccinees 
slightly earlier than in old, whereas the IgG and IgA responses were indifferent between both 
age groups. Moreover, onset of detectable YF-specific IgM production showed a good 
correlation with neutralizing titers on day 10, collectively suggesting that the generation of 
early neutralizing capacity is probably mediated through IgM antibodies, as shown for 
smallpox vaccination (Moyron-Quiroz et al., 2009) and is critically delayed in elderly vaccinees. 
Beside the aspect of direct virus neutralization, IgM antibodies have been shown to be highly 
efficient at opsonisation compared to IgG (Park and Nahm, 2011). Thus a small age-related 
delay in IgM production might be significant for virus elimination in old age. In addition, the 
produced IgM amount might be reduced in our aged cohort, but our semi-quantitative IIFA did 
not allow a precise comparison, though reduced IgM and IgA responses to pneumococcal 
booster vaccination have been reported for old people (Ademokun et al., 2011; Park and 
Nahm, 2011). It remains open for future research, to which extent each isotype is contributing 
to the total neutralizing capacity and how much this is altered in the elderly. Another 
interesting aspect is antibody affinity and avidity, which has been shown to be decreased in 
primary responses in aged mice (Doria et al., 1978). For humans, study results in this respect 
are ambiguous, with reports finding no age-related differences (Sasaki et al., 2011; Stiasny et 
al., 2012) or decreased affinities in the elderly (Khurana et al., 2012). As antibody affinity has 
not yet been investigated in the context of a primary immune response against live-virus in 
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humans, a potential impact on virus elimination needs to be determined by in the future. 
4.3 Increased acute plasmablast responses in the elderly 
In addition to our analysis of serological immunity, we assessed the B-cell response, in 
particular acutely induced plasmablasts. Plasmablasts usually generated in the germinal 
center reaction are major producers of antibodies in the acute response phase and might 
differentiate into secondary lymphoid organ-resident plasma cells. We identified plasmablasts 
with the marker combination CD19low/CD20neg/CD27hi/CD38hi (Odendahl et al., 2005; Fink, 
2012), but as we did not include CD138 we could not define the proportion of putative plasma 
cells within this population (Caraux et al., 2010; Qian et al., 2010). Our analysis revealed a 
distinct peak of acutely induced plasmablasts around day 10 and 14 post vaccination in both 
age groups, resembling a typical primary response kinetic, which has been previously reported 
by us and another group for YF vaccination and primary dengue virus infection (Kohler et al., 
2012; Wrammert et al., 2012). This is in contrast to secondary responses e.g. to inactivated 
influenza and tetanus vaccinations, which show a transient acute plasmablast response 
around day 7 (Cox et al., 1994; Odendahl et al., 2005; Wrammert et al., 2008; He et al., 2011). 
Unexpectedly, the magnitude of the YF induced acute plasmablast response was significantly 
higher in our elderly cohort than in the young, which is in stark contrast to secondary flu 
vaccinations, where the opposite was found (Sasaki et al., 2011; Frasca et al., 2012). As we did 
not further characterize the plasmablasts, we can only speculate about the underlying cause 
for our observation. Thus it might be possible that (A) plasmablasts from aged individuals 
have a lower per-cell antibody production or express antibodies of lower affinity, requiring 
more plasmablasts to compensate this defect. However, in flu vaccination no such qualitative 
difference was found (Sasaki et al., 2011). It might also be possible that (B) other specificities 
than against YF, so called bystander specificities, are induced more pronounced in the elderly. 
So far bystander induction has been investigated only in young adults and while bystander 
induction evidently takes place (Bernasconi et al., 2002), the proportion of unrelated 
plasmablasts in the total plasmablast response strongly varies between different reports 
(Odendahl et al., 2005; Wrammert et al., 2008, 2012; Lee et al., 2011; Hong et al., 2013). 
Alternatively, the stronger plasmablast peak might reflect (C) an exaggerated immune 
response in the elderly, due to e.g. less efficient early virus control and thus prolonged 
presence of antigen. Indeed, in dengue infection the magnitude of plasmablast induction 
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correlates with disease severity (Garcia-Bates et al., 2013). It should be noted that more 
plasmablasts lead to more virus-specific antibodies (Wrammert et al., 2012), but not 
automatically to higher virus-neutralizing antibody titers as seen in our study and in dengue 
infections (Garcia-Bates et al., 2013), rendering an exaggerated plasmablast response not 
necessarily more effective. Interestingly and analogous to the plasmablast response, we 
observed as well exaggerated YF-specific CD4+ T-cell responses in our elderly vaccinees, as 
discussed later on. As both response magnitudes correlated with each other, it is very likely 
that both can be attributed to the same underlying cause, e.g. ineffective early virus control. 
Apart from plasmablasts, we monitored naive and memory B cells in the course of the 
response. Both showed very distinct kinetics, which are probably specific migration patterns, 
as discussed in chapter 4.8. Probably due to our small study size we could not observe the 
modest age-related decline in naive B cells, reported in the literature (Johnson and Cambier, 
2004). Further, pre-vaccination numbers of naive B cells were not predictive for subsequent 
plasmablast or neutralizing antibody responses, but there was the interesting finding that 
vaccinees with higher numbers of naive B cells on day 7 mounted subsequently stronger 
plasmablast responses. As day 7 marks the low point in the peripheral naive B-cell kinetic, 
which we interpret as a sign of migration to secondary lymphoid organs, it is imaginable that 
higher remnant numbers of naive B cells at this day reflect compromised lymphoid homing. In 
consequence, virus elimination and humoral response is possibly delayed, triggering a 
(compensatory) exaggerated plasmablast response. Although this is a highly speculative 
assumption, reports from aged mice indeed demonstrated reduced germinal center formation 
(Kosco et al., 1989; Szakal et al., 1990; Han et al., 2003). Another study showed an altered 
composition of germinal centers in aged human tonsils (Kolar et al., 2006). This and the fact 
that such a correlation was found only for naive but not for memory B cells on day 7 speak for 
decisive age-related alterations in the early phase of the naive B cell response, that need 
detailed analysis in future studies. 
4.4 Diminished acute YF-specific CD8+ T-cell responses in the elderly 
CD8+ T cells, capable of killing virus-infected cells, represent an important immune effector 
mechanism essentially limiting virus dissemination in the body. As recently demonstrated in 
the murine YF model, CD8+ T cells complement humoral protection mediated through YF-
neutralizing antibodies. In a B-cell knockout situation 25 % of mice survived an otherwise 
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100 % lethal intracerebral YFV injection (Bassi et al., 2015). For tracking YF-specific CD8+ T cell 
in the acute phase, we took advantage of the expression of the activation marker combination 
CD38 and HLA-DR, which can be measured directly ex vivo and which is applicable to all 
vaccinees regardless of their HLA types. In this kind of measurement it is unavoidable that 
some unspecific CD8+ T cells are co-detected, as seen in our baseline data, however CD8+ T 
cells expressing CD38+/HLADR+ in the acute response phase (between day 4 and 28) are 
almost exclusively YF-specific, as demonstrated in several publications (Miller et al., 2008; 
Akondy et al., 2009, 2015; Ahmed and Akondy, 2011; Kohler et al., 2012; Blom et al., 2013; 
DeWitt et al., 2015). In accordance with these reports, YF-specific CD38+/HLADR+ CD8+ T cells 
in our study expanded extensively until about day 17 and returned to basal levels by day 28, 
which we could demonstrate was kinetically true for both age groups. However, the 
magnitude of the YF-specific CD8+ T cell response was strikingly reduced in the elderly, which 
is another key finding of our study and confirms for the first time similar observations made in 
various aged animal models (Murasko and Jiang, 2005; Brien et al., 2009; Nikolich-Žugich et 
al., 2012) for a human setting. Thus, both major anti-viral effector mechanisms, neutralizing 
antibodies and specific CD8+ T cells, are obviously quantitatively diminished in the elderly, 
which we assume affects clearance of YF virus. 
We furthermore investigated possible qualitative differences in the YF-specific CD8+ T-cell 
response for which we stimulated PBMCs with the very immunodominant HLA-A0201-
restricted peptide LLWNGPMAV (Akondy et al., 2009). Only 5 young and 5 old vaccinees were 
carriers of HLA-A0201 in our study and thus statistics was underpowered. Nevertheless and in 
agreement with published data (Akondy et al., 2009; Querec et al., 2009), specific cell 
numbers in the acute phase obtained by peptide stimulation strongly overlapped with our 
CD38/HLADR measurements, indicating that results of the HLA-A0201+ subgroup are probably 
applicable to all YF vaccinees. Interestingly, YF-specific CD8+ T cells in aged vaccinees were 
characterized by increased expression of Granzyme A and B and decreased amounts of 
Perforin, while IFNγ, IL2 and CD40L expression was indifferent, which is in contrast to a 
publication comparing West-Nile-specific CD8+ T cells in young and old infected individuals, 
reporting no qualitative differences at all (Lelic et al., 2012). However, these West-Nile-specific 
CD8+ T cells were measured 3-4 months after disease onset and therefore might not reflect 
the acute state we observed within the first month after infection. This time difference might 
also explain why this group could not find any age-difference in the West-Nile-specific CD8+ 
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response magnitude in an earlier publication (Parsons et al., 2008). Whether the observed 
age-related qualitative alterations, which certainly require validation in larger cohorts, further 
deteriorate the already quantitatively reduced YF-specific CD8+ T cell response, remains an 
open question. Future studies might employ ex vivo functional assays, e.g. specific killing 
assays of peptide-pulsed or infected target cells, which we could not conduct in this study due 
to the restricted blood volume we were limited to. Such analysis may help to uncover 
qualitative deficits in YF-specific CD8+ T cells in the elderly. 
Beside that, it would be interesting to analyze the influence of the individual HLA composition, 
which we, except for HLA-A0201, did not consider in our study. In acute dengue patients it has 
been shown that certain HLA alleles correlate with stronger CD8+ response magnitudes 
(Weiskopf et al., 2013). Therefore individual HLA composition might bias our quantitative 
results and should be included in future studies, though this will require much larger cohorts. 
Another aspect is bystander activation, which has been shown to exist in the CD8+ 
compartment in severe infections, such as with Hepatitis B, dengue, adeno-, hanta- and 
Influenza A virus, where a significant proportion of CD38+/HLA-DR+ CD8+ T cells are CMV or 
EBV specific (Tuuminen et al., 2007; Sandalova et al., 2010; Rivino et al., 2015). But this has 
not been observed after experimental YF or smallpox infection (Miller et al., 2008) or 
naturally-acquired TBE virus infection (Blom et al., 2015). The reason for these conflicting 
observations might be due to the fact that severe virus infections cause high levels of 
inflammation, inducing frequencies of more than 20 % of acutely activated CD38+/HLA-DR+ 
CD8+ T cells. In contrast, the infection with attenuated YF vaccine virus is usually very mild and 
typically induces CD38+/HLA-DR+ CD8+ T-cell frequencies below 10 %. As we did not determine 
CMV or EBV specific CD8+ T cells in the acute phase and such an analysis has never been done 
in aged donors, we cannot rule out that bystander CMV or EBV-specific CD8+ T cells 
contributed to the measured CD8+ response magnitude in our study. In case this had occurred 
in our elderly vaccinees, their net CD8+ response would have been even lower, which thus 
would have even worsened virus elimination. 
Future studies should also address CD8+ T-cell clonality, which has been very recently 
investigated in YF vaccination in young adults. Based on deep sequencing of the CDR3 locus of 
the TCRβ chain, DeWitt et al. identified on average 2.000 YF-specific CD8+ T-cell clones at the 
peak of the acute response in each subject (DeWitt et al., 2015). It would be interesting, 
whether clonality is reduced in aged vaccinees, which could be another factor beside 
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quantitative and qualitative differences influencing vaccination outcome, though quite large 
amounts of blood are required for proper analysis.  
Collectively, the cytotoxic CD8+ T-cell response appeared to be considerably reduced in aged 
YF vaccinees, which might be detrimental in the anti-viral defense. 
4.5 Quantitative and qualitative alterations in the acute YF-specific CD4+ T cell response 
in the elderly 
We next studied the YF-specific CD4+ T-cell response, which has been analyzed so far only in 
young adults in a limited number of publications (Kohler et al., 2012; Blom et al., 2013; James 
et al., 2013). We assessed YF-specific CD4+ T cells in two ways: A) In analogy to the assessment 
of YF-specific CD8+ T cells and similarly to Blom et al. (Blom et al., 2013), we tracked them by 
the co-expression of Ki-67 and CD38. And B) we performed ex vivo short-term stimulations of 
blood with whole vaccine and detected YF-specific CD4+ T cells by ICS. Both types of 
measurements showed a high degree of concordance in the acute phase in most of the 
vaccinees, though the stimulation assay showed higher variability. Both age groups started to 
mount comparable early acute Ki-67+/CD38+ CD4+ T-cell responses. But interestingly, while the 
response in nearly all young adults was culminating already on day 10, in about half of the 
aged vaccinees CD4+ T cells continued to expand until day 14, leading to a significantly 
enhanced total CD4+ expansion in the aged group, which is consistent with data from aged 
macaques after primary WNV infection (Wertheimer et al., 2010). Of note, good early YF-
specific CD4+ T-cell responses e.g. on days 4, 7 and 10, but not later, seemed to be key for 
better subsequent humoral and cytotoxic T-cell responses and in turn earlier viral control. In 
contrast, increased late expansion on day 14 was strongly associated with delayed virus 
control and, as outlined before, with the exaggerated plasmablast response. Thus it seems to 
us, that both increased late CD4+ expansion and the inflated plasmablast response in the 
elderly are a consequence of the same cause, possibly prolonged presence of YF antigen due 
to delayed virus control. 
Overall, we revealed on the one hand and as expected from textbook knowledge, a beneficial 
effect of quantitative early YF-specific CD4+ responsiveness on anti-viral effector mechanisms, 
though an influence of age was not statistically detectable in this early phase. On the other 
hand, under certain circumstances, acute CD4+ T-cell responses can become also prolonged or 
exaggerated, as seen in many aged YF vaccinees, which we think represents perhaps a 
countermeasure to still adequately fight back a viral attack in an immunosenescent situation 
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with a weakened virus defense. Interestingly, a study comparing CD4+ T-cell responses in 
healthy adult and frail elderly after flu vaccination as well observed a positive association 
between early CD4+ responsiveness and humoral immunity. They also could show an 
unfavorable prolonged specific CD4+ T-cell response in frail subjects, though they report in 
contrast to us no excessive responses, which might be in their study due to the application of 
a non-replicating vaccine (Deng et al., 2004). Nonetheless, also alternative explanations for 
the exaggerated response such as increased bystander activation in the elderly should be 
considered, though at least in young YF vaccinees Tetanus-toxoid-specific memory CD4+ T cells 
were disproven to express the proliferation marker Ki-67 in the acute response phase (Kohler 
et al., 2012), which, however, does not rule out bystander activation of other specificities with 
less stringed activation requirements such as EBV- or CMV-specific CD4+ T cells. 
Assessing YF-specific CD4+ T cells by stimulation assay and ICS, revealed a typical anti-viral 
response (Swain et al., 2012) dominated by TH1 cells, expressing TNFα and IFNγ, as shown 
earlier by our group (Kohler et al., 2012). Quantitative age differences in the cytokine 
production of TNFα, IFNγ and IL4 were found only on day 2 and 7, but no further correlations 
with anti-viral effector mechanisms could be identified. Beside the age aspect, we observed 
three other interesting findings: First, there is a small but significant peak of YF-specific CD4+ T 
cells on day 2, preceding the main response, which becomes apparent after day 7. The same 
observation was made also by Bethke and Kohler (Bethke, 2011; Kohler et al., 2012). It is 
possible that this early peak reflects priming or re-activation of CD4+ T cells at the injection 
site, whereas the main response is probably a result of massive priming and expansion in 
lymphoid tissue, a notion supported also by our T-cell migration patterns, as discussed later. It 
would be interesting to verify, whether these early YF-specific T cells origin from truly naive or 
cross-reactive memory T cells (Welsh and Selin, 2002; Bacher et al., 2013; Su and Davis, 2013), 
which could be approached by a deep TCR repertoire sequencing. A possible involvement of 
cross-reactive memory is supported by the fact that already prior vaccination all vaccinees 
possessed very small amounts of CD4+ T cells, reactive to stimulation with the YF vaccine, 
despite rigorous exclusion of individuals with flavivirus-cross-reactive serology. Furthermore, 
these pre-vaccination cells expressed almost exclusively TNFα and/or IFNγ, but not e.g. IL2, 
rendering them very similar to the phenotype observed on day 2, but very different to YF-
specific CD4+ T cells of the main response, predominantly co-expressing IL2. In addition, pre-
vaccination numbers of these cells also positively correlated with the early peak on day 2 
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(data not shown). Thus we think, YF-specific CD4+ T cells on day 2 most likely descend from 
apparently cross-reactive CD4+ T cells, though it is unclear to which extent they contribute to 
the subsequent main response and whether this has any effect on other aspects of the 
immune response and viral clearance.  
Second, we observed IL4 being produced predominately by TH1-like cells throughout the 
response, rather than by classical TH2 cells, thus questioning the fixed TH1/TH2 paradigm. Our 
findings fit to early human in vitro studies reporting that IFNγ and IL4 expression are not 
mutually exclusive features and can be co-expressed (Maggi et al., 1992). Also human memory 
TH1 cells can acquire the capacity to additionally express IL4 in vitro (Messi et al., 2003) and 
mixed TH1/TH2 phenotype cells expressing both master transcription factors GATA-3 and T-bet 
or the cytokines IFNγ and IL4 at the same time can arise in vivo in mice after primary infection 
with a parasite (Peine et al., 2013; Deaton et al., 2014). Our observations confirm the 
existence of such cells in vivo in human subjects in the context of a strong TH1-inducing 
immune response, suggesting that TH1 and TH2 cell fates are more plastic than previously 
thought, although detailed further phenotypic and epigenetic analysis is needed. Moreover, it 
would be interesting to explore, whether those cells fully take over functions believed to be 
exerted by classical TH2 cells and which advantage they possess by expressing both, TH1 
cytokines and IL4. 
The third interesting observation was the transient occurrence of IL17/IL22-expressing YF-
specific CD4+ T cells. With an early peak on day 7, those cells displayed a kinetic, strongly 
differing from the general YF-specific CD4+ response. Although a minor subset, we revealed 
that they were highly polyfunctional, always co-expressing IL2, TNFα and partially IFNγ, which 
is not unexpected given the high plasticity of TH17 cells (Annunziato and Romagnani, 2009; 
Romagnani et al., 2009; Cosmi et al., 2014; Geginat et al., 2014). So far, the role of TH17 cells 
in fighting acute viral infections is ill defined, thought presence of virus-specific TH17 cells have 
been documented e.g. for HIV, CMV and acute viral hepatitis (Yue et al., 2008; Hou et al., 
2013). Since our study is the first to show the human TH17 dynamics to an acute viral 
infection, it is difficult to define the exact role of these TH17 cells in the YF-specific immune 
response. In view of the early peak of TH17 cells on day 7, preceding the main CD4+ response, 
one could speculate that they enter the site of inflammation earlier, thereby promoting 
subsequent recruitment of other immune cells, e.g. of TH1 and cytotoxic CD8+ T cells, in 
analogy to what has been observed in mice during Mycobacterium tuberculosis infection, 
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adenovirus-induced acute hepatitis and ovalbumin vaccination (Khader et al., 2007; Pötzl et 
al., 2008; Hou et al., 2013). In this context one also should note the second IL17 peak on day 
21, clearly succeeding the main CD4+ response. It is possible that these late TH17 cells, that 
might have acquired the capacity to express e.g. IL10 (Ayyoub et al., 2009; Sallusto et al., 
2012; Geginat et al., 2014), mediate in the contraction phase an immune-dampening function, 
but for a more definite conclusion a deeper phenotypic characterization of those cells at 
different timepoints, e.g. by mass cytometry, would be required.  
Having assessed in parallel six different cytokines allowed us to determine not only quantity 
but also the composition of the YF-specific CD4+ T-cell response. Changes in the functional 
composition of YF-specific CD4+ T-cells were mostly observed over time rather than between 
both age groups. Thus it became apparent that the qualitative composition on day 7 was 
different from day 14, which differed again from day 28, reflecting possibly functional 
adaption required in different phases of the immune response. The time course however also 
revealed that in comparison to young vaccinees, particularly the monofunctional IL2+ CD4+ 
T-cell subset, lacking other investigated effector cytokines, was strongly inflated around the 
CD4+ response peak in the elderly. This would fit well to the increased expansion of 
Ki-67+/CD38+ CD4+ T cells in aged vaccinees and indeed we identified a highly significant 
correlation between those IL2 single-producers e.g. at day 14 and the acutely-induced 
CD4+ expansion. Whether this particular subset is a response to the deferred viral clearance or 
just a driving force to enhance proliferation in elderly YF vaccinees is difficult to tell, however 
the fact that it represents a very prominent subset constituting up to a quarter of the total YF-
specific response on day 14 and 17 in the elderly suggests an important role. 
Related to this is another cardinal finding of this study. YF-specific CD4+ T cells in elderly 
vaccinees were significantly less polyfunctional and conversely more monofunctional than 
their counterparts in young individuals. Although summing up cytokine expression seems to 
be a rather arbitrary measure, increased ability of a particular cell to co-express several 
cytokines has been shown to be associated with higher cytokine expression levels and better 
other functionalities (Darrah et al., 2007; Kannanganat et al., 2007), which we observed in our 
study as well (data not shown). Accordingly, the qualitative polyfunctionality index has been 
reported to relate to improved pathogen control and better vaccination responses (Seder et 
al., 2008). Strikingly, also in our study, higher CD4+ polyfunctionality, characteristic for young 
vaccinees, was strongly correlated to better neutralizing antibody titers and CD8+ T-cell 
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responses. Thereby, our study proves that age clearly impacts qualitative functionality in an 
acute primary response. 
Altogether, we uncovered age-related alterations in the YF-specific CD4+ T-cell immunity at the 
quantitative and qualitative level and both seemed to be interlinked with each other, as 
specific CD4+ T-cell numbers at day 10 correlated with the capacity to co-express multiple 
cytokines. Our correlation analysis further revealed that these alterations likely affect humoral 
and cellular effector responses and thereby also viral clearance.  
4.6 Impact of pre-vaccination T-cell composition, in particular of naive CD8+ T cells and 
CD4+ RTE, on the immune response to YF 
Having identified prominent age-related alterations in YF-specific adaptive immunity, we next 
sought to find immune signatures prevalent before or early after vaccination that critically 
influence subsequent adaptive immunity and vaccination outcome. Several studies have 
described age-related, compositional changes in circulating T-cell phenotypes at the steady 
state (Hong et al., 2004; Saule et al., 2006; Weinberger et al., 2007; Provinciali et al., 2009; Di 
Benedetto et al., 2015) and some have also shown an effect on booster vaccinations 
(Trzonkowski et al., 2003; Kang et al., 2004; Moro-García et al., 2012; Derhovanessian et al., 
2013). However, whether and how the present phenotypic T-cell composition influences a 
de novo immune response has not been explored so far in humans, which led us to investigate 
this subject with a special focus on naive T cells, assumed to play a pivotal role in primary 
responses. Our immunophenotyping at day 0 revealed a significant reduction of naive CD8+ T 
cell numbers in the elderly, which has been reported to be a very prominent compositional 
change with age (Fagnoni et al., 2000; Appay and Sauce, 2014). Differences in other T-cell 
subsets, such as EM and Eff T cells did not reach statistical significance between both age 
groups, though studies with larger cohorts were able to reveal differences in some of those 
individually more variable T-cell subsets (Fülöp et al., 2013; Adriaensen et al., 2015; Di 
Benedetto et al., 2015). Interestingly, although numbers of naive CD4+ T cells were 
comparable between young and old subjects, confirming a recent cross-sectional study 
(Wertheimer et al., 2014), the frequency (and in consequence also number) of CD31-
expressing CD4+ RTE, contained therein, was highly significantly reduced in aged individuals in 
our study. This is a clear sign of reduced thymic activity in the elderly and was expected from a 
number of earlier studies (Kimmig et al., 2002; Gomez et al., 2003; Kohler et al., 2005; Junge 
et al., 2007; Kilpatrick et al., 2008; Tanaskovic et al., 2010; den Braber et al., 2012). While we 
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did not analyze the naive TCR repertoire directly, our CD4+ RTE data strongly implies that our 
aged study participants had a less diverse TCR repertoire than the young ones, as CD4+ RTE 
have been demonstrated to be the primary, essential repository for highly diverse naive CD4+ 
T cells comprising also newly generated T-cell specificities (Kohler et al., 2005). 
But do reduced pre-vaccine numbers of naive CD8+ T cells and CD4+ RTE, characteristic for the 
elderly vaccinees, matter when it comes to a primary infection? The correlation analysis we 
performed suggests, that indeed weaker YF-specific T-cell responses are strongly associated 
with limited availability of naive CD8+ T cells and CD4+ RTE prior to vaccination. For example, 
vaccinees with low amounts of CD4+ RTE clearly mounted quantitatively reduced, early YF-
specific CD4+ T-cell responses and generated less polyfunctional YF-specific CD4+ T cells. This 
key finding of our study, experimentally demonstrated for the first time in humans, was not 
completely unexpected as experiments in mice have suggested this association (Yager et al., 
2008; Blackman and Woodland, 2011). But given the fundamental difference in naive CD4+ T-
cell homeostasis between mice and man, which relies in man predominately on peripheral 
proliferation rather than on thymic output (den Braber et al., 2012), it is remarkable that 
antigen-specific adaptive T-cell immunity after primary infection is nevertheless strongly 
determined by the number of CD4+ RTE and not by total naive CD4+ T cells. This points out 
that thymic output, as the only process to generate new T-cell specificities, is of essential 
importance for the generation of an effective primary response to a neoantigen. Notably and 
in opposite to what has been found in booster vaccinations, the pre-immune status of 
memory or effector T cells did not influence the YF-specific response, emphasizing again the 
predominant role of naive CD4+ RTE in a de novo challenge. 
For CD8+ T cells we could show that individuals with low initial numbers of naive CD8+ T cells 
generate subsequently weak YF-specific CD8+ T-cell responses. Obviously here the size of the 
total naive CD8+ T cell pool is already a decisive factor, similar to what has been reported from 
primary infections in rhesus monkeys (Cicin-Sain et al., 2010). For yet unknown reasons, 
thymic involution affects the naive CD8+ T-cell compartment much more than its entire naive 
CD4+ counterpart (Appay and Sauce, 2014). In consequence, age-related changes, such as 
contraction of the naive pool and loss of the naive repertoire diversity (Buchholz et al., 2011), 
become apparent earlier and more noticeable in naive CD8+ T cells than in naive CD4+ T cells. 
The initial number of total naive CD8+ T cells in our study is hence strongly connected to 
individual thymic activity in a similar way as CD4+ RTEs. Both parameters also correlate highly 
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significantly with each other (data not shown). Thus in analogy to CD4+ RTE, limited availability 
of naive CD8+ T cells is a factor that critically dictates the magnitude of a primary YF-specific 
CD8+ T-cell response. 
Our observations provide a plausible explanation for the high incidence of YF-SAE in 
thymectomized vaccinees (Eidex, 2004), who rely for obvious reasons solely on peripheral 
naive T-cell proliferation and cannot produce new T-cell specificities. Similarly, reduced 
numbers of CD4+ RTE and naive CD8+ T cells might be a reason for the increased incidence of 
YF-SAE in individuals older than 60 (Monath et al., 2005; Rafferty et al., 2013). Although only 
some study participants were older than 60 and none of the vaccinees experienced YF-SAE, 
we might have observed mild first signs of a beginning diminution of responsiveness due to 
reduced thymic output and repertoire loss in our old study cohort. At e.g. more advanced age, 
the accumulated lack of many essential T-cell specificities, in other words the increased 
presence of “holes” in the TCR repertoire (Yager et al., 2008), found also in studies with aged 
mice (Smithey et al., 2012), might prevent under certain circumstances the generation of a 
sufficient primary response repressing spread of the YF vaccine virus. Alternatively or in 
addition to complete extinction of certain naive TCR specificities, which are estimated at least 
to range between 100 and 1000 T cells per clone in humans (Arstila et al., 1999), it is 
imaginable that at advanced age individual clone size is quantitatively reduced to such an 
extent that secondary lymphoid organs are insufficiently covered (Buchholz et al., 2011). Thus, 
the few remaining naive T cells might reach the site of infection too late and/or are 
insufficiently primed. It would be highly interesting to elucidate directly whether naive TCR 
repertoire constriction or clone size reduction or a combination of both is responsible for the 
reduced responsiveness to de novo challenges in the elderly. Thus, for future confirmatory 
studies it would be indispensable to include a detailed TCR repertoire analysis, e.g. by a deep 
sequencing approach. By a highly sophisticated combination of Tetramer-enrichment of naive 
CD8+ T cells (Alanio et al., 2010) and deep-sequencing it would be even possible to assess and 
compare quantity and quality of certain YF-epitope-specific naive precursors between young 
and old vaccinees. Another aspect we have not touched is to test naive functionality in vitro 
and relate it to in vivo correlations. Altogether, reduced availability of naive CD8 T cells and 
CD4+ RTE in the elderly is an immune signature associated with poor primary responsiveness 
to YF vaccination and with further validation both measures could be included in pre-
vaccination risk assessment strategies for elderly or immune compromised individuals. 
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4.7 Age-alterations in YF-induced innate immunity and the impact on adaptive immunity 
Innate immunity provides the basis for efficient initiation of an adaptive immune response. It 
has been shown that YF vaccination strongly induces an innate immune response in the first 
days after vaccination (Gaucher et al., 2008; Querec et al., 2009; Kyogoku et al., 2013). 
However, it is completely unknown, which and how different innate cell types are induced and 
whether aging affects the innate response to experimental YF infection. Our tight 
immunophenotyping of peripheral innate cell types revealed distinct kinetic patterns: Some 
innate subsets such as pDCs and CD11c+ mDCs showed a sharp early peak at day 4, while 
others such as CD14+/CD16+ nonclassical monocytes peaked slightly later at day 7. Finally, 
several subsets such as CD141+ mDCs and basophils did not show such early peaks and 
remained stable or transiently declined in numbers. Thus, YF vaccination seems to trigger an 
orchestrated innate sequence of distinct quantitative changes in blood, which likely reflects 
migration patterns to or from secondary lymphoid organs or the site of infection. Although 
the observed early dynamics in innate immunity after YF infection did not contain very 
prominent age signatures, they are from an immunological point of view highly interesting 
and have not yet been reported in humans, as only experimental infections provide the 
opportunity to study such early time points after inoculation in humans. At least for a better 
understanding of the YF-induced pDC dynamics, we can refer to work done in rhesus 
macaques infected acutely with Simian immunodeficiency virus (SIV) (Malleret et al., 2008a; 
Brown et al., 2009; Bruel et al., 2014). Comparable to our data, these studies report an acute 
pDC peak between days 3-6 post SIV infection, followed by a strong decline below baseline 
numbers by day 10. This concerted disappearance from the periphery could be explained by 
migration to lymph nodes (LN) as blood-derived pDCs started to accumulate and produce IFNα 
there. Yet, the origin of the early pDC peak remains unclear from the SIV studies, which only 
could show that at this stage pDCs were not activated, proliferating nor acutely mobilized 
from bone marrow. Thus, the early pDC peak can only be explained by a transient mobilization 
of pDCs from peripheral and or secondary lymphoid tissue into the blood stream, though this 
remains to be proven. The information on pDCs can be to some extent probably also applied 
to other innate subsets, such as recently reported for CD14+/CD16+ monocytes (Kwissa et al., 
2014), but for a complete understanding of the observed patterns an even deeper 
immunophenotyping, such as by mass cytometry, needs to be done, which could include 
analysis for chemokine receptors, activation markers and proliferation state. 
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As already mentioned, differences related to age were less prominent in the early innate 
dynamics. Rather, we observed striking quantitative age differences in certain innate subsets, 
such as pDCs, CD11c+ mDCs and CD14+/CD16+ nonclassical monocytes, which became even 
more apparent after onset of the innate immune response. Thus, most of the elderly are 
clearly compromised in their pDC and mDC compartments, confirming several reports 
obtained at the steady state (Shodell and Siegal, 2002; Pérez-Cabezas et al., 2007; Jing et al., 
2009; Garbe et al., 2012; Orsini et al., 2012; Verschoor et al., 2014a). Further about half of 
them showed a monocyte profile skewed towards pro-inflammatory nonclassical monocytes 
(Sadeghi et al., 1999; Seidler et al., 2010; Hearps et al., 2012; Verschoor et al., 2014b), 
thought to be associated with “inflamm-aging”. These signatures become also major 
determinants when peripheral innate immunity is viewed in its entirety by multivariate 
analysis such as PCA or clustering. Better than each innate immune parameter alone, both 
systemic approaches segregated well old from young vaccinees based upon their complete 
individual innate immune states at day 4, indicating the existence of age-typical innate 
immune conditions. However, age-segregation was not always perfect. For example, three 
young individuals had relatively low pDC and high nonclassical monocytes counts, 
characteristic of an aged innate immune system and thereby were grouped to old vaccinees. 
Vice versa, one old person exhibited features of a well preserved innate immune system and 
consequently was clustering with young individuals. Thus, aging strongly affects innate 
immunity, but there is additional individual variability beyond the level of pure age-
discrimination, probably attributed to other in- and/or extrinsic factors. 
Mild adverse reactions after YF vaccination, such as fever, headache or myalgias, not to be 
confused with YF-SAE, fall within the time window of innate responsiveness and are thought 
to be caused by the release of systemically-effective cytokines such as TNFα, IL1α and IFNα 
(Barnett, 2007). From two large studies it has been reported that elderly YF vaccinees have a 
reduced incidence of these mild reactions (Monath et al., 2002, 2005), which was observed 
also in our study. Our results indicate, that this reduced incidence of mild reactions may be 
attributed to low numbers of pDCs, producing pro-inflammatory cytokines (Hacker et al., 
1998), as those YF vaccinees in our study without any symptoms after vaccination, i.e. mostly 
elderly ones, had significantly fewer pDCs. In addition, but not explored by our study, further 
functional age-related defects at the cellular level might apply (Panda et al., 2010; Agrawal 
and Gupta, 2011; Garbe et al., 2012; Solana et al., 2012; Qian et al., 2015). Collectively, it 
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seems to us that absence of any mild symptoms along with low pDC numbers reflects a state 
of poor innate immune activation, which leads to the question; do those mostly age-related 
quantitative changes in innate immunity affect YF-specific adaptive immunity? 
Our correlation analysis suggests that at least numbers of pDCs and CD11c+ mDCs have a 
strong influence on the induction of adaptive immunity, i.e. low numbers of pDCs at day 4 
were strongly associated with poor YF-specific CD8+ responsiveness and reduced YF-specific 
CD4+ polyfunctionality. Similarly, individuals with low CD11c+ mDC counts developed weaker 
YF-specific CD8+ and CD4+ T-cell responses. Consistently, this could be visualized also in our 
multivariate-analyses. Although these associations were somewhat expected from textbook 
knowledge based mostly on animal experiments (i.e. strong induction of innate immunity is a 
pre-requisite for good adaptive responsiveness) our report is one of the few experimentally 
showing that this is indeed true also in humans being infected by a virus. Our data further 
points out the crucial role of DCs in YF vaccination, which have been in shown in vitro to 
become activated after sensing YF virus and to produce IFNα (Querec et al., 2006; Mandl et 
al., 2011; Bruni et al., 2015). Consequently, our findings suggest that quantitative DC 
immunosenescence is, beside limited availability of naive CD8+ T cells and CD4+ RTE, a main 
factor for reduced adaptive responsiveness to YF vaccination in the elderly. This might be 
further restricted by age-related functional impairments in DCs, reported to occur at least in 
infections with other flaviviruses, such as WNV (Kong et al., 2008; Qian et al., 2011). To further 
validate our findings for pDCs, serum samples from our study are currently investigated for 
IFNα levels, which we expect to be decreased in the elderly and to correlate with adaptive 
immunity as suggested by observations in WNV-infected patients (Tobler et al., 2008). 
We did not observe significant correlations of adaptive responsiveness with innate cell types 
other than pDCs and CD11c+ mDCs, although this cannot be ruled out due to the low 
statistical power of our study. For example, a recent publication comparing immune responses 
in African and European YF vaccinees found a strong association between high numbers of 
pro-inflammatory CD14+/CD16+ monocytes and poor humoral adaptive responsiveness 
(Muyanja et al., 2014). There, the African cohort showed an elevated baseline level of 
CD14+/CD16+ monocytes, probably due to more frequent exposure to infectious diseases. It is 
possible that this is true also for aged vaccinees, as several but not all old participants in our 
study had increased numbers of pro-inflammatory CD14+/CD16+ monocytes as well. However, 
the low sample size did not allow us to investigate this effect with stratified data. Another 
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study that compared baseline immunological profiles of individuals with asymptomatic versus 
severe WNV infection identified high levels of CD14+/CD16+ monocytes and low levels of pDCs 
to be associated with a disease severity (Qian et al., 2015). As age was roughly comparable 
between severe and asymptomatic patients it emphasizes the importance of the individual 
innate immune constitution, which is obviously not only shaped by age but also by other 
factors such as history of exposure to infectious diseases and which must be considered when 
evaluating immunological responsiveness. In this view it is interesting to note that those four 
individuals being “age-misclassified” in our multivariate analyses often exhibited adaptive 
responses closely resembling those of circumjacent subjects. For example, the three young 
vaccinees having low pDC and high CD14+/CD16+ monocyte counts, also did not generate very 
magnificent YF-specific CD8+ T-cell responses, while one old vaccinee with a well preserved 
innate immune system, had a very strong CD8+ response. 
Further it is important to note that our correlation analysis cannot be used to infer causality. 
Although it is very likely that quantitative scarcity of pDCs and CD11+ mDCs in the elderly leads 
to a state of poor innate immune activation and reduced antigen-presentation consequently 
affecting priming and actuation of adaptive immunity, alternative explanations might be 
possible. With DCs being a main target of infection by the virus and an important vehicle for 
virus replication and spread (Barba-Spaeth et al., 2005; Palmer et al., 2007; Gandini et al., 
2011), one can imagine that limited availability of these target cells in the elderly also alters 
virus propagation in the host. Thus it might be possible that virus spread occurs less quickly in 
the elderly, leading to a delayed sensing by and reduced induction of adaptive immunity, 
which would fit as well to our data set. Thus the exact causality for the observed correlations 
remains open and should be studied in future in animal experiments, e.g. with traceable YF 
virus. Furthermore, future YF studies might dissect the dependency of the three variables age, 
DCs and naive T cells of each other and the contribution of each to the observed effect on 
adaptive immunity. In other words it would be important to examine confounding and effect 
modification, which could be done by stratification or regression model analysis, though these 
require a much larger sample size than available in our study. Taken together our study 
revealed profound age-related alterations in innate immunity, especially in the DC 
compartment, which were associated with impairments in the acutely-induced YF-specific T-
cell response. After further validations, DC numbers might thus be another immune signature 
that seems worthwhile to be considered in individualized pre-vaccination risk assessment. 
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4.8 Patterns of immune cell dynamics after YF vaccination and the possible influence on 
vaccination outcome 
Direct enumeration of immune cells in peripheral blood at tight intervals enabled us to 
examine the temporospatial distribution and composition in the entire course of the infection. 
As indicated already before, we found very specific kinetic patterns. For example many innate 
cell types, such as monocytes and DCs showed an early peak around day 4 or day 7, as 
discussed in the previous chapter. Conversely, numbers of peripheral T and B cells significantly 
dropped from day 0 to day 7 in all vaccinees regardless of age and then started to reappear 
again, as also reported in a previous YF-study conducted by our group (Bethke, 2011). The 
same early transient drop in T-cell counts was observed after experimental primary 
inoculation of healthy adults with vaccinia virus (Zaunders et al., 2006), which was 
accompanied by local LN tenderness around day 7. By day 10 after vaccinia infection, T-cell 
numbers increased again and LN swelling decreased, while inflammation and induration 
started at the inoculation site. This suggests that T lymphocytes from the periphery start to 
migrate massively to LNs, where they are sequestered around day 7 and probably meet 
antigen-presenting cells, such as pDCs or mDCs, which is also supported by data from primary 
SIV infection in macaques (Malleret et al., 2008b; Bruel et al., 2014). The subsequent increase 
of counts in the periphery reflects in part most likely the release of highly proliferating 
antigen-specific T cells, which indeed show the strongest increase in whole blood counts after 
day 7 in our study. Additionally and probably to a much greater extent, unrelated T-cell 
specificities attracted to the LN but not participating in the response might get released back 
to the blood stream. The concept that T and B lymphocytes massively home to secondary 
lymphoid tissue in the first 7 days after infection was further supported when we separately 
examined different cellular subsets. Indeed, only subsets with the capability to home to LNs, 
i.e. naive and CM T cells and naive and memory B cells which express CCR7 (Henneken et al., 
2005; Payne et al., 2009) showed the characteristic drop towards day 7. Surprisingly also 
CD56br NK cells, known to express CCR7 (Campbell et al., 2001), followed this pattern. 
Accordingly, subsets lacking CCR7 expression such as EM and Eff T cells and also CD56dim NK 
cells did not drop in comparison to baseline. The unexpected migration of both naive and CM 
T cells to LNs even in a primary response with no pre-existing memory nevertheless is 
reasonable, as the immune system does not know at this early stage whether it has already 
experienced the pathogen or not. As the subset-specific cell migration patterns extensively 
83 
 DISCUSSION 
correlated with each other within each individual, we hypothesized that they are dependent 
on the strength of innate immune activation; however neither counts of any DC nor monocyte 
subset correlated with the observed transient declines. Thus it remains open which factors 
induce this early migration wave to secondary lymphoid tissues, which probably depends on 
the CCR7-ligands CCL19 and CCL21 (Förster et al., 2008) as shown in SIV infected macaques 
(Choi et al., 2003). Currently investigated candidates are “acute response” cytokines such as 
IL1β or TNFα that can be released by epithelial cells or innate components after YF infection 
(Gaucher et al., 2008; Pulendran, 2009; Querec et al., 2009). Our other finding that the 
decline is strongly influenced by the initial cell number of the respective subset speaks for a 
stochastic migration. Based on this data and perhaps new data from the ongoing serum 
cytokine analysis a detailed modeling of the kinetic patterns seems to be appealing. But do 
these early migration dynamics affect the YF-specific adaptive response? In our correlation 
analysis we could not find any relationship, i.e. also old vaccinees, with diminished adaptive 
immunity showed migration patterns comparable to young vaccinees. Collectively, although 
larger studies might find a relationship, early B and T-lymphocyte migration seemed not to be 
a major factor influencing adaptive responsiveness. 
4.9 Influence of CMV and EBV status on vaccination outcome 
Chronic viral infections such as CMV and EBV infections are thought to accelerate 
immunological aging as they constantly challenge the immune system of their host (Brunner 
et al., 2011). Therefore they represent potential confounders, which have to be considered 
when evaluating vaccination responsiveness. We analyzed the CMV/EBV baseline status in our 
vaccinees at the cellular and humoral level, which showed a high degree of concordance. 
Our study was too small to reveal neither any age-related increase in CMV seropositivity 
shown in large population surveys (Staras et al., 2006; Bate et al., 2010) nor an increase of 
CMV-specific humoral and cellular immunity by age (Musiani et al., 1988; Weymouth et al., 
1990; Khan et al., 2004; Stowe et al., 2007). As all participants were seropositive for EBV, we 
could only compare levels of EBV-specific humoral and cellular immunity, which has been 
reported to increase with age (Glaser et al., 1985; Stowe et al., 2007). However, similar to 
CMV, no age-difference was found between both age cohorts of our study. Nevertheless, CMV 
and EBV baseline status had a clear impact on distribution and phenotype of certain leukocyte 
subsets. For example, CMV seropositivity was strongly associated with a skewed monocyte to 
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mDC ratio. As CMV latently resides in monocytes (Sinclair and Reeves, 2014) and becomes 
activated upon differentiation e.g. into both mDC subsets (Reeves and Sinclair, 2013), it seems 
reasonable that that CMV infection alters monocyte differentiation and thus also the ratio in 
peripheral blood. Indeed, in vitro experiments have demonstrated that CMV can inhibit 
differentiation of monocytes to mature mDCs through a multitude of mechanisms (Gredmark 
and Söderberg-Nauclér, 2003; Gredmark-Russ and Söderberg-Nauclér, 2012), including 
expression of viral-encoded IL10 (Chang et al., 2004; Raftery et al., 2004; Avdic et al., 2011). In 
analogy to that, it is possible that EBV affects also monocyte differentiation which might 
explain the inverse association of EBV immunity and mDC baseline counts observed in our 
study. In fact, studies have shown that EBV infects or enters monocytes and DCs (Savard et al., 
2000; Tugizov et al., 2007) and prevents in vitro the development of DCs (Li et al., 2002; 
Guerreiro-Cacais et al., 2004). Regarding baseline T-cell constitution, we could show that CMV 
seropositivity led to increased numbers of Eff CD8+ and EM CD4+ T cells, which is consistent 
with previous reports (Chidrawar et al., 2009; Litjens et al., 2011; Wertheimer et al., 2014). 
Also EBV-specific immunity seemed to drive Eff CD8+ T-cell expansion in our study perhaps at 
the expense of CM cells, however no proper study exists that explored the impact of EBV on 
the phenotypic distribution of T cells. Importantly and consistent with other reports in man 
(Litjens et al., 2011; Vescovini et al., 2014; Wertheimer et al., 2014) and mice (Mekker et al., 
2012; Smithey et al., 2012), neither CMV nor EBV showed any association with reduced initial 
naive T-cell counts or CD4+ RTE, suggesting that the observed quantitative decline is mostly 
attributable to age rather than to persistent infections. In this context and despite the 
CMV/EBV-induced alterations in innate and adaptive immunity, CMV or EBV status did not 
show any measurable influence on the YF-specific immune response, indicating that CMV/EBV 
driven alterations do not limit the ability of the host to respond to a novel infection, which is 
consistent with the reports of Lelic et al. and Vezys et al. (Vezys et al., 2009; Lelic et al., 2012). 
Nevertheless one should note, that given the size of our study, we cannot completely rule out 
any influence of persistent viral infections on the vaccine response outcome. Other studies in 
aged mice have reported a negative effect (Cicin-Sain et al., 2012; Mekker et al., 2012; 
Smithey et al., 2012), but also a positive effect, especially in young CMV+ individuals might be 
possible (Furman et al., 2015). Collectively, persistent CMV and EBV infection clearly shape the 
immune system of their hosts, however their impact on an acute de novo challenge seem to 
be rather low in comparison to other immune signatures we have found. 
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4.10 Long-term YF-specific immunity in young and old vaccinees 
YF vaccination is one of the most potent vaccines, conferring essentially life-long protection 
(Monath and Vasconcelos, 2015). Whether and how immune aging affects such long-term 
immunity has not yet been studied in great detail. We therefore re-invited our participants 
and assessed YF-specific humoral and adaptive immunity up to 3 years after primary 
vaccination. All YF vaccinees still demonstrated protective YF-neutralizing titers and no age-
differences were found in titer levels or in their decline from day 28 levels, which has been 
observed also in a large YF vaccination trial (Monath et al., 2005). In contrast, specific 
antibody levels induced by inactivated TBE and tetanus vaccinations have been shown to be 
age-dependent (Hainz et al., 2005). Thus, YF live-viral vaccination seems to be potent enough 
to overcome effects of immune senescence on long-term humoral immunity otherwise 
relevant in e.g. inactivated vaccines. Similar to humoral immunity and despite the strong 
contraction of these cells from day 28 levels, all HLA-A0201+ vaccinees still possessed 
detectable YF-specific CD8+ T cells 2-3 years after vaccination. Consistent to acute WNV 
infection in humans (Lelic et al., 2012), we did not observe any age-difference, though one 
should note that we only analyzed nine vaccinees. In contrast to this, long-term YF-specific 
CD4+ T-cell immunity differed between young and old vaccinees. While numbers of YF-specific 
IL2, IL4 and TNFα producers were not significantly affected by age, CD4+ IFNγ+ T cells were 
clearly reduced in the elderly, which is also the underlying reason for the reduced frequency 
of polyfunctional CD4+ T cells in the aged cohort. The consequence of these alterations in 
long-term memory in aged vaccinees is unclear, especially as there is no other comparable 
data available. In light of a recent WHO announcement suggesting that YF booster 
vaccinations are dispensable (Who, 2015), the altered YF-specific CD4+ T-cell memory in our 
elderly vaccinees raises however the possibility that this recommendation may not be 
generally applicable to all elderly subjects. 
Integrating pre-vaccination, acute response phase and long-term memory data, our study 
revealed that the magnitude of the acute YF-specific T-cell response strongly determines late-
memory T-cell immunity, as predicted from fundamental work in LCMV-infected mice (Murali-
Krishna et al., 1998). Consequently, pre-vaccination CD4+ RTE and early pDCs numbers, 
important for strong acute T-cell responses, also were closely associated with long-term YF-
specific T-cell immunity, which emphasized that these initial and early immune signatures are 
as well key factors for the induction of proficient and long-lasting T-cell memory. 
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In addition, we also assessed which factors possibly influence the contraction of YF-specific 
immunity from day 28 to long-term levels. Interestingly, persistent CMV and EBV infection 
seemed to play a central role, as high levels of CMV-specific CD4+ T cells were associated with 
a more profound contraction of YF-specific CD8+ T cells, which is to some extent similar to 
what has been observed for EBV-specific CD8+ T cells in the context of CMV seropositivity 
(Khan et al., 2004). On the other hand and somewhat unexpected, strong EBV-specific 
immunity seemed to promote stability of YF-specific humoral immunity. Interestingly, humoral 
EBV immunity was also positively associated with CMV antibody levels in CMV+ individuals in 
our YF study and in a flu-vaccination study we have conducted, which hints for a yet 
undefined role of EBV in the maintenance of humoral immunity, though this clearly requires 
validation in further studies. 
Altogether our study provides evidence that long-term YF immunity, despite some qualitative 
defects in CD4+ T cells, is relatively comparable in old and young vaccinees and largely 
dependent on the strength of the previous acute YF response. We hope that we can follow up 
our study cohorts also in the next years, in order to study whether age-related defects in YF-
specific memory become perhaps apparent after a longer time. 
4.11 Implications for YF vaccination in the elderly 
The findings of our study might have several implications for YF vaccination in elderly people 
or immunocompromised subjects in general. At first, our humoral and cellular data together 
with the report by Roukens et al. (Roukens et al., 2011), speaks for a slightly delayed onset of 
protection in elderly vaccinees. Thus it might be advisable to extent the recommended time 
window of 10 days before entering a YF endemic area for aged vaccinees.  
At second and as indicated in the previous chapter, long-term immunity might be slightly 
altered in the elderly, raising the possibility that YF booster vaccinations are still required in 
certain risk groups. Although it has been reported that protective neutralizing antibody titers 
are maintained in elderly vaccinees that have been vaccinated more than 10 years ago 
(Coulange Bodilis et al., 2011), which led to the conclusion that YF booster vaccinations are 
dispensable as outlined in a recent meta-analysis (Gotuzzo et al., 2013), it is still possible that 
cellular immunity is not as long lasting in the elderly. Given that it is only assumed that 
humoral immunity alone gives complete protection (Slifka, 2014) and CD8+ T cells 
complemented antibody-mediated protection in the murine YF model (Bassi et al., 2015), the 
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decline in cellular adaptive immunity needs further investigation particularly in the aged. 
Thus, it might be advisable that for safety reasons YF booster vaccinations should be still 
applied in elderly vaccinees, especially as they are very well tolerated even at advanced age 
(Monath, 2012). 
At third, persons at special risk to develop YF-SAE might benefit from an individual pre-
vaccination risk assessment based on immune markers found in our study, such as numbers of 
CD4+ RTE, naive CD8+ T cells or pDCs. Although clearly these parameters need further 
validation and risk levels have to be established, the growing number of travelers exceeding 
the age of 60 could clearly benefit from it, as in many countries they otherwise would not be 
vaccinated under current recommendation guidelines. Further, this would improve safety in 
mass vaccination campaigns for aged or otherwise immunocompromised persons living in YF-
endemic regions. 
All this points also to future directions of vaccinology, in which many flavivirus-caused 
diseases, such as Dengue fever or Japanese encephalitis (JE) could be prevented by chimeric, 
live-viral vaccines based on a recombinant YF backbone (Bonaldo et al., 2014). These vaccines 
are currently tested in phase 2/3 trials and commercial production, e.g. of ChimeriVax-JE will 
start soon (Monath et al., 2015). In principle, all our findings can be translated to these new 
recombinant vaccines, which emphasize the importance of such investigations as millions of 
people including elderly will receive them. In this regard, it should be mentioned, that YFV-
17D and YF-based live-viral vaccines are probably much more potent than any inactivated 
vaccine, especially in old people which often have difficulties to achieve protective immunity. 
On the other hand, vaccine safety needs to be rigorously assured in live-viral vaccinations, 
which again speaks for an individual pre-vaccination risk-benefit analysis supported by 
immunological signatures, such as e.g. CD4+ RTE. Alternatively, an inactivated YF vaccine 
(Monath et al., 2011) could be applied to such risk groups, which showed an efficacy and 
safety profile comparable to other inactivated flavivirus vaccines (Heinz and Stiasny, 2012). 
However, it is unclear, to which extent long-lasting protection is achieved with this vaccine in 
elderly persons (Hayes, 2010), which stresses the necessity of a comparative study between 
live-viral and inactivated YF vaccination for this age group. 
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4.12 Concluding remarks 
Collectively, this study demonstrates that the primary immune response to a living virus is 
compromised in elderly humans on manifold levels, with naive T cells and DCs representing 
the most restrictive elements. It is widely accepted that these two cell types are limited in 
their availability in the elderly and therefore it is plausible that this contributes to the 
generally high susceptibility of the elderly to infections by newly emerging pathogens, such as 
WNV (Jean et al., 2007) or SARS coronavirus (Peiris et al., 2003). Importantly, age-related 
immune deficiencies in response to vaccination start to develop already in the early fifties, as 
seen in the relatively “young” aged cohort. Although these changes were relatively mild at 
that age, causing an only slightly prolonged YF viremia, they might become dangerous when 
extrapolated to individuals more advanced in age, which potentially explains why the 
incidence of life-threatening YF-SAE increases with age. Nevertheless, more immunological 
research should be done on samples of aged YF-SAE patients to definitely identify the cause of 
this severe complication.  
This study further proves that albeit the response to YF vaccination was reduced in the elderly 
cohort, protective immunity was eventually achieved in all vaccinees regardless of age, which 
render YF-based vaccination strategies a powerful tool for immune specificities difficult to 
induce in aged individuals (Liniger et al., 2007). In addition, this work points out that YF 
vaccination is an ideal model for basic immunologists to precisely investigate immune 
responses in humans. In this respect, the novel findings in aged YF vaccinees provide the basis 
for future studies uncovering the mechanisms of immune aging in the elderly. 
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6. Appendix 
6.1 Supplementary figures 
 
Suppl. fig. 1: YF-specific CD4+ T-cell response after re-stimulation with YF-vaccine (frequencies) 
(A-F) Frequencies of YF-specific CD4+ T cells assessed by co-expression of CD40L and a cytokine (CD40L/TNFα: 
day 2 p=0.03; day 7 p=0.03; CD40L/IFNγ: day 2 p=0.05; day 7 p=0.006; CD40L/IL4: day 2 p=0.04; day 7 p=0.05). 
Lines indicate the median with interquartile error bars. Young: filled circles; elderly: open circles 
Suppl. fig. 2: Overlay of selected YF 
immune signatures on innate PCA 
Color overlay of median separated 
values of (A) numbers of activated HLA-
DR+/CD38+ CD8+ T cells at day 14, (B) 
numbers of Ki-67+ CD38+ CD4+ T cells at 
day 7, (C) qualitative YF-specific single 
and (D) quadruple CD4+ functionality on 
the PCA of innate immunity at day 4. 
Red: values >median; Blue: values 
<median; Young: filled circles; Elderly: 
open circles 
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Suppl. fig. 3: Temporospatial distribution and composition of immune cells in peripheral blood 
(A-G) Absolute cell counts of (A) naive CD4+, (B) CM CD4+, (C) EM CD4+, (D) CD56br NK, (E) CD56dim NK, (F) naive B 
and (G) memory B cells in peripheral blood in the course of the vaccine-induced immune response. Lines indicate 
the median with interquartile error bars. Wilcoxon paired signed rank tests were performed for each age group. 
Asterisks indicate significances in young and stars in elderly vaccinees. P-values are listed in suppl. table 3. Young: 
filled circles; elderly: open circles 
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6.2 Supplementary tables 
Suppl. table 1: P-values of innate cell subsets 
Subset Day P-Value 
Class. monocytes (CD14++/CD16-) 7 0.02 
Noncl. monocytes (CD14+/CD16+) 
10 0.02 
21 0.01 
28 0.0005 
Interm. monocytes (CD14++/CD16+) 10 0.03 
Plasmacytoid DCs 
0 0.004 
4 0.0006 
7 0.005 
10 0.03 
14 0.009 
17 0.006 
21 0.02 
28 0.03 
CD11c+ myeloid DCs 0 0.05 4 0.03 
Basophils 7 0.02 
Neutrophils 0 0.03 
 
Suppl. table 2: P-values of immune cell migration patterns I 
Subset Comparison Age P-Value 
CD19+ B cells 
Day 0  Day 7 Young 0.001 Old 0.0002 
Day 7  Day 17 Young 0.002 Old 0.0002 
CD4+ T cells 
Day 0  Day 7 Young 0.001 Old 0.006 
Day 7  Day 14 Young 0.002 Old 0.001 
CD8+ T cells 
Day 0  Day 7 Young 0.001 Old 0.02 
Day 7  Day 17 Young 0.03 Old 0.0005 
Naive CD8+ T cells 
Day 0  Day 7 Young 0.001 Old 0.0002 
Day 7  Day 10 Young 0.003 Old 0.0005 
Central-memory  
CD8+ T cells 
Day 0  Day 7 Young 0.001 Old 0.0002 
Day 7  Day 14 Young 0.003 Old 0.002 
Effector-memory  
CD8+ T cells 
Day 0  Day 7 Young 0.76 Old 0.94 
Day 7  Day 17 Young 0.63 Old 0.02 
Effector CD8+ T cells 
Day 0  Day 7 Young 0.24 Old 0.19 
Day 7  Day 17 Young 0.92 Old 0.06 
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Suppl. table 3: P-values of immune cell migration patterns II 
Subset Comparison Age P-Value 
Naive CD4+ T cells 
Day 0  Day 7 Young 0.004 Old 0.02 
Day 7  Day 10 Young 0.03 Old 0.03 
Central-memory  
CD4+ T cells 
Day 0  Day 7 Young 0.04 Old 0.19 
Day 7  Day 17 Young 0.008 Old 0.004 
Effector-memory  
CD4+ T cells 
Day 0  Day 7 Young 0.07 Old 0.82 
Day 7  Day 17 Young 0.04 Old 0.73 
CD56br NK cells 
Day 0  Day 7 Young 0.003 Old 0.002 
Day 7  Day 14 Young 0.001 Old 0.0002 
CD56dim NK cells 
Day 0  Day 7 Young 1 Old 0.62 
Day 7  Day 14 Young 0.28 Old 0.17 
Naive B cells 
Day 0  Day 7 Young 0.001 Old 0.001 
Day 7  Day 17 Young 0.004 Old 0.0005 
Memory B cells 
Day 0  Day 7 Young 0.001 Old 0.001 
Day 7  Day 17 Young 0.004 Old 0.0005 
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6.3 List of abbreviations 
ACA Automated clustering analysis 
AID Activation-induced cytidine deaminase 
ASC Antibody-secreting cell 
BSA Bovine serum albumin 
BZLF1 BamHI Z Leftward reading Frame 1 (an EBV immediate early-protein) 
CCR CC chemokine receptor 
CD Cluster of differentiation 
CM Central-memory 
CMV Cytomegalovirus 
CTL Cytotoxic T lymphocyte 
DAPI 4',6-Diamidino-2-Phenylindole 
DC Dendritic cell 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethylsulfoxide 
EBNA1 Epstein-Barr virus nuclear antigen 1 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
Eff Effector 
EM Effector-memory 
FACS Fluorescence-activated cell sorting 
FoxP3 Forkhead box P3 
GFV Gelbfiebervirus 
Grz Granzyme 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
ICS Intracellular cytokine staining 
IE-1 Human cytomegalovirus immediate early-protein 1 
IFN Interferon 
Ig Immunoglobulin 
IIFA Indirect immunofluorescence assay 
IL Interleukin 
LN Lymph node 
MAIT cells Mucosal associated invariant T cells 
mDCs Myeloid dendritic cells 
min Minute 
N Naive 
NCBI National Center for Biotechnology Information 
NK cells Natural killer cells 
NKT cells Natural killer T cells 
NS4b Nonstructural protein 4b 
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PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCA Principal component analysis 
pDCs Plasmacytoid dendritic cells 
pp65 Human cytomegalovirus phosphoprotein 65 
PRNT90 Plaque reduction neutralization test 90 
RANTES Regulated on activation, normal T cell expressed and secreted 
RKI Robert Koch-Institute 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
RTE Recent thymic emigrants 
RT-PCR Real-time polymerase chain reaction 
SARS Severe acute respiratory syndrome 
SIV Simian immunodeficiency virus 
TBE Tick-borne encephalitis 
TCR T-cell receptor 
TH1 Type 1 T Helper cells 
TH17 Type 17 T Helper cells 
TH2 Type 2 T Helper cells 
TLRs Toll-like receptors 
TNFα Tumor necrosis factor α 
Treg Regulatory T cells 
VZV Varicella zoster virus 
WHO World Health Organization 
YEL-AND YFV-associated neurotropic disease 
YEL-AVD YFV-associated viscerotropic disease 
YF Yellow fever 
YF-SAE YFV-related severe adverse events 
YFV Yellow fever virus 
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